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During	 the	 last	 decade	 azole	 resistance	 has	 increasingly	 been	 reported	 in	Aspergillus	
fumigatus,	 which	 is	 a	 fungal	 pathogen	 involved	 in	 the	 vast	 majority	 of	 invasive	
aspergillosis	infections	in	humans,	and	is	now	a	global	public	health	concern	(Snelders	
et	al.	2008;	Arendrup	et	al.	2010;	Lockhart	et	al.	2011;	Mortensen	et	al.	2011;	Pfaller	et	
al.	2011;	Chowdhary	et	al.	2012;	Morio	et	al.	2012;	Gisi	2013;	Bignell	2014;	Chowdhary	
et	al.	2014;	Wiederhold	et	al.	2015).	Antifungal	azoles,	especially	triazoles,	are	the	drugs	
of	choice	for	medical	treatment.	However,	this	treatment	is	hampered	by	the	emergence	
of	 multi‐azole	 resistant	 A.	 fumigatus	 isolates,	 especially	 the	 highly	 resistant	 variants	
TR34/L98H	and	TR46	/Y121F/T289A.	Therefore,	to	control	this	disease,	it	is	essential	to	
elucidate	 by	 what	 mechanisms	 resistance	 emerges,	 how	 resistance	 spreads	 and	 how	
resistant	 genotypes	 persist	 in	 environments	without	 azoles.	 These	 research	 questions	
are	central	to	this	thesis.			
This	chapter	will	discuss	the	current	state	of	knowledge	on	the	factors	that	are	relevant	
for	 the	 development	 of	 azole	 resistance	 in	 A.	 fumigatus	 and	 its	 implications	 for	
prevention	 and	 patient	 treatment.	 These	 factors	 include	 the	 specific	 biology	 of	 A.	
fumigatus	 and	 how	 it	 affects	 the	 mutation	 supply,	 natural	 selection,	 the	 possible	
environments	 in	 which	 resistance	 can	 arise	 (the	 co‐called	 development	 routes),	 the	
human	lung	as	a	suitable	habitat	for	A.	fumigatus,	and	the	process	of	adaptation.	Finally,	
this	chapter	contains	an	outline	of	the	rest	of	the	thesis.		
Aspergillus	fumigatus	nomenclature		
A.	fumigatus	 is	a	 filamentous	saprotrophic	 fungus,	and	an	 important	 family	member	of	
the	 genus	 aspergillus	 (Figure	 1).	 It	 was	 originally	 described	 as	 an	 asexual	 fungus	 by	
Fresenius	in	1863	and	it	was	named	Aspergillus	fumigatus.	In	2009	sexual	reproduction	
was	 discovered	 (O’	 Gorman	 et	 al	 2009)	 and	 A.	 fumigatus	 was	 assigned	 to	 the	 genus	
Neosartorya	 fumigatus	 based	 on	 the	 similarity	 of	 the	 sexual	 fruiting	 bodies	 to	
Neusartorya	 (cleistothecia	 and	 ascospores)	 (Rydholm	 et	 al.	 2006;	 Samson	 et	 al.	 2007;	
O'Gorman	et	al.	2009).		
	
Figure	1.	Morphology	of	A.	fumigatus	
A:	Colony	of	A. 	fumigatus 	growing	on	solid	medium,	B:	spore	head,	C: 	A. 	fumigatus 	wild	type	
(Blueish‐green)	and	colour	mutant	(yellowish)	colonies	(photos	by	J 	Zhang)	 	
	
30µm
A B C 
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General	characteristics	of	growth,	life‐cycle	and	genome	
A.	 fumigatus	 is	 capable	 of	 surviving	 under	 a	 wide	 range	 of	 environmental	 conditions,	
such	as	temperatures	of	12‐65Ԩ,	pH	from	3.7	to	7.6	and	so	on.	Surprisingly,	the	optimal	
growth	 temperature	 of	A.	 fumigatus	 is	 37	Ԩ,	 which	 is	 significantly	 higher	 than	 other	
ascomycetes.	 Blueish‐green	 conidia	 (asexual	 spores)	 can	 persist	 over	 long	 periods	 of	
time	 under	 various	 (stress)	 conditions.	 The	 hydrophobicity	 gives	 spores	 airborne	
features	that	facilitate	efficient	dispersion	–	higher	than	comparable	species	A.	nidulans	
and	A.	niger.	This	also	makes	A.	fumigatus	a	challenge	to	manage	during	experiments.		
Similar	 to	 the	model	 species	A.	nidulans,	 there	are	various	stages	 in	 the	 life	 cycle	of	A.	
fumigatus	for	sexual,	asexual	and	parasexual	processes	(Figure	2).	For	A.	nidulans	it	has	
been	shown	that	this	life‐cycle	flexibility	can	facilitate	adaptation	and	the	development	
of	 resistance	 (Schoustra	 et	 al	 2007).	 This	 suggests	 that	 specifics	 on	 the	 biology	 of	A.	
fumigatus	will	 have	an	 impact	 on	 the	development	of	 azole	 resistance	 in	A.	fumigatus.	
For	instance,	during	the	large	number	of	mitotic	divisions	that	take	place	during	asexual	
reproduction,	spontaneous	mutations	have	a	high	likelihood	to	occur,	and	might	provide	
the	mutational	resource	for	A.	fumigatus	to	adapt	to	azole	environment.	The	process	of	
sexual	 reproduction	 shuffles	 the	whole	 genome	 (such	 as	 recombination	 as	 a	 result	 of	
cross	overs,	gene	conversion	and	so	on)	and	will	generate	novel	genetic	variation.		
Parasexual	processes	 involve	a	natural	alternation	between	haploid	and	diploid	states.	
This	 may	 lead	 to	 mitotic	 recombination	 (crossing‐over	 during	 mitosis	 between	
homologues)	 and	 random	 chromosome	 loss	 through	 repeated	 non‐disjunction	 can	
restore	the	haploid	chromosome	number.	When	two	different	nuclear	genotypes	occur	
in	a	common	cytoplasm,	recombination	by	a	parasexual	process	can	generate	substantial	
genetic	variation	and	can	serve	as	an	alternative	for	sexual	recombination	(Pontecorvo	
et	al,	1958).		
The	 full	 genome	 of	A.	fumigatus	has	 been	 sequenced	 and	was	 first	 described	 in	 2002	
(Denning	et	al.	2002).	Regarding	 the	whole	genome,	A.	fumigatus	genomes	are	smaller	
and	substantially	 less	gene	rich	than	genomes	of	related	species	A.	oryzae	and	A.	flavus	
(Gibbons	and	Rokas	2013).	Population	genomic	analysis	of	24	independent	sensitive	and	
resistant	 isolates	 from	 the	Netherlands	 and	United	Kingdom	have	 shown	A.	fumigatus	
has	high	genetic	diversity	based	on	SNPs	screened	 through	whole‐genome	sequencing	
(Abdolrasouli	et	al.	2015).	
Ecology	of	A.	fumigatus		
A.	 fumigatus	 is	 a	 ubiquitous	 fungus	 widely	 spread	 in	 nature,	 such	 as	 in	 soil,	 air	 and	
especially	 in	 decaying	 plant	material,	where	 it	 plays	 an	 important	 role	 in	 carbon	 and	
nitrogen	recycling.	For	instance,	100,000	colony	forming	units	per	gram	can	be	found	in	
compost	 (Anastasi	 et	 al.	 2005;	 Deacon	 et	 al.	 2009).	 In	 greenhouse	 and	 garden	 soil	A.	
fumigatus	makes	up	35‐70	%	of	the	total	number	of	colony	forming	fungi	(Jensen	1931).		
A.	fumigatus	can	also	be	found	indoors,	for	example	in	the	kitchen,	bathroom,	basement	
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Figure	2.	The	genotype	diversity	generated	via	multiple	modes	of	reproduction	in	
A.	fumigatus.	
A.	 The	 life	 cycles	 of	 A. 	 fumigatus . 	 B. 	 Formation	 of	 conidiospores	 on	 aerial 	 conidiophores	 by	
repeated	mitotic	 divisions	 in	 phiallide	 cells	 (~100/conidiophore). 	 Each	 phiallide	 divides	 upto	100	
times,	 therefore	 each	 conidiophore	 contains	 upto	 104	 spores	 that	 are	 easily	 dispersed	 by	 air	
(Figure	 3). 	 C. 	 Sexual	 reproduction	 requires	 introduction	 of	 a	 male	 nucleus	 to	 a	 female	 cell 	 of	
opposite	 mating	 type. 	 Subsequent	 synchronized	 divisions	 of	 the	 two	 nuclei	 eventually	 results	 in	
A 
D
B 
C 
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numerous	 essentially	 identical	 meiocytes	 that	 undergo	 meiosis	 and	 a	 post‐meiotic	 mitosis. 	 Each	
meiocyte	 thus	 results	 in	 an	 ascus	 with	 eight	 ascospores. 	 In	 total	 a	 fruiting	 body	 (cleistothecium)	
may	 contain	 upto	 104	 asci. 	 D. 	 Mitotic	 recombination	 in	 fungi	 during	 somatic	 growth	 has	 been	
termed	parasex.	Mycelial 	growth	involves	branching	and	hyphal	 fusion	(anastomosis). 	Upon	hyphal	
fusion	 heterokaryotic	 cells	 can	 be	 formed,	 if 	 the	 anastomosing	 hyphae	 are	 of	 dissimilar	 genotype.	
Such	 heterokaryon	 may	 again	 segregate	 into	 homokaryons,	 but	 nuclear	 fusion	 between	 different	
nuclei	 can	 also	 occur.	 The	 resulting	heterozygous	 diploid	 nuclei	 can	 segregate	 into	diploid	 sectors	
and/or	 diploid	 spores.	 During	 mitotic	 division	 of	 heterozygous	 diploid	 nuclei, 	 mitotic	
recombination	 (non‐disjunction	 or	 crossing	 over)	 may	 occur	 and	 result 	 in	 loss	 of	 heterozygosity. 	
Then,	 upon	 haploidisation	 recombinant	 haploids	 are	 formed.	 Thus	 the	 processes	 of	 recombination	
(inter‐	 and	 intrachromosomal	 recombination)	 as	 observed	 during	 the	 two	 meiotic	 divisions	 also	
occur	 during	 parasex, 	 be	 it 	 at	 a	 lower	 frequency	 and	 less	 controlled	 in	 time	 in	 during	 multiple	
mitotic	divisions.	(Drawing	by	Marc	Maas)	
	
Figure	3.	Morphological	changes	during	asexual	sporulation	in	Aspergillus	
fumigatus	tracked	via	scanning	electron	micrographs	
A:	Vesicle	formation	from	the	tip	of	the	stalk. 	B:	Developed	phialides. 	C: 	Early	stage	of	
conidiophores	bearing	short‐chains	of	conidia. 	D:	Extended	long‐chain	of	conidia. 	E, 	F: 	Mature	
conidiospores	with	around	200µm	length	of	chains	of	conidia. 	(Photo’s 	J . 	Zhang)	
 
A B 
30µm
C
30µm
D 
40µm
E
100µm
F
5µ 10µm
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flower	pot	soil	and	so	on	(Gisi	2013).	In	air	the	A.	fumigatus	concentration	could	easily	
reach	the	level	of	10‐200	conidia	per	m3;	each	day	everybody	inhales	several	hundreds	
of	spores.		
Diseases	caused	by	A.	fumigatus	in	immunosuppressed	patients	
A.	 fumigatus	 is	 considered	 an	 opportunistic	 pathogen	 because	 it	 only	 infects	
immunosuppressed	individuals,	such	as	AIDS	patients,	by	inhalation	of	conidia.	Invasive	
infection	 in	 the	 lung	 represents	 a	 major	 cause	 of	 morbidity	 and	 mortality	 in	 these	
individuals	(Camps	et	al.	2012a).	Specifically,	there	is	a	wide	range	of	diseases	related	to	
A.	fumigatus	infection,	such	as	allergic	bronchopulmonary	aspergillosis	(ABPA);	invasive	
aspergillosis	 (IA);	 central	 nervous	 system	 invasive	 aspergillosis	 (CNS	 IA);	 and	 cavity	
aspergillus	disease	(aspergilloma).	Different	morphs	of	A.	fumigatus	(spores	or	hyphae)	
were	detected	depending	the	specific	type	of	disease.	In	general,	A.	fumigatus	can	cause	
disease	by	growing	in	the	lungs	in	biofilms/mucus	which	are	places	the	immune	system	
cannot	easily	reach	(in	e.g.	cystic	fibrosis	and	COPD	‐	Chronic	obstructive	lung	disease	‐	
patients).	Upon	a	total	failure	of	the	immune	system,	it	can	also	spread	from	the	lungs	to	
other	 parts	 of	 the	 body.	 In	 this	way,	A.	fumigatus	 can	 result	 in	 deep‐seated	 infections	
such	as	kidney	and	brain	infection,	with	a	patient	mortality	of	99%	(Balloy	et	al.	2005).	
In	all	cases,	medical	triazoles	are	the	main	pharmaceutical	treatment	tool.		
A.	fumigatus	not	only	infects	immunosuppressed	patients,	but	also	domestic	animals.	It	
is	 primarily	 a	 respiratory	 infection,	 although	 tissue	 infected	 varies	 among	 species	
(https://en.wikivet.net/Aspergillosis).			
Several	 specific	 features	 contribute	 to	 the	pathogenicity	of	A.	fumigatus.	These	 include	
firstly	 specifics	 on	 the	 host	 environment	 (the	 patient)	 and	 secondly	 specific	 growth	
characteristics.	Regarding	the	host	environment,	several	reviews	on	the	pathogenicity	of	
A.	 fumigatus	from	 the	 perspective	 of	 its	 biology,	 pathogenesis,	molecular	 biology,	 and	
virulence	factors	suggest	A.	fumigatus	requires	an	immunocompromised	host	to	exhibit	
pathogenicity	(Latgé	2001;	Brakhage	and	Langfelder	2002;	Tekaia	and	Latgé	2005;	Hohl	
and	Feldmesser	2007;	Dagenais	and	Keller	2009;	Latgé	and	Steinbach	2009).	Only	when	
the	 immune	 system	 of	 the	 human	 host	 is	 weak,	 A.	 fumigatus	 is	 exerting	 as	 a	 human	
pathogen.		
Regarding	the	specific	growth	characteristics,	the	following	four	features	are	believed	to	
equip	A.	fumigatus	for	being	pathogen	(Kwon‐Chung	and	Sugui	2013).		
(I)	High	spore	production	and	effective	dispersal	of	spores	by	air.	After	a	week	of	growth,	
spore	production	 (asexual	 conidiospores)	of	 an	A.	fumigatus	 colony	 could	easily	 reach	
109.	Combined	with	high	hydrophobicity	these	airborne	spores	can	effectively	disperse	
and	could	also	be	transported	by	swarming	soil	bacteria	or	nematodes.	In	comparison,	A.	
fumigatus	spores	are	dispersed	much	more	efficiently	than	the	spores	of	other	fungi.	
(II)	Physical	characteristics	that	allow	conidiospores	to	reach	the	distal	airways.	The	small	
size	 of	 conidiospores	 contributes	 to	 respiratory	 tract	 diseases.	 	 A.	 fumigatus	
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conidiospores	with	a	size	of	2.0‐3.5	µm	are	significantly	smaller	than	those	of	A.	nidulans	
and	 A.	 niger,	 can	 reach	 the	 lower	 airway.	 Melanin	 in	 the	 conidial	 wall	 provides	
protection	from	ROS	(reactive	oxygen	species)	and	lysis	 in	the	host	cell	(Brakhage	and	
Langfelder	2002).	Negatively	charged	sialic	acid	residues	on	the	conidial	surface	allows	
effective	binding	to	the	host	(Wasylnka	et	al.	2001).	
(III)	Survival	in	a	wide	range	of	environmental	conditions.	A.	fumigatus	 is	able	to	grow	in	
the	temperature	range	of	12‐65Ԩ	and	in	acid	as	well	as	slightly	alkaline	environments	
(3.7‐7.6).	 Sexual	 ascospores	 are	 able	 to	 survive	 a	 70Ԩ	 heat	 shock	 for	 1	 hour.	
Furthermore,	A.	fumigatus	exerts	optimal	growth	and	spore	production	at	37	Ԩ,	making	
the	human	or	other	mammalian	host	a	favourable	niche.		
(IV)	Rapid	adaptation	 to	changing	environments.	 Plasticity	 of	 the	A.	 fumigatus	 genome	
with	 rich	 and	 diversified	 gene	 clusters	 facilitates	 A.	 fumigatus	 to	 adapt	 to	 changing	
environments.	A.	fumigatus	 is	 fully	equipped	for	adjusting	gene	expression	in	response	
to	 host	 stress.	 This	 allows	 for	 adaptation	 to	 strong	 host‐defence	 systems	 such	 as	 the	
production	 of	 potent	 secondary	 metabolites	 (16	 metabolites	 identified)	 (Frisvad	 and	
Samson	1990)	efflux	pumps,	and	specific	enzymes	such	as	catalases	(Burns	et	al.	2005).		
Triazole	treatment	for	A.	fumigatus	infected	patients	
The	ergosterol	biosynthesis	pathway	is	the	general	target	for	inhibition	of	fungal	growth	
in	 the	 management	 of	 A.	 fumigatus	 infections	 (Figure	 4).	 There	 are	 three	 types	 of	
antifungal	agents	for	treatment	of	 infections:	polyenes	(amphotercin	B),	echinocandins	
(caspofungin)	 and	 azoles,	 of	 which	 triazoles	 are	 the	 most	 widely	 used	 in	 medical	
treatment,	especially	itraconazole,	posaconazole,	and	voriconazole	(Albarrag	et	al.	2011).	
These	 triazoles	 inhibit	 the	 enzyme	 sterol	 14α‐demethylase	 (Erg11),	 encoded	 by	 the	
cyp51	 gene,	 thereby	 blocking	 its	 function	 of	 the	 conversion	 of	 lanosterol	 within	 the	
ergosterol	biosynthesis	pathway,	resulting	in	ergosterol	depletion	and	accumulation	of	
lanosterol	which	is	toxic	(Snelders	et	al.	2012).	Itraconazole,	clinically	licensed	in	1997,	
is	 commonly	 used	 for	 the	 treatment	 of	 chronic	 and	 allergic	 conditions.	 Voriconazole,	
clinically	 licensed	 in	 2002,	 is	 the	 recommended	 first	 choice	 therapy	 for	 invasive	
aspergillosis	 and	 posaconazole,	 clinically	 licensed	 in	 2006,	 is	 effective	 in	 preventing	
invasive	 aspergillosis	 in	 patients	with	 certain	 hematologic	malignancies	 (Camps	 et	 al.	
2012a).		
Azole	resistance	in	A.	fumigatus	and	resistance	mechanisms	
A	variety	of	azoles	have	been	used	over	the	years	as	the	main	treatment	therapy.	Over	
the	last	decades,	azole	resistance	has	increasingly	been	reported.	Notably,	if	patients	are	
infected	with	 resistant	A.	fumigatus,	 the	mortality	associated	with	aspergillosis	 is	high	
and	the	rate	of	treatment	failure	is	much	higher	(Howard	et	al.	2009;	van	der	Linden	et	
al.	 2011;	 van	 der	 Linden	 et	 al.	 2015).	 The	 majority	 of	 azole	 resistance	 is	 caused	 by	
alterations	 in	 the	 target	 protein	 sterol	 14α‐demethylase,	 encoded	by	 the	 cyp51A	 gene	
(Diaz‐Guerra	et	al.	2003;	Mellado	et	al.	2004;	Chen	et	al.	2005;	Lockhart	et	al.	2011).	
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Figure	4.	Ergosterol	biosynthesis	pathway	and	antifungal	targets	in	A.	fumigatus	
(Onyewu	et	al.	2003).		
	
Point	mutations	in	the	coding	region	of	cyp51A	can	lead	to	structural	alterations	to	the	
enzyme.	Point	mutation	hotspots	in	the	gene	include	codons	54	(Diaz‐Guerra	et	al.	2003;	
Nascimento	et	al.	2003;	Chen	et	al.	2005)	and	220	(da	Silva	Ferreira	et	al.	2004;	Mellado	
et	al.	2004)(Latgé	and	Steinbach	2009).		
A	 new	 resistance	 mechanism	 is	 the	 combination	 of	 a	 tandem	 repeat	 (TR)	 in	 the	
promoter	region	of	cyp51A	combined	with	a	point	mutation	in	the	coding	region	of	the	
cyp51A	gene	(Figure	5),	which	was	first	detected	in	1998.	The	first	type	was	TR34/L98H	
(the	substitution	of	leucine	98	for	histidine,	together	with	the	presence	of	two	copies	of	
a	34‐bp	sequence	in	tandem	in	the	promoter	of	the	cyp51A	gene)	and	was	found	in	the	
Netherlands	in	1998	in	the	environment	and	in	immunosuppressed	patients.	
Subsequently,	 this	genotype	was	found	in	multiple	European	Member	States,	 including	
the	United	Kingdom,	Spain,	Belgium,	France,	Italy,	Austria	and	Denmark,	and	worldwide	
(Figure	6)	(Snelders	et	al.	2008;	Arendrup	et	al.	2010;	Lockhart	et	al.	2011;	Mortensen	et	
al.	2011;	Pfaller	et	al.	2011;	Chowdhary	et	al.	2012;	Morio	et	al.	2012;	Rath	et	al.	2012;	
Seyedmousavi	et	al.	2013;	Chowdhary	et	al.	2014;	Wiederhold	et	al.	2015).	TR34/L98H	is	
highly	 resistant	 to	 itraconazole	 (minimal	 inhibitory	 concentration	 100%	 (MIC)	 >	 16),	
but	not	to	voriconazole	and	posaconazole.	In	2006	another	resistant	type	carrying	a	53	
bp	 tandem	 repeat	 (TR53)	 was	 isolated	 from	 a	 patient	 with	 chronic	 granulomatous	
disease.	This	 isolate	was	resistant	 to	 itraconazole	as	well	as	voriconazole,	and	showed	
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reduced	 susceptibility	 to	 posaconazole.	 Fortunately,	 for	 mutants	 carrying	 TR53,	 long	
term	of	posaconazole	 treatment	has	been	shown	 to	still	be	effective	 (Hodiamont	et	al.	
2009;	Camps	et	al.	2012c).	
The	 next	 wide‐spread	 mutant	 type	 that	 appeared	 was	 TR46/Y121F/T289A;	 it	 first	
showed	up	in	clinical	isolates	cultured	on	31	December	2009	in	Utrecht.	From	December	
2009	to	January	2011,	21	TR46/Y121F/T289A	A.	fumigatus	isolates	were	obtained	from	
15	patients	in	six	different	university	hospitals	in	the	Netherlands.	Soon	after,	the	same	
mutant	 type	 was	 detected	 in	 neighbouring	 European	 countries	 including	 Belgium	
(2012),	Denmark	(2014),	France	(2015),	and	outside	Europe,	for	instance	in	India	(2014)	
(Vermeulen	et	al.	2012;	van	der	Linden	et	al.	2013;	Astvad	et	al.	2014;	Montesinos	et	al.	
2014;	Lavergne	et	al.	2015;	Pelaez	et	al.	2015;	Wiederhold	et	al.	2015)	(Figure	6).	In	the	
Netherlands	 TR46/Y121F/T289A	 was	 also	 found	 in	 environmental	 samples.	 Although	
there	 is	 variation	 in	 the	 resistance	 level	 among	 these	 TR46/Y121F/T289A	 isolates	 to	
different	 triazoles,	 the	strains/genotypes	exhibit	high	resistance	 to	voriconazole,	 some	
are	highly	resistant	to	itraconazole,	and	some	are	highly	resistant	to	posaconazole.	
	
	
Figure	5.	(A)	The	first	year	of	observation	of	different	azole‐resistant	mutant	types	
of	A.	fumigatus	since	1998	in	the	Netherlands	and	(B)	illustration	of	resistant	
tandem	repeat	variants	on	the	cyp51	gene	(promoter	and	coding	region)  
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Figure	6.	Countries	that	report	the	TR34/L98H	and	TR46/Y121F/T289A	resistance	
mechanism	in	clinical	or	environmental	A.	fumigatus	isolates	in	last	decade	
(picture	from	P	Verweij	et	al.,	2015).	
	
Genetic	 relatedness	of	TR34/L98H,	TR46/Y121F/T289A	 and	 the	wild‐	
type	
Even	 though	 TR34/L98H	 and	 TR46/Y121F/T289A	 spread	 globally,	 genotyping	 has	
revealed	 high	 genetic	 similarity	 among	 geographically	 unrelated	 strains	 based	 on	
microsatellite	 locus	 analysis	 (Camps	 et	 al.	 2012b).	 Especially	 isolates	 harboring	
TR46/Y121F/T289A	 were	 found	 to	 be	 genetically	 highly	 similar	 between	 the	
Netherlands	and	India	(Chowdhary	et	al.	2014),	while	allele‐sharing	distance	matrices	of	
microsatellite	genotypes	showed	that	clinical	strains	carrying	either	TR46/Y121F/T289A	
or	 TR34/L98H	were	 highly	 genetically	 different	 from	 local	wild‐type	 isolates	 (van	 der	
Linden	et	al.	2013).	This	information	suggests	that	either	the	mutations	(TR34/L98H	or	
TR46/Y121F/T289A)	 arose	 more	 than	 once	 in	 similar	 genetic	 backgrounds,	 or	 these	
mutations	arose	only	once	and	subsequent	variation	in	microsatellite	loci	patterns	arose	
by	mutation	or	recombination	through	sexual	reproduction.	Either	way,	this	 illustrates	
the	 need	 to	 elucidate	 what	 factors	 are	 driving	 resistance	 development	 not	 only	 for	
understanding	 the	 recent	evolutionary	history	but	 also	 for	 the	design	of	measures	 for	
preventing	future	resistance	development.	
Resistance	development	routes	
As	the	resistant	isolates	are	both	found	in	the	environment	and	in	patients,	it	is	generally	
accepted	 that	 there	 are	 two	 routes	 to	 develop	 azole	 resistance	 in	 A.	 fumigatus:	 (1)	
through	selection	pressure	of	azoles	from	medical	drugs	in	human	patients	–	the	clinical	
route	 and	 (2)	 through	 the	 selection	 pressure	 from	 the	 use	 of	 azole	 fungicides	 in	
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agricultural	and	environment	–	the	environmental	route.	(Mellado	et	al.	2007;	Howard	
et	al.	2009;	Snelders	et	al.	2009;	Arendrup	et	al.	2010;	Mortensen	et	al.	2010).		
(1)	Clinical	route.	 Resistance	 development	 in	 the	 clinic	 is	 likely	 to	 happen	 in	 patients	
with	invasive	fungal	infection	diseases	and	that	are	exposed	to	long‐term	medical	azole	
therapy.	It	was	found	that	such	therapy	rapidly	selects	for	azole	resistance	(Camps	et	al.	
2012c).	Furthermore,	it	has	been	argued	by	Gisi	that	medical	triazoles	are	10‐100	times	
more	 active	 than	most	 agricultural	 fungicides	 for	A.	fumigatus	 control	 and	 potentially	
exert	stronger	selection	pressure	for	resistance	(Gisi	2013).			
(2)	Environmental	route.	Agricultural	fungicides	are	triazole	derivatives	and	abundantly	
used	in	our	environment	for	agricultural	crop	protection	(Verweij	et	al.	2009;	Snelders	
et	 al.	 2012;	 Stensvold	 et	 al.	 2012).	 The	 volume	 of	 azoles	 and	 azole‐like	 agricultural	
fungicides	 that	was	used	 in	 the	Netherlands	 in	2004	was	about	320‐times	higher	 than	
that	 of	 azoles	 used	 in	 clinical	medicine	 (about	 130	 000	 kg	 vs	 400	 kg)	 (Verweij	 et	 al.	
2009).	The	triazoles	are	the	only	class	of	compounds	that	are	used	both	 in	agriculture	
and	in	clinical	medicine.	The	volume	of	triazoles	sold	has	almost	doubled	between	1995	
and	2007	in	the	European	Union.			
Support	for	the	idea	that	clinical	resistance	can	arise	in	the	environment	comes	from	the	
observation	 that	 resistant	 isolates	were	 found	 in	patients	 that	had	never	been	 treated	
with	 azoles	 before	 diagnosis.	 In	 these	 cases	 patients	 likely	 inhaled	 spores	 from	 (a)	
resistance	 isolate(s)	 from	 the	 environment	 (Verweij	 et	 al.	 2009).	 Furthermore,	 all	
clinical	 resistant	 isolates	 (TR34/L98H)	 from	 the	 patients	 were	 resistant	 to	 five	
agricultural	fungicides	which	strongly	supports	the	environmental	route	(Snelders	et	al.	
2012).	 Furthermore,	 when	 exposing	 A.	 fumigatus	 to	 the	 agricultural	 azole	 fungicide	
prochloraz,	A.	fumigatus	 could	develop	 cross	 resistance	 to	 clinical	 azoles	 voriconazole,	
posaconazole	 and	 itraconazole,	 to	 tolerance	 levels	 that	 were	 256	 times	 higher(Faria‐
Ramos	et	al.	2014).	Snelders	discussed	that	these	agricultural	azoles	share	the	same	core	
structure	 with	 medical	 azoles.	 Due	 to	 this	 similarity	 they	 adopt	 much	 the	 same	
stereometric	poses	in	the	active	site	of	A.	fumigatus	as	the	medical	azoles,	based	on	the	
docking	information	of	these	agricultural	azoles	and	3D‐CYP51	of	A.	fumigatus	(Snelders	
et	al	2012).		
Although	there	have	been	no	reported	cases	of	an	“escape”	of	a	resistant	strain	from	a	
patient	to	the	environment,	both	routes	are	hampering	treatment	in	patients.	Given	the	
potentially	 different	 selection	 pressures	 in	 both	 environments,	 research	 is	 needed	 to	
identify	 the	 driving	 factors	 selecting	 for	 resistance.	 Interestingly	 the	 widely	 spread	
resistant	 isolates	 TR46/Y121F/T289A	 and	 TR34/L98H	 have	 never	 be	 generated	 under	
laboratory	 conditions.	 Therefore,	 it	 currently	 remains	 unclear	what	 shapes	 the	 actual	
resistance‐development	routes	of	these	two	commonly	observed	resistance	type.	
Evolutionary	perspective	on	azole	resistance	
In	 essence,	 the	 development	 of	 resistance	 to	 fungicides	 is	 an	 evolutionary	 process.		
Fungicides	 reduce	 the	 growth	 rate	 (fitness)	 in	 susceptible	 types.	 Genetic	 variation	
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generated	by	 spontaneous	mutations	and	recombination	 followed	by	natural	 selection	
are	the	evolutionary	process	by	which	resistance	develops	and	spreads	in	populations.	
This	 evolutionary	 process	 of	 adaptation	 can	 be	 studied	 in	 the	 laboratory	 using	
microorganisms,	such	as	bacteria	and	viruses	as	well	as	unicellular	algae	and	fungi.	This	
type	of	 study	 is	known	as	experimental	evolution	and	has	developed	 into	a	 successful	
field	of	 research	 (Figure	7).	This	 relies	on	 the	 fact	 that	 the	microorganisms	used	have	
short	generation	time,	allowing	many	generations	in	a	short	time,	large	populations	in	a	
small	 space,	 and	 the	 possibility	 to	 freeze	 samples	 for	 later	 comparative	 analysis	 of	
evolved	 and	 ancestral	 types.	 Furthermore,	 abundant	 molecular	 and	 genomic	 data,	 as	
well	 as	 techniques	 for	 their	 precise	 genetic	 analyses	 and	 manipulation	 are	 available	
(Elena	 and	 Lenski	 2003).	 Studying	 the	 drug	 resistance	 in	 Candida	 albicans	 via	
experimental	evolution	provides	a	good	example	 for	how	to	study	 the	development	of	
drug	resistance	and	dynamics	of	evolutionary	adaptation	(Cowen	et	al.	2000;	Huang	et	al.	
2011).	This	 illustrates	how	experimental	evolution	can	be	used	as	a	tool	to	 investigate	
how	A.	fumigatus	develops	resistance	by	propagating	strains	in	the	laboratory	under	the	
exposure	of	azoles.	 In	these	experiments,	 it	 is	possible	to	apply	various	conditions	and	
starting	points	 to	 study	how	biological	 features	 such	as	 reproduction	modes	 influence	
the	evolution	of	azole	resistance.		
		
	
Figure	7.	This	example	of	a	fitness	trajectory	shows	step‐wise	increases	in	fitness,	
indicating	the	fixation	of	beneficial	mutations.	Over	evolutionary	time,	organisms	
can	increase	their	fitness	by	adapting	to	a	certain	environment	(Lenski	and	
Travisano	1994).		
	
Setup	and	aim	of	this	thesis	
	
This	 thesis	 highlights	 the	 relevance	 of	 A.	 fumigatus	 biology	 and	 evolution	 for	 azole‐
resistance	development	and	persistence.	 In	this	thesis,	 I	 firstly	exploit	 the	relevance	of	
aspects	of	the	life	cycle	of	A.	fumigatus	for	the	occurrence	of	azole	resistance	in	natural	
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isolates.	 Next,	 I	 develop	 an	 experimental‐evolution	 approach	 to	 study	 the	 long‐term	
dynamics	and	mechanisms	of	azole‐resistance	evolution.	In	addition,	I	investigate	what	
condition	makes	an	environment	a	possible	hotspot	 for	the	development	of	resistance.	
Finally,	 I	 link	 this	 to	 the	 potential	 conditions	 under	which	 resistance	 can	 emerge	 and	
spread	in	the	lungs	of	humans	and	how	this	depends	on	the	specific	azole	used.	
Chapter	 2	 highlights	 the	 current	 dilemma	 on	 the	 management	 of	 patient‐acquired	
resistance	 in	 A.	 fumigatus:	 stopping	 the	 use	 of	 clinical	 triazoles	 or	 changing	 to	 new	
triazoles?	 	 These	 two	 scenarios	 are	 generally	 used	 to	 control	 the	 emergence	 of	 azole	
resistant	 A.	 fumigatus.	 On	 the	 one	 hand,	 after	 stopping	 the	 use	 of	 clinical	 triazoles,	
resistant	 A.	 fumigatus	 may	 suffer	 from	 a	 cost	 of	 resistance	 due	 to	 its	 adaptation	 to	
triazoles	 making	 the	 free‐azole	 environment	 unfavourable.	 On	 the	 other	 hand,	
compensatory	mutations	may	mitigate	the	initial	cost	of	resistance	and	aid	to	retain	the	
resistance	 phenotype.	 Therefore,	 compensatory	 mutations	 are	 required	 for	 azole	
resistance	to	persist	during	intermittent	use	of	triazoles	in	clinics.	Similarly,	changing	to	
new	triazoles	will	promote	the	development	of	additional	mutations	and	could	result	in	
pan‐resistance	 to	 all	 clinical	 triazoles.	 In	Chapter	2,	we	provide	 a	 patient	 case	with	 a	
failure	 of	 azole	 treatment.	 These	 cultures	 exert	 multiple‐phenotypes	 (with	 respect	 to	
resistance	 level	 and	 morphotypes)	 over	 the	 azole	 treatment.	 As	 the	 current	 two	
treatment	solutions,	compensatory	mutations	and	additional	resistance	mutations	may	
arise	and	contribute	to	the	treatment	failure	of	A.	fumigatus	infection.		
Despite	the	high	prevalence	of	resistant	A.	fumigatus	globally,	the	role	of	various	aspects	
of	 the	 life	 cycle	 in	 the	 development	 and	 persistence	 of	 azole	 resistance	 has	 not	 been	
studied	well.	 For	 instance,	 in	 clinical	 practice,	 in	 cavitary	Aspergillus	 diseases,	 such	 as	
chronic	 cavitary	 aspergillosis	 and	 aspergilloma,	 A.	 fumigatus	 undergoes	 asexual	
sporulation,	 as	 opposed	 to	 invasive	 aspergillosis,	 which	 involves	 only	 hyphal	 growth.	
This	 clinical	 observation	 also	 shows	 that	 various	 fungal	 morphotypes	 exist	 within	
patients.	 This	 suggests	 a	 link	 between	 sporulation	 and	 resistance	 development	 in	
patients.	 	 In	Chapter	3,	We	 test	 the	 hypothesis	 that	 asexual	 sporulation	 (one	 part	 of	
asexual	life	cycle)	is	required	for	the	spread	of	azole	resistance	in	A.	fumigatus,	because	
the	 asexual	 sporulation	 process	 aids	 to	 release	 the	 resistant	 nuclei	 from	multinuclear	
hypha	to	single	conidiospores,	which	can	regenerate	into	a	fully	resistant	homokaryotic	
mycelium.	 We	 performed	 experimental	 evolution	 with	 treatments	 where	 the	 fungus	
does	and	does	not	undergo	asexual	sporulation.	We	provide	evidence	that	the	cultures	
that	 underwent	 asexual	 sporulation	 reached	 higher	 resistance	 levels	 compared	 to	
cultures	that	did	not	undergo	asexual	sporulation.	We	conclude	that	asexual	sporulation	
indeed	plays	an	 important	role	 in	 the	emergency	of	azole	resistance	development.	We	
demonstrate	that	azole	resistance	is	not	fully	dominant	but	partially	recessive,	which	is	
in	 line	with	 the	hypothesis	 that	 asexual	 sporulation	 is	 required	 to	help	 the	 resistance	
nuclei	 escape	 from	 the	multicellular	 hypha.	 In	 addition,	we	 put	 forward	 an	 additional	
hypothesis	 that	 asexual	 sporulation	 could	 increase	 mutation	 load	 due	 to	 the	 large	
number	 of	 mitotic	 division	 involved	 in	 the	 asexual	 sporulation	 process.	 This	 has	
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implications	for	the	increase	in	resistance	over	treatment	in	the	cavities	of	aspergillosis	
patients,	where	asexual	sporulation	takes	place.	
In	 Chapter	 4,	 we	 explore	 the	 potential	 of	 two	 possible	 routes	 of	 azole‐resistance	
development,	 through	 azole	 exposure	 in	 clinics	 and	 the	 environment.	 While	 the	
environmental	route	has	been	suggested	to	be	important,	there	is	no	direct	evidence	of	
the	development	of	 clinical	 resistance	via	 this	 route.	We	apply	experimental	evolution	
and	exposed	a	sensitive	ancestor	to	five	agricultural	fungicides	that	have	been	used	the	
past	 30	 years.	 We	 examine	 whether	 highly	 resistant	 isolates	 or	 isolates	 with	 the	
commonly	found	TR34/L98H	resistance	mechanism	emerged	and	whether	these	isolates	
developed	cross	resistance	to	medical	azoles.	The	patterns	of	evolutionary	trajectories	
of	evolving	strains	assayed	on	medical	and	agricultural	azoles	show	high	similarity.	This	
supports	 the	 environmental	 route:	 the	 development	 of	 clinical	 resistance	 can	 emerge	
through	the	exposure	to	agricultural	azoles.	We	observe	dynamic	changes	in	phenotype	
and	genotype	over	the	nine	weeks	of	the	experiment,	which	shows	also	within	lineages	
evolved	 isolates	 differ	 in	 resistance	 level,	 growth	 rate,	 colony	 structure	 and	 time	 of	
sporulation.	Even	though	no	TR34/L98H	mutants	were	discovered,	we	find	one	mutation	
in	 the	cyp51	gene	 (G138S)	 in	one	out	of	36	 lineages.	Lastly,	potential	 candidate	genes	
that	 are	 related	 to	 resistance	 mechanism	 were	 investigated	 after	 whole‐genome	
sequencing.		
Chapter	 5	 follows	 up	 on	 the	 observation	 of	 different	 morphotypes	 occurring	 within	
evolving	 lineages	 in	 the	 evolutionary	 experiment	 of	Chapter	3,	as	well	 as	 in	 samples	
obtained	 from	 clinical	 isolates	 of	 single	 patients,	 which	 suggests	 that	 morphology	 of	
isolates	may	play	a	role	in	azole‐resistance	development.	We	investigated	whether	these	
isolates	 with	 different	 morphotypes	 are	 vegetatively	 compatible	 and	 considered	 the	
relevance	 of	 heterokaryon	 formation	 in	 the	 development	 of	 azole	 resistance	 in	 A.	
fumigatus.	 Heterokaryon	 compatibility	 tests	 show	 that	 all	 morphotypes	 isolated	 from	
the	 same	 patient	 are	 vegetatively	 compatible,	 while	 isolates	 taken	 from	 different	
patients	 are	 not.	 This	 indicates	 that	 different	 morphotypes	 from	 one	 patient	 likely	
originated	 from	 one	 original	 isolate	 and	 that	 diversification	 takes	 places	 within	 the	
patient	 in	 response	 to	 selection.	 Furthermore,	 we	 show	 how	 the	 flexibility	 of	 the	
heterokaryon	 aids	 adaptation	 to	 changing	 azole	 environments,	 which	 promotes	 the	
persistence	of	azole	resistance	in	A.	fumigatus.	
A.	fumigatus	is	a	ubiquitous	fungus.	However,	the	hotspot	for	resistance	development	in	
the	 environment	is	 unknown.	 Further,	 it	 has	 been	 suggested	 that	 sexual	 reproduction	
can	aid	resistance	development;	evidence	for	this	notion	is	also	still	lacking.	In	Chapter	
6,	we	investigate	two	compost–heaps,	one	containing	and	one	not	containing	azoles.	We	
find	 a	 high	 incidence	 of	A.	fumigatus	 isolates	 in	 both,	 but	 a	 larger	 genetic	 diversity	 of	
resistant	A.	fumigatus	within	azole‐containing	compost	than	within	azole‐free	compost.	
This	 suggests	 that	 azole‐containing	 compost	 is	 a	 hotspot	 for	 the	 development	 and	
maintenance	of	azole	resistance	in	A.	fumigatus.	Importantly,	we	find	a	novel	resistance	
mechanism	 with	 TR463/	 Y121F/	 M172I/T289A/G448S,	 a	 type	 that	 is	 resistant	 to	 all	
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available	medical	 triazoles.	 Upon	 investigation,	 this	 novel	mutation	 is	 also	 present	 in	
several	patients	from	different	hospitals	in	the	Netherlands.	The	existence	of	two	mating	
types	among	the	isolates	containing	the	TR463/	Y121F/	M172I/T289A/G448S	mutations	
and	 the	 possibility	 to	 generate	 TR463/	 Y121F/	 M172I/T289A/G448S	 during	 a	 sexual	
cross	with	two	strains	containing	TR46		suggest	that	the	occurrence	of	sex	in	compost	is	
highly	 likely.	 However,	 more	 evidence	 is	 needed.	 This	 finding	 illustrates	 how	 rapid	
development	 of	 resistance	 in	 A.	 fumigatus	 could	 arise	 and	 further	 supports	 the	
presumed	possible	role	of	sexual	reproduction	in	the	development	of	azole	resistance.		
In	Chapter	7,	 I	put	 the	 results	attained	 through	 the	whole	 thesis	 in	a	broader	context	
and	 I	highlight	 the	relevance	of	 these	 findings	 to	A.	fumigatus	 infections	 from	both	 the	
clinical	perspective	as	well	as	the	perspective	of	fungicide	management	in	agriculture.		
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Abstract 
Aspergillus fumigatus causes a range of diseases in humans, some of which are characterized by fungal persistence. A. fumigatus may persist by adapting to the human lung environment through physiological and genomic changes. The former is based on the large biochemical versatility of the fungus, the latter on its capacity to generate genetic diversity by spontaneous mutations and recombination, and subsequent selection of genotypes most adapted to the new environment. Stress factors such as triazole exposure causes mutations to emerge that render resistance. The mode of reproduction, i.e. sexual, parasexual, or asexual, is probably crucial for the adaptive potential of Aspergillus. As any change in the environment may provoke adaptation, switching between triazoles in patients with chronic pulmonary aspergillosis (CPA) may result in a high-level pan-triazole-resistant phenotype through the accumulation of resistance mutations. Alternatively, when triazole therapy is stopped, an azole-free environment is created that may prompt selection for compensatory mutations that overcome any fitness costs that are expected to accompany resistance development. As a consequence, starting, switching, and stopping azole therapy has the risk of selecting for highly resistant strains with wild-type fitness. As similar adaptation is expected to occur in response to other stress factors such as endogenous antimicrobial peptides, over time the fungus will become increasingly adapted to the lung environment thereby limiting the probability of eradication. Our hypothesis challenges current management strategies and future research should investigate the genomic dynamics during infection in order to understand the key factors facilitating adaptation of Aspergillus.  
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Introduction 
Aspergillus fumigatus is a ubiquitous fungus that plays an important role in carbon and nitrogen recycling in nature by degradation of organic biomass.1,2 The most well-known habitat is the compost pile, which is considered a harsh and competitive environment.3-5 Various biological characteristics allow A. fumigatus to thrive in this environment, including rapid and efficient germination, growth at elevated temperatures, and a metabolism that is responsive to variation in nutrient sources.6 Furthermore, A. 
fumigatus propagates via asexual spores that can be dispersed over large geographic distances by air currents and that can germinate to grow under a broad range of environmental conditions.7-9 This remarkable biochemical versatility of A. fumigatus contributes to its role as the predominant fungal pathogen of immunocompromised patients.10 Several diseases may be caused by A. fumigatus ranging from allergic conditions to acute invasive aspergillosis (IA).11 Furthermore, in order to survive and thrive Aspergillus needs to rapidly adapt in these environments that often entail various challenges.  Genetic adaptation can be defined as the acquisition of heritable modifications in an organism through natural selection that enable it to survive and reproduce in the prevailing or new environment.12-15 One example of this process of adaptation is the development of azole resistance. Triazoles have become the cornerstone of prevention and treatment of Aspergillus-related diseases.16 Although triazole resistance may develop during patient therapy,17,18 the main route of resistance selection in A. fumigatus is believed to be through exposure to azole fungicides in the environment.19 Azole compounds are widely used for food production, plant protection, and material preservation.20,21 Patient-acquired resistance and environmental resistance both require an active reproducing fungus and exposure to azole compounds. We hypothesize that A. 
fumigatus is capable of adapting to the human host during infection, and that adaptation is an important fungal property that contributes to treatment failure and persistence of the fungus. Here, we review adaptation strategies of A. fumigatus in relation to azole-resistance-selection and the clinical implications thereof for management of Aspergillus diseases. 
Adaptation strategies in A. fumigatus Three modes of reproduction are recognized in A. fumigatus, namely asexual, sexual, and parasexual reproduction (Figure 1A). In contrast to sexual and asexual reproduction that are known to widely occur in many microorganisms, parasex is more a fungal strategy to generate genetic diversity than a reproduction mode. The consequence of these aspects of the lifecycle is an increased genetic diversity, through spontaneous mutations and reshuffling of genotypes, thereby increasing the likelihood that the offspring includes types that are better adapted to a new environment. Azoles are not known to be mutagenic or recombinogenic per se, but exposure of A. fumigatus will provoke a strong selection pressure for azole resistance.  
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When conditions are right, a fungal colony is initiated from the germination of a single spore that will give rise to a network of hyphae. After a few days, when vegetative hyphae are exposed to air, aerial hyphae form asexual reproductive structures, conidiophores, that each produce up to 104 asexual spores.22 Consequently, after one week a colony may have produced up to 109 spores that easily become air-borne. During each mitosis there is a very small probability of a mutation arising. However, given the large number of mitotic divisions that take place during asexual reproduction, asexual spores provide a large supply of spontaneous mutations e.g. for new azole resistance mutations to be selected in the azole environment (Figure 1B).23 Sexual reproduction requires two parental strains of opposite mating type (MAT1-1 and MAT 1-2).24 After fertilization, a fruiting body (cleistothecium) is formed that may contain 104 sexual spores that originated from the same zygote and that are genetically different due to recombination during meiosis. Genetic variation that is present in the parental strains is thus enhanced through the reshuffling of these genotypes. Genes and alleles associated with low-level resistance might thus evolve to a high(er) resistant phenotype when placed in a different genetic background (Figure 1C). Persistent and/or increased azole pressure will facilitate the emergence of such high-level resistant phenotypes through natural selection. Sexual reproduction, which has thus far been demonstrated only under specific laboratory conditions, can take several months to complete.17,24-27 It is believed that the sexual stage is the main source of increased variation in fungi, but in A. fumigatus it has not yet been demonstrated in nature (Table 1).28 Parasexual recombination also contributes to increased genetic variation through reshuffling of genes, which may occur in genetically different, but compatible hyphae. Fusion of hyphae allows the nuclei to fuse as well, resulting in a temporally diploid phase where mitotic recombination may occur, before reverting to the normal haploid stage (Figure 1D).29,30 Again, existing genetic variation is thus increased enabling the production of genotypes that are better adapted to a new environment. 
Patient-acquired resistance to azoles In addition to the above-mentioned fungal characteristics, properties related to the drug are important with respect to resistance development. Rapid fungicidal drug activity might reduce the ability of fungi to adapt. In vitro experiments indicate that the polyene amphotericin B is fungicidal against most fungi, including A. fumigatus.31,32 Acquired resistance against polyenes is extremely rare, despite the use of this class in clinical medicine for over 50 years.31 Triazoles show differential fungicidal activity against 
Aspergillus species, and are commonly fungistatic.32 In one study voriconazole exhibited fungistatic activity against 15 of 16 (94%) clinical isolates.32 A. fumigatus may thus survive in the azole-environment, thereby enabling adaptation to occur. However, in 
vitro conditions do not simulate well the in vivo microenvironment, with fluctuating drug concentrations and the presence of effectors of the innate immunity and serum 
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Figure 1. Reproduction modes in A. fumigatus and adaptation strategies in 
response to azole exposure. Panel A, Sexual reproduction (blue line); asexual reproduction (orange line), and parasexual  recombination (purple line). Panel B: Asexual reproduction increases spontaneous mutation supply 
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from mitotic divisions during the production of numerous conidiospores that are produced. Rare resistance mutations may be selected for when exposed to azoles. Panel C: sexual reproduction as an important strategy to enhance genetic diversity in fungi through meiotic recombination. Panel D:  parasexual cycle , which relies on heterokaryons that may arise by mutation or fusion of genetically  different but compatible hyphae and subsequent nuclear fusion. This allows (mitotic) recombination to occur in the transient diploid stage, which results in increased genetic variation.  Whether the presence of  azoles in the environment inf luences these life stages by for instance increasing the mutation frequency or the frequency of any of the reproduction modes (early in the process) is unclear, but it  will provide strong selection pressure after resistant phenotypes have emerged. Black indicates wild-type, and red azole-resistant nuclei .  Other colors represent genetic  variability of the nuclei .   proteins.33 The fungicidal activity of voriconazole increased when tested in the presence of serum, 33 underscoring the more complex dynamics during infection in the host. Azole-resistance selection has been observed in patients during azole therapy. In 154 patients, with mainly chronic pulmonary aspergillosis (CPA), a relationship was found between triazole-treatment history and A. fumigatus triazole MIC.34 The itraconazole-dosage duration positively correlated with the itraconazole MIC (r=0.5700, P<0.0001), and all itraconazole-resistant isolates (MIC > 2 mg/l) were cultured from patients that had been exposed to itraconazole for more than 115 days.34 However, recovery of azole-resistant A. fumigatus during azole therapy could originate through two routes. The patients could inhale azole-resistant airborne spores that are present in the environment, or azole-susceptible A. fumigatus might develop azole-resistance mutations during infection in the host.35,36 Azole-resistance mutations that are associated with the environment commonly consist of alterations in the cyp51A target gene combined with transcriptional enhancers in the promoter region.20,36 Patient-acquired resistance is characterized by point mutations in the Cyp51A-gene or unknown resistance mechanisms.18 However, both environmental and patient-acquired resistance mutations can be found in azole-treated patients.18,37 Patient-acquired resistance can be proven when a switch in phenotype is observed via the culturing of isogenic isolates from consecutive respiratory samples.17,38-41 In a review of eight patients with documented conversion of wild-type to triazole-resistant A. fumigatus, the time between the last culture of an isolate with an azole-susceptible phenotype and the first isolate with an azole-resistant phenotype varied between three weeks to 23 months (median, four months).17 Furthermore, in the majority of patients with patient-acquired resistance, multiple azole-resistance mechanisms emerged during therapy.17,18,34 As many patients with CPA remain culture negative, molecular detection of Aspergillus and resistance mutations directly in respiratory secretions provides further insight in resistance development. For instance, in one study Aspergillus DNA was detected in 15 of 19 patients (78.9%) with allergic bronchopulmonary aspergillosis (ABPA), while all patients were culture negative.37 In CPA patients Aspergillus PCR was positive in 71.4% of patients, compared to 16.9% who were Aspergillus culture-positive.37 In six of eight (75%) ABPA patients and 12 of 24 (50%) with CPA resistance markers were detected by PCR. In four patients cyp51 point mutations were found compared to 16 patients who harbored the combined TR34/L98H mutation, indicating patient- and environment-acquired resistance, respectively.37  
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The risk for patient-acquired resistance appears to be associated with a lung cavity, i.e. chronic cavitary pulmonary aspergillosis or an aspergilloma.17,18,38-40 Histologically, aspergillomas show layers of hyphal growth with a variably dense-layered appearance consistent with extracellular matrix and extracellular DNA, representing an extreme form of biofilm.42 Sometimes conidiophores are present, which might be a key factor for the development of resistance mutations. Indeed, in vitro studies showed that the azole-resistance level in A. fumigatus gradually increased when the fungus was exposed to azole fungicides and underwent asexual sporulation.23 On average, resistance levels were twice as high compared to the same isolates exposed under non-sporulating conditions.23 This is explained by the fact that asexual sporulation provides the opportunity for mutations to be released from the non-resistant mycelium and to fully express their phenotype into a newly formed mycelium founded by this resistant single uninucleate spore (Figure 1B).23 Moreover, asexual sporulation greatly increases the population size allowing for many more possible mutants to be exposed to (azole) selection pressure by increasing the mutation supply through the numerous additional mitoses required to generate all the spores.23 A. fumigatus isolates recovered from sputum of patients with aspergillomas often exhibit a highly atypical macroscopic morphology in culture, with slow growth and poor sporulation.43,44 Microsatellite genotyping of multiple triazole-susceptible and triazole-resistant A. fumigatus colonies derived from dissected aspergillomas indicated extensive genetic changes.42 Both phenotypic and genotypic observations suggest a remarkable ability of A. fumigatus to change within the lung environment. Unlike in cavitary Aspergillus disease, the histology of invasive aspergillosis (IA) shows A. 
fumigatus growing in tissue exclusively through hyphal elongation. As the fungus cannot benefit from one of the above-mentioned reproduction modes, the ability to increase genetic variation is restricted and consequently the risk of azole-resistance development is significantly reduced. Consistent with this notion patient-acquired resistance in IA has not been reported, even in triazole-exposed patients. Long-term prophylactic exposure to posaconazole in 22 lung-transplant recipients colonized with A. fumigatus or with IA showed no evidence for the emergence of resistance.45 The cases of triazole resistance in this patient group are all associated with environmental resistance selection, where 
Aspergillus spores already resistant to azoles are inhaled, rather than resistance selection during therapy.46,47 In cystic fibrosis (CF), patients may be chronically colonized with A. fumigatus. Genotyping indicates that both identical and variable genotypes may be found in sputum cultured over multiple years.48 Triazole resistance in CF has been investigated in several studies. An azole-resistance frequency of 3.4% (4 of 119 colonized CF patients) was reported in Germany,49 4.6% (6 of 131 patients) and 8% (4 of 50 patients) in France,50,51 and 4.5% (6 of 133 patients) in Denmark.48 Several studies indicated that resistance or increased resistance frequency was associated with itraconazole therapy.48,50 The resistance mutations that are found in CF suggest that both environmental- and patient-acquired resistance plays a role.48-51 However, it remains unclear how patient-acquired 
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resistance develops in CF, i.e. which reproductive mode is involved as pulmonary cavities are rarely present. In CF it is thought that A. fumigatus forms hyphal networks that resemble biofilm structures,52 where the fungus may be captured in a hyphal state. As the lungs typically harbor genetically diverse Aspergillus spores,53 this may be a condition where parasex can take place, although this has not been investigated. In IA genetically diverse aspergilli may also be present in the lung,54 but the spores evolve into individual nodular lesions, thus precluding interaction between genetically different hyphae. 
Adaptation to other environmental factors Recent studies indicate that fungi including A. fumigatus sense the host’s immune environment.55,56 Interleukin-17A is the characteristic cytokine of the T-helper 17 (Th17) response that is important for anti-Aspergillus host defense.57,58 In addition to its role of recruiting neutrophils to the site of infection and the induction of antimicrobial peptides, IL-17A can also augment adhesion and filamentous growth of A. fumigatus itself, resulting in enhanced biofilm formation and resistance to local antifungal defenses.55 Furthermore, in vitro models indicate that A. fumigatus becomes increasingly resistant to polyene, azole, and echinocandin antifungal agents throughout morphological differentiation, with the lowest effects against A. fumigatus that had formed an extracellular matrix.59 In addition, effectors of the innate immunity such as antimicrobial peptides, which are induced in bronchial epithelial cells in response to A. fumigatus, exhibit antifungal activity.60 Adaptation through biofilm formation or possibly antimicrobial-peptide-resistance mutations will further enable the fungus to persist in the host. 
Fitness cost and compensatory mutations It is generally expected that resistance mutations come with a cost: in the absence of the antifungal, the resistant genotype has a lower fitness than wild-type isolates.61,62 Due to this fitness cost, the resistant type may disappear when in competition with wild-type isolates in antifungal-free environments. However, A. fumigatus triazole-resistance mechanisms that are associated with the environment, i.e. TR34/L98H and TR46/Y121F/T289A, have no apparent fitness cost and have been successful in survival and migration in the environment.63,64 There are several hypotheses that might explain the lack of a fitness cost: (i) the resistant strains may show this cost in specific environments alone, and so far strains have only been tested under optimal laboratory conditions, (ii) TR34/L98H and TR46/Y121F/T289A may have already developed mutations that compensate for any fitness cost by exposure to an azole-free environment (compensatory evolution; see below), and (iii) the tandem repeat (TR) in the promoter region might be the compensatory mutation for the point mutations present in the Cyp51A-gene. When wild-type A. fumigatus is cultured in the presence of an azole, the colony will grow at a much slower rate than in the azole-free environment (Figure 2). Following prolonged azole exposure a sector may appear due to the outgrowth of A. fumigatus that 
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has acquired azole resistance and thus has an increased growth rate in the presence of the azole. However, when this azole-resistant colony is transferred to an azole-free environment, the growth rate is lower compared to the original wild-type isolate. The reduced growth rate is considered the fitness cost associated with the acquisition of azole resistance. Continued incubation in the azole-free environment shows the emergence of one or multiple sectors with an increased growth rate (Figure 2). These sectors contain A. fumigatus that has (partly) overcome the fitness cost due to compensatory mutation(s). The isolate remains azole-resistant, but now has high fitness both in azole-containing and azole-free environments. Similar observations have been reported in A. nidulans when exposed to the fungicide fludioxonil.62 Thus, alternating between growth conditions with and without the fungicide resulted in a growth rate that was actually greater than that of the original isolate.62 Comparably, triazole-resistant A. fumigatus cultured from triazole-treated CPA-patients may show an abnormal growth rate or sporulation when brought from an azole-exposed lung tissue to an azole-free agar plate; starkly different conditions that are likely to reveal any resistance-associated fitness cost.43 However, in such azole-free environments, the resistant genotype may regain fitness by accumulating mutations that decrease the fitness disadvantage while resistance remains unaffected.  Importantly, when the concept of compensatory evolution is extrapolated to Aspergillus infections, stopping triazole therapy would be an incentive for resistant A. fumigatus to accumulate compensatory mutations that overcome any potential fitness costs. As A. 
fumigatus is able to adapt to an azole-free environment under laboratory conditions, it seems likely that this might also occur in the human lung during infection or colonization. This hypothesis is currently unexplored in Aspergillus diseases, but its potentially significant implications for patient disease management warrants research into these aspects of adaptation. 
A clinical example A 36-year-old male diagnosed with X-linked chronic granulomatous disease was admitted to the hospital due to swelling and pain of the right clavicula without previous trauma. The patient had a long history of A. fumigatus diseases including aspergilloma and three episodes of IA. He had developed severe chronic obstructive pulmonary disease (Gold IV) and allergic bronchopulmonary aspergillosis. He later developed a second aspergilloma, which could not be surgically removed due to his poor respiratory condition. The patient received prophylaxis with interferon-gamma, trimethoprim-sulphamethoxazole, and itraconazole. CT-scan showed a subcutaneous abscess with involvement of the sterno-clavicular joint. Tissue biopsies confirmed the presence of A. 
fumigatus. Between 2011 and 2013 the patient was treated with various antifungal regimens including switching between various azole drugs, combination therapy or polyene-based therapy (Figure 3). Despite these efforts, eradication of the fungus was not achieved and the patient died. Between 2011 and 2013 thirteen A. fumigatus isolates were cultured with various, often atypical, macroscopic phenotypes (Figure 3), while 
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genotyping using microsatellite markers showed the same genotype in all 13 isolates.54 Analysis of the azole-resistance phenotype and genotype, showed increasing resistance to the medical triazoles over time, ultimately resulting in a high-level pan-triazole-resistant phenotype (Figure 3). The variation of the colony morphology suggests that azole resistance was accompanied with a fitness cost, i.e. the fungus had adapted to growth in the azole-exposed lung environment, and showed difficulty in growing in the absence of azoles. However, the phenotypes in terms of growth rate and sporulation were highly diverse, suggesting that some strains were better adapted to growth in the absence of azoles than others.  
On the horns of a dilemma We hypothesize that A. fumigatus is capable of efficiently adapting to the lung environment through the successive acquisition and selection of mutations that increases its fitness in the new environment. As the fungus is exposed to many stress factors, including antifungal azoles and effectors of the innate immunity, the generation of new mutations and subsequent natural selection will facilitate that it can overcome these factors. The mode of reproduction is probably important, with clinical and experimental data supporting a pivotal role for asexual reproduction. Switching between triazole compounds is recommended in the management of CPA in patients who are intolerant or fail to other azole compounds.11,65 However, this approach might lead to accumulation of new resistance mutations, ultimately resulting in a high-level pan-triazole-resistant phenotype. Patients with high-level pan-triazole-resistant A. 
fumigatus have been reported, some with a history of multiple-triazole-treatment regimens.66 Switching between triazoles will ultimately be ineffective if eradication of 
Aspergillus is not achieved (Figure 4). Moreover, experimental evolution indicates that when A. fumigatus is brought into an azole-free environment, compensatory mutations might occur that overcome any fitness costs associated with resistance development (Figure 2). Triazole therapy is commonly stopped in patients when azole resistance is documented and clinical experts recently recommended moving away from triazole monotherapy in azole-resistant Aspergillus disease.67 In patients with CPA this approach may result in gain of fitness of the fungus, especially in case repeated courses of triazoles are given and again stopped (Figure 4). The presence and clinical implications of compensatory evolution in A. fumigatus is largely unknown. Mutations associated with the patient route of resistance development, M220 and G54, have recently been recovered from the environment.68,69 Although it is unclear whether these mutations arose through hospital azole use, any fitness cost could have been overcome by compensatory evolution thus allowing survival in their natural environments.  The two above-mentioned scenario’s lead to outcomes neither of which are desirable for 
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the patient, but these evolutionary trajectories ultimately benefit the fungus. Our hypothesis is that the longer the fungus is tolerated in the human lung environment and has the opportunity to adapt, the more difficult it will become to achieve eradication. More studies are needed to gain insight in the genomic dynamics of A. fumigatus during human infection, as these concepts challenge current management strategies. At present chronic colonization is accepted in some patient groups, especially if the clinical implications of colonization are unclear (CF) or colonization is asymptomatic (aspergilloma). The question is whether this “adaptation opportunity” will decrease the likelihood of fungal eradication when treatment is indicated. Long-term triazole monotherapy is recommended in CPA, with response evaluations after six or nine months of therapy.65 The accumulation of resistance mutations in triazole-treated patients, indicates that this approach allows for fungal adaptation and questions whether a multi-targeted approach might be more successful in preventing or delaying adaptation. For instance, first-line combination therapy might be more effective, despite the obvious drawbacks of administration of the non-azole drug or antifungal therapy in combination with immune enhancement. For instance, experimental models indicate that the clearance of invasive pulmonary aspergillosis is enhanced by overexpression of gamma interferon.70 
Figure 4. Two scenarios both leading to unfavorable clinical outcomes in patients 
with persistence of A. fumigatus infection
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Future research Adaptation and persistence of A. fumigatus will be difficult to avoid as some patients have life-long conditions that make them vulnerable to aspergillosis. However, recent insights in azole-resistance development warrants further research into the biology of A. 
fumigatus in the human environment. It is important to investigate which strategies A. 
fumigatus employs during infection to increase its genetic diversity, especially in relation to the mode of reproduction and Aspergillus disease. This starts with analyzing individual colonies cultured from patients with chronic Aspergillus diseases. Serially-isolated strains could be subjected to high-resolution genotyping through next-generation sequencing (NGS), as this would give insight in the dynamics of genomic changes. With greater access to this technology studies are emerging that apply NGS to clinical Aspergillus isolates, reporting both accumulation of mutations and genomic deletions that appeared to have occurred randomly in isolates recovered from an aspergilloma.71,72 Genomic changes could also provide clues to the mode of reproduction from which the changes originated. The observed genetic changes need to be correlated to phenotypic changes, such as resistance or general fitness, which might prove difficult given the diversity of stress factors the fungus is exposed to. Therefore, experimental evolution may in addition be utilized to identify specific genes or factors that are associated with adaptation. Furthermore, sexual crossings with A. fumigatus have been successfully used to identify mutations that are associated with azole resistance.73,74 Discovery of such resistance mechanisms allow us to improve (molecular) diagnostics for resistance detection, and may also provide new targets for drug development. With the biologicals that target important components of the anti-Aspergillus host defense, such as anti-TNF and anti-IL-17, it can be expected that the inflammatory environment is significantly altered leading to a different composition of immune cells and cytokines and therefore a different environmental pressure on Aspergillus. Insights in the fungus-host interaction might provide leads for new treatment strategies and ultimately will help us to improve our management strategies of patients with aspergillosis. 
Conclusions Azole resistance is the showcase of efficient adaptation strategies in A. fumigatus in the human host. The fungus can utilize various strategies to overcome environmental stress factors depending on its morphological state. As fungal adaptation results in treatment failure and fungal persistence, the biology of A. fumigatus during infection and colonization needs to be understood in order to design strategies that prevent or overcome adaptation.  
Search strategy and selection criteria We searched PubMed from Jan 1, 1966, to March 31, 2016, using the terms “Aspergillus 
fumigatus and azole and resistance” and “fungal and adaptation”, and selected the most relevant articles. Only articles in English were reviewed. Relevant references included in these publications were also used. We added additional references from our personal files as needed. 
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Abstract	
Understanding	the	occurrence	and	spread	of	azole	resistance	in	Aspergillus	fumigatus	is	
crucial	 for	 public	 health.	 It	 has	 been	 hypothesized	 that	 asexual	 sporulation,	 which	 is	
abundant	in	nature,	is	essential	for	phenotypic	expression	of	azole‐resistance	mutations	
in	A.	fumigatus	 facilitating	 subsequent	 spread	 through	 natural	 selection.	 Furthermore,	
the	 disease	 aspergilloma	 is	 associated	 with	 asexual	 sporulation	 within	 the	 lungs	 of	
patients	 and	 the	 emergence	 of	 azole	 resistance.	 This	 study	 assessed	 the	 evolutionary	
advantage	of	 asexual	 sporulation	by	growing	 the	 fungus	under	pressure	of	one	of	 five	
different	 azole	 fungicides	 over	 seven	weeks	 and	 by	 comparing	 the	 rate	 of	 adaptation	
between	 scenarios	 of	 culturing	 with	 and	 without	 asexual	 sporulation.	 Results	
unequivocally	 show	 that	 asexual	 sporulation	 facilitates	 adaptation.	 This	 can	 be	
explained	by	the	combination	of	more	effective	selection	because	of	the	transition	from	
a	 multicellular	 to	 a	 unicellular	 stage,	 and	 by	 increased	 mutation	 supply	 due	 to	 the	
production	 of	 spores,	 which	 involves	 numerous	 mitotic	 divisions.	 Insights	 from	 this	
study	 are	 essential	 to	 unravel	 the	 resistance	mechanisms	 of	 sporulating	 pathogens	 to	
chemical	 compounds	 and	 disease	 agents	 in	 general,	 and	 for	 designing	 strategies	 that	
prevent	or	overcome	the	emerging	threat	of	azole	resistance	in	particular.		
Key	words:	Aspergillus	fumigatus;	 azole	 resistance;	 asexual	 sporulation;	 experimental	
evolution;	alternation	between	unicellular	and	multicellular	growth;	MIC	value;	mycelial	
growth	rate	
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Introduction	
Aspergillus	fumigatus,	 a	 common	 saprophytic	 fungus,	 is	 abundant	 in	 soil	 and	decaying	
organic	matter	(Bignell	2014;	Cuenca‐Estrella	2014)	and	produces	numerous	airborne	
spores.	As	such	it	is	generally	considered	to	be	harmless	to	humans	and	can	be	found	in	
houses	 (e.g.	 bathrooms),	 offices	 (e.g.	 ventilation	 vents),	 and	 also	 in	 hospitals	 (Haas	
2011).	 However,	 this	 fungus	 may	 cause	 a	 wide	 range	 of	 non‐invasive	 or	 invasive	
diseases	 in	 immunocompromised	 patients	 (Latgé	 1999;	 Rhodes	 2006;	 Snelders	 et	 al.	
2012;	Kwon‐Chung	 and	Sugui	 2013;	Bignell	 2014;	Rocchi	 et	 al.	 2014),	where	 invasive	
aspergillosis	is	a	major	cause	of	mortality	and	morbidity	(Cunha	et	al.	2013).	Azoles	are	
the	most	widely	used	antifungal	drugs	in	medical	treatment,	especially	triazoles,	such	as	
itraconazole,	 posaconazole	 and	 voriconazole	 (Albarrag	 et	 al.	 2011).	 These	 triazoles	
inhibit	 sterol	 14α‐demethylase,	 encoded	 by	 the	 cyp51A	 gene,	 thereby	 blocking	 its	
function	in	the	fungal	ergosterol	biosynthesis	pathway,	resulting	in	ergosterol	depletion	
and	accumulation	of	toxic	sterols	(Joseph‐Horne	and	Hollomon	1997).		
Unfortunately,	 the	 emergence	 and	 spread	 of	 azole	 resistance	 has	 been	 increasingly	
reported,	 with	 prevalence	 from	 0.8	 ‐	 9.5%	 in	 the	 various	 medical	 centres	 in	 the	
Netherlands	during	2007‐2009	(van	der	Linden	et	al.	2011).	In	the	United	Kingdom,	the	
National	Aspergillosis	Centre	(Manchester,	UK)	described	an	increase	of	azole‐resistant	
isolates,	increasing	from	7%	in	1997	to	20%	in	2009	(Howard	et	al.	2006;	Howard	et	al.	
2009;	 Bueid	 et	 al.	 2010).	 Indeed,	 azole	 resistance	 has	 been	 reported	 also	 in	 other	
European	 countries,	 the	Middle	East,	Asia,	 and	most	 recently	 in	Africa	 (Snelders	 et	 al.	
2008;	Arendrup	 et	 al.	 2010;	 Lockhart	 et	 al.	 2011;	Mortensen	 et	 al.	 2011;	 Pfaller	 et	 al.	
2011;	Chowdhary	et	al.	2012;	Morio	et	al.	2012;	Gisi	2013;	Bignell	2014;	Chowdhary	et	
al.	2014).	Clearly,	azole	resistance	is	a	growing	concern	as	patients	with	azole‐resistant	
A.	 fumigatus	 have	 a	 high	 probability	 of	 treatment	 failure,	 and	 alternative	 treatment	
options	 are	 limited	 (Seyedmousavi	 et	 al.	 2014).	 To	 control	 this	 problem	 we	 need	 to	
elucidate	 by	what	mechanism(s)	 the	 resistance	 emerges,	 how	 it	 can	 spread,	 and	 how	
resistant	genotypes	can	persist	in	environments	without	azoles.	
Several	studies	focussed	on	the	origin	of	azole	resistance	and	tested	A.	fumigatus	strains	
for	azole	resistance	isolated	from	both	clinical	and	environmental	settings	(Mellado	et	al.	
2007;	Howard	et	al.	2009;	Snelders	et	al.	2009;	Arendrup	et	al.	2010;	Mortensen	et	al.	
2010).	These	studies	showed	that	highly	resistant	strains	were	recovered	from	compost,	
flowerbeds	and	agricultural	fields,	as	well	as	from	patients	with	Aspergillus	diseases.	In	
addition,	recent	studies	indicated	that	azoles	used	in	agricultural	settings	can	select	for	
resistance	(Snelders	et	al.	2012;	Chowdhary	et	al.	2013;	Verweij	et	al.	2013;	Bowyer	and	
Denning	 2014),	 especially	 the	 azole	 fungicides	 bromuconazole,	 tebuconazole,	
epoxiconazole,	 difenoconazole	 and	 propiconazole,	 which	 are	 widely	 used	 in	 crop	
protection	 and	 material	 preservation.	 It	 is	 hypothesised	 that	 resistance	 to	 these	
fungicides	 is	 selected	 especially	 in	 these	 non‐clinical	 environments.	When	 susceptible	
patients	subsequently	inhale	fungicide‐resistant	A.	fumigatus	spores,	Aspergillus	disease	
CHAPTER III                                  
50 
 
may	 develop	 to	 which	 the	 medical	 triazoles	 are	 ineffective	 due	 to	 high	 molecule	
similarity	 to	 the	 five	 “environmental”	 azole	 fungicides.	 However,	 previous	 studies	 did	
not	allow	for	the	identification	of	the	factors	facilitating	the	emergence	of	resistance	and	
the	 responsible	 evolutionary	 mechanism(s).	 This	 is	 what	 we	 address	 in	 the	 present	
study.	
This	study	focuses	on	the	asexual	stages	of	the	life	cycle	of	A.	fumigatus	and	in	particular	
on	 the	 possible	 role	 of	 asexual	 sporulation	 in	 facilitating	 adaptation	 of	 the	 fungus	 to	
azole	 environments.	 Similar	 to	 that	 of	 the	 model	 species	 A.	nidulans,	 unicellular	 and	
multicellular	 states	 alternate	 during	 the	 life	 cycle	 (whether	 it	 be	 asexual,	 sexual,	 or	
parasexual)	and	selection	can	act	on	both	states	(Casselton	and	Zolan	2002;	Bruggeman	
et	al.	2004;	Mah	and	Yu	2006;	Schoustra	et	al.	2006;	O’Gorman	et	al.	2008).	The	asexual	
part	 of	 the	 life	 cycle	 is	 by	 far	 the	 most	 common	 in	 nature	 providing	 an	 alternation	
between	multicellular	and	unicellular	states	by	the	generation	of	ubiquitous	uninucleate	
asexual	 spores	 (through	 numerous	 mitotic	 divisions)	 that	 after	 dispersal	 and	
germination	 can	 generate	multinucleate	mycelia	 that	 again	 produce	 numerous	 spores	
that	become	airborne	(Figure	1A).		
	
Figure	1.	The	asexual	life	cycle	of	Aspergillus	fumigatus	and	hypothesis	of	escaping	
strategy	
A:	The	asexual	cycle	starts	with	the	formation	of	a	mycelium	that	can	be	initiated	by	a	single	
uninucleate	haploid	spore	(either	an	asexual	conidiospore	or	a	sexual	ascospore). 	Mitotic	division	
in	the	mycelium	takes	place	in	the	apical	cells	at	the	growing	front	of	the	colony	(Casselton, 	2002). 	
After	one	to	two	days, 	mycelial 	cells	differentiate	into	aerial	hyphae	with	a	foot	cell 	and	a	spore	
head	(conidiophore)	covered	with	conidiogenous	cells	(phialides). 	Around	three	days	after	
initiation	of	the	multicellular	mycelium	these	conidiogenous	cells	produce	numerous	unicellular	
and	uninucleate	asexual	spores	by	mitotic	divisions. 	Thus	a	single	spore	may	give	rise	to	up	to	109	
new	asexual	spores	in	3‐4	days	under	favourable	conditions.	
B: 	In	the	multicellular	mycelium	with	mixed	nuclei, 	resistant	mutated	nuclei 	have	l imited	or	no	
effect	on	the	resistance	phenotype	as	they	are	outnumbered	by	sensitive	nuclei. 	After	asexual	
sporulation	(alternation	from	multicellular	mycelium	to	unicellular	spores), 	the	resistant	and	
sensitive	nuclei 	get	separated	and	the	former	can	express	their	superior	phenotypes	in	an	azole	
environment	(modified	with	permission	from	P. 	E	Verweij, 	(Verweij, 	2009). 	
Previously,	 Verweij	 et	 al.	 hypothesized	 that	 asexual	 sporulation	 is	 essential	 for	
phenotypic	expression	of	azole‐resistance	mutations	 in	A.	fumigatus	in	 clinical	 settings	
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(Verweij	 et	 al.	 2009).	 This	 idea	 is	 based	 on	 the	 fact	 that	 when	 a	 resistance	mutation	
occurs	during	vegetative	growth	in	the	multinucleate	mycelium,	the	resulting	resistant	
nucleus	is	initially	surrounded	by	sensitive	nuclei	in	a	heterokaryotic	cell.	All	else	being	
equal,	 if	 resistance	 mutations	 are	 at	 least	 partially	 recessive,	 resistance	 is	 not	 fully	
expressed	 into	 the	phenotype	when	also	 sensitive	nuclei	 are	present	 in	 the	mycelium.	
Crucially	then,	the	formation	of	uninucleate	asexual	spores	would	allow	resistant	nuclei	
to	 escape	 from	 the	 heterokaryotic	 mycelium	 so	 that,	 after	 germination,	 the	 resistant	
phenotype	 would	 be	 fully	 expressed	 (Figure	 1B).	 This	 mechanism	 could	 take	 place	
within	 the	 lungs	 of	 patients,	 since	 sporulation	 propagative	 structures	 have	 been	
observed	 in	 patients	 with	 cavitary	 Aspergillus	 diseases.	 Furthermore,	 resistance	
selection	during	azole	therapy	has	been	reported	in	these	patients	(Camps	et	al.	2012).	
In	cavitary	Aspergillus	diseases,	such	as	chronic	cavitary	aspergillosis	and	aspergilloma,	
A.	fumigatus	undergoes	asexual	sporulation,	as	opposed	to	invasive	aspergillosis,	which	
involves	 only	 hyphal	 growth.	 This	 clinical	 observation	 also	 shows	 that	 various	 fungal	
morphotypes	exist	within	patients	and	suggests	that	there	is	a	link	between	sporulation	
and	 resistance	 development	 in	 patients.	 Therefore,	 it	 is	 crucial	 to	 study	 the	 role	 and	
consequence	 of	 asexual	 sporulation	 to	 understand	 the	 invasive	 infection	 in	 immune‐
compromised	patients.	
In	 this	 study,	 we	 investigated	 the	 effect	 of	 asexual	 sporulation	 on	 the	 emergence	 of	
resistance	to	five	different	azole	fungicides	of	A.	fumigatus	 in	a	laboratory	evolutionary	
experiment.	 This	 was	 done	 by	 contrasting	 the	 rate	 of	 development	 of	 resistance	 to	
azoles	 in	A.	fumigatus	during	 seven	weeks,	 in	 six	 replicate	 cultures,	with	 two	different	
treatments:	 cultured	either	without	 asexual	 sporulation	 (continued	mycelium	growth)	
or	 serially	 cultured	 allowing	 asexual	 sporulation.	 For	 the	 experimentally	 evolved	
cultures	 of	 each	 contrast	 and	 replicate,	 we	 measured	 resistance	 levels	 and	 mycelial	
growth	 rate	 (fitness).	 Five	different	 azole	 fungicides	were	 compared	 for	 their	 induced	
levels	of	azole	resistance.	Furthermore,	we	assayed	whether	resistance	mutations	were	
dominant	 or	 recessive	 in	 one	 of	 the	 evolutionary	 lineages,	 testing	 the	 underlying	
assumption	 that	 resistant	 nuclei	 are	 not	 (fully)	 expressed	 in	 the	 phenotype	 of	
multicellular	mycelium.		
	
Materials	and	Methods	
	
Fungal	isolates	and	azole	fungicides		
Azole	 fungicides	 (bromuconazole	 [b],	 tebuconazole	 [t],	 epoxiconazole	 [e],	
difenoconazole	[d],	and	propiconazole	[p])	were	purchased	from	Sigma	Company	(Sigma	
Aldrich,	 Germany).	 Aspergillus	 fumigatus	 CBS	 140053	 was	 isolated	 from	 an	
environmental	field	in	Wageningen	in	1992	in	our	laboratory	at	Wageningen	University	
before	 these	 azole	 fungicides	were	 applied	 to	 the	 environment	 (Snelders	 et	 al.	 2012;	
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Bowyer	and	Denning	2014).	This	strain	is	sensitive	to	our	five	azole	fungicides	and	was	
used	as	the	ancestor	of	the	evolution	experiment.	
Experimental	 evolution	 of	 A.	 fumigatus	 with	 and	 without	 asexual	
sporulation	under	the	selection	pressure	of	azole	fungicides		
In	 a	 seven‐week	 experimental	 evolution	 set‐up,	 the	 culturing	 of	 A.	 fumigatus	 CBS	
140053	with	and	without	asexual	sporulation	was	contrasted.	For	both	 treatments	we	
founded	six	 lineages	 for	each	of	 the	 five	azole	 fungicides	and	six	 lineages	without	any	
fungicide	as	a	 control.	 Seven	 time	points	 for	each	 lineage	were	sampled	and	stored	 in	
our	“frozen	fossil	record”.	Thus,	the	total	number	of	samples	was	505	[two	treatments	*	
(5	azoles	+	control)	*	6	replicates	*	7	time	points	+	ancestor	=	505].	
For	the	serial	sub‐culturing	treatment	allowing	for	asexual	sporulation,	parallel	lineages	
were	inoculated	with	104	ancestral	spores	in	a	5	µl	droplet	into	a	bottle	with	10	ml	solid	
Malt	 Extract	 Agar	 (MEA)	medium,	 which	 contained	 1	 µg/mL	 of	 one	 of	 the	 five	 azole	
fungicides.	 This	 amount	 of	 azole	 is	 based	 on	 the	 application	 of	 these	 fungicides	
estimated	 if	 a	 soil	 layer	of	1	 cm	 is	 considered	 in	agricultural	 fields	 (Gisi	2013).	Under	
this	 concentration	A.	fumigatus	 is	 able	 to	 sporulate.	 After	 seven	 days	 of	 incubation	 at	
37	 Ԩ,	 all	 material	 including	 spores	 from	 each	 bottle	 was	 harvested:	 2	 mL	 of	 saline	
(distilled	 water	 with	 NaCl	 0.8	 g/L)	 supplemented	 with	 Tween	 80	 (0.05	 %	 v/v)	 and	
beads	were	 added	 to	 the	bottle	 that	was	 subsequently	 vortexed	 for	5	minutes	 (Sigma	
Aldrich,	 Germany).	 Five	 µL	 of	 each	 suspension	was	 used	 to	 initiate	 the	 next	 selection	
cycle	 and	 the	 rest	 was	 stored	 at	 ‐80Ԩ	 after	 adding	 one	 volume	 of	 a	 50%	 glycerol	
solution	for	the	“frozen	fossil	record”(Schoustra	et	al.	2006;	Schoustra	et	al.	2009).	This	
procedure	was	repeated	every	seven	days	for	seven	rounds	of	selection.		
For	 the	 treatment	where	asexual	 sporulation	was	not	 allowed,	 cultures	were	 initiated	
with	spores	at	one	end	of	a	race	tube	and	allowed	to	grow	undisturbed	for	seven	weeks.	
A	race	 tube	 is	a	50	mL	disposable	pipette	 filled	with	25	mL	MEA	medium,	and	 for	 the	
azole	 treatment	 supplemented	 with	 1	 µg/mL	 of	 one	 of	 each	 of	 the	 azole	 fungicides,	
solidified	horizontally,	in	which	the	mycelial	growth	can	be	tracked.	The	race	tubes	were	
then	incubated	in	a	37	Ԩ	incubator	for	seven	weeks.	Without	disturbing	the	race	tubes	
(so	that	the	asexual	spores	produced	behind	the	growth	front	of	the	mycelia	could	not	
contribute	 to	 the	 development	 of	 azole	 resistance),	 the	 growth‐front	 of	 the	 fungi	was	
marked	 every	 week.	 After	 seven	weeks	 of	 continued	mycelial	 growth,	 the	 race	 tubes	
were	opened	 at	 the	weekly	markings	 to	harvest	material	 that	we	 suspended	 in	 saline	
(distilled	water	with	NaCl	0.8	g/L)	supplemented	with	Tween	80	(0.05%	v/v)	and	one	
volume	of	a	50%	glycerol	solution	for	storage	in	our	“frozen	fossil	record”.	
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Resistance	 testing	 of	 cultures	 evolved	 with	 and	 without	 asexual	
sporulation	against	azole	fungicides		
The	resistance	level	of	all	lineages	that	had	evolved	in	the	presence	or	absence	of	azole	
fungicides	 over	 seven	 weeks	 was	 tested.	 Half	 the	 cultures	 had	 gone	 through	 seven	
weekly	cycles	of	asexual	sporulation,	while	the	other	half	had	grown	by	seven	weeks	of	
mycelial	extension	continuously.	Resistance	level	was	defined	as	the	minimal	inhibitory	
concentration	 (MIC)	 of	 the	 azole	 fungicide	 that	 results	 in	 100%	 growth	 inhibition	 of	
fungal	growth.	The	relative	MIC	is	defined	as	the	average	MIC	divided	by	the	MIC	of	the	
azole	 fungicide	 sensitive	 ancestor	 A.	 fumigatus	 CBS	 140053.	 The	 resistance	 test	 was	
performed	 following	 the	 European	 Committee	 on	 Antimicrobial	 Susceptibility	 Testing	
(EUCAST)	reference	method	(Lass‐Flörl	et	al.	2008):	RPMI‐1640‐	2	%	glucose	medium	
(Sigma	 Aldrich,	 Germany)	 was	 supplemented	 with	 bromuconazole,	 tebuconazole,	
epoxiconazole,	difenoconazole	or	propiconazole,	ranging	from	0.016	to	16	mg/L	in	two‐
fold	 concentration	 steps	 and	 loaded	 into	 96‐well	 plates.	 Spore	 suspensions	 used	 to	
initiate	 the	 assay	 were	 prepared	 in	 saline	 with	 0.05%	 Tween	 80	 (Sigma	 Aldrich,	
Germany)	 and	 counted	 on	 a	 Coulter	 counter	 (Coulter	 USA)	 to	 standardize	 the	
concentration	of	spores	to	1‐2.5×105	CFU/mL	(Bos	et	al.	1988).	The	standardized	spore	
suspension	 was	 inoculated	 into	 flat‐bottomed	 96‐well	 microtiter	 plates	 containing	 a	
series	with	increasing	amounts	of	fungicide	in	RPMI‐1640‐	2%	G	medium,	and	incubated	
at	 37Ԩ	 for	 48	 h.	 Readings	 from	 the	 bottom	 of	 the	microtiter	 plates	 were	 performed	
using	 a	 mirror	 to	 determine	 at	 which	 concentration	 we	 observed	 100	 %	 inhibition,	
resulting	 in	 the	MIC	value	estimates	 (Camps	et	 al.	 2012).	 Six	 replicates	 for	each	assay	
were	 used.	 We	 (arbitrarily)	 classified	 the	 MIC	 as	 32	 mg/L	 when	 we	 observed	 no	
inhibition	at	the	concentration	of	16	mg/L.		
	
Mycelial	 growth	 rate	 of	 cultures	 evolved	 with	 and	 without	 asexual	
sporulation	
The	 mycelial	 growth	 rate	 (MGR)	 of	 all	 cultures	 that	 had	 evolved	 under	 laboratory	
conditions	in	the	presence	or	absence	of	azole	fungicides	over	seven	weeks	was	assayed.	
Spore	suspensions	of	all	evolved	cultures	were	 inoculated	onto	Petri	dishes	with	solid	
MEA	 medium	 containing	 1	 μg/mL	 of	 the	 azole	 fungicide	 that	 was	 used	 during	 the	
evolution	 experiment,	 either	 with	 an	 inoculation	 needle	 or	 with	 a	 five	 µL	 spore	
suspension.	After	4	days	of	incubation	at	37	Ԩ,	the	MGR	was	determined	by	averaging	
the	 colony	 diameters	 (in	 mm)	 as	 measured	 in	 two	 randomly	 chosen	 perpendicular	
directions.	The	relative	MGR	is	defined	as	the	MGR	divided	by	the	colony	diameter	of	the	
azole	 fungicides	 sensitive	 ancestor	A.	 fumigatus	 CBS	 140053,	 grown	 on	MEA	medium	
without	 azole	 fungicides	 (De	Visser	 et	 al.	 1997;	 Schoustra	 et	 al.	 2006;	 Schoustra	 et	 al.	
2009).		
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Dominance	 test	of	resistance	mutation	 in	diploids	and	heterokaryon	
of	one	of	the	evolutionary	lineages			
A.	 fumigatus	 predominantly	 grows	 as	 a	 haploid.	 Whether	 azole‐resistance	 mutations	
were	 dominant	 or	 recessive	 in	 a	 heterozygous	 diploid	 as	 well	 as	 in	 a	 heterokaryon	
(mycelium	 containing	 multiple	 types	 of	 nuclei)	 was	 investigated	 from	 one	 of	 the	
evolutionary	 lineages.	 Spontaneous	 nitrate	 non‐utilizing	 mutations	 nia	 (nitrate	 non‐
utilizing)	and	cnx	(nitrate	and	hypoxanthine	non‐utilizing)	were	selected	on	the	basis	of	
chlorate	 resistance	as	selective	complementing	markers	 to	 facilitate	heterokaryon	and	
diploid	construction	(Cove	1976;	Debets	et	al.	1990).	Heterokaryons	and	diploids	were	
constructed	 using	 standard	 methods:	 an	 azole	 sensitive	nia‐strain	 and	 a	 highly	 azole	
resistant	 cnx	–strain	 (D1‐7#,	 derived	 from	 the	 end	 culture	 evolved	 in	 the	 presence	 of	
difenoconazole)	 were	 used	 for	 selection	 of	 heterokaryons	 on	 minimal	 medium	 (MM)	
with	nitrate	 as	 the	only	N‐source.	Asexual	 spores	 from	heterokaryons	were	harvested	
and	plated	in	sandwich	plates	to	select	for	heterozygous	diploids	(Todd	et	al.	2007).	We	
found	a	 frequency	of	heterozygous	diploid	 spores	of	 approximately	10‐5.	Diploidy	was	
verified	by	measuring	the	size	of	condiospores	‐	the	diameter	of	spores	of	diploids	is	3.2	
μm	(±0.2	SEM),	which	is	1.45	times	that	of	haploids	(2.2	μm	±0.2SEM)	‐	 the	volume	of	
diploid	spores	thus	being	three	times	that	of	haploids.	The	growth	of	the	azole	sensitive	
nia	 mutant	 and	 the	 highly	 azole‐resistant	 evolved	 strain	 D1‐7#	(cnx),	 were	 tested	 on	
MM+5mM	 urea	with	 1	 µg/ml	 concentration	 of	 difenoconazole.	 The	 heterokaryon	 and	
diploid	were	tested	on	MM	medium	with	1µg/ml	concentration	of	difenoconazole.	The	
level	of	resistance	was	measured	as	the	relative	MGR	(see	above).	
	
Stability	test	of	azole	fungicides	over	the	evolutionary	experiment		
In	order	to	verify	whether	the	five	azole	fungicides	were	stable	during	the	seven	weeks	
of	 experimental	 evolution,	 24	 petri	 dishes	 with	 1	 µg/mL	 of	 each	 of	 the	 five	 azole	
fungicides	were	prepared.	Of	these,	21	plates	were	incubated	at	37	Ԩ	and	the	remaining	
three	plates	were	kept	at	4	Ԩ	as	the	control.	At	the	end	of	each	week,	three	plates	were	
removed	from	the	incubator	and	stored	at	4	Ԩ	till	the	end	of	week	seven,	when	all	plates	
had	been	removed.	After	 this,	5	µL	of	a	 fresh	ancestor	A.	fumigatus	CBS	140053	spore	
suspension	was	 inoculated	 in	 the	middle	of	 each	plate	 and	 incubated	at	37	Ԩ	 for	 five	
days.	The	mycelial	 growth	 rate	on	all	 plates	was	 recorded,	MGR	was	 compared	 to	 the	
three	stored	control	plates	and	the	known	MGR	of	the	strain	on	freshly	prepared	plates.	
	
Statistical	analysis	
We	used	a	 general	 linear	model	 (analysis	of	 variance;	ANOVA)	 that	 included	 the	 fixed	
factors	 “sporulation	 treatment”	 and	 “azole	 fungicide”,	 and	 their	 interaction,	 to	 explain	
the	observed	variation	in	relative	MGR	and	relative	MIC	of	the	evolved	strains	(model:	
Relative	MGR~	azole	fungicide	(A),	sporulation	treatment	(S),	A*S;	Relative	MIC~	azole	
fungicide	 (A),	 sporulation	 treatment	 (S),	 A*S).	 Furthermore,	 since	 the	 effects	 of	 the	
sporulation	treatment	depended	on	the	azole	fungicide	(see	Results),	we	performed	one	
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way	 ANOVAs	 to	 test	 for	 the	 effect	 of	 sporulation	 treatment	 for	 each	 azole	 separately	
(model	 for	 each	 azole	 separately:	 Relative	 MGR~	 sporulation	 treatment	 and	 Relative	
MIC~	 sporulation	 treatment).	 Finally,	 a	 one	 way	 ANOVA	 and	 following	 post‐hoc	 LSD	
tests	were	used	to	check	whether	the	achieved	level	of	resistance	depended	on	the	azole	
fungicide	used	 for	 selection.	This	was	done	 separately	 for	each	 sporulation	 treatment,	
using	 the	 following	model	 (Relative	 MGR~	 azole	 treatment,	 and	 Relative	 MIC~	 azole	
treatment).	A	one	way	ANOVA	and	following	post‐hoc	LSD	tests	were	also	used	to	test	
the	difference	in	the	induced	level	among	five	azole	fungicides,	for	the	difference	in	the	
MGR	of	diploid,	haploid	and	heterokaryons.	
	
Results	
	
Asexual	sporulation	enhanced	resistance	level	over	evolutionary	time		
The	 resistance	 level	 was	 assayed	 of	 all	 lineages	 that	 had	 evolved	 under	 laboratory	
conditions	in	the	presence	or	absence	of	an	azole	fungicide	over	seven	weeks.	Half	the	
cultures	had	gone	through	seven	cycles	of	asexual	sporulation,	while	the	other	half	had	
grown	continuously	by	mycelial	extension.	Five	different	azole	fungicides	were	applied.	
Figures	 2A	and	2B	 show	 the	 average	 resistance	 level	 (defined	 as	 the	 relative	Minimal	
Inhibitory	 Concentration,	 of	 a	 given	 azole	 relative	 to	 the	 MIC	 of	 the	 ancestor)	 and	
evolutionary	dynamics	of	the	average	of	the	six	replicate	lineages	within	each	treatment.	
Our	 statistical	 analysis	 showed	 that	 the	 sporulation	 treatment	 is	 a	 key	 factor	 (F1,	50	=	
31.696,	P	 <	 0.0001;	 Supplement	 1A)	 in	 explaining	 the	 differences	 in	 the	 relative	MIC	
between	 evolved	 strains	 and	 that	 these	 differences	 also	 depended	 on	 which	 azole	
fungicide	was	used	(Sporulation	treatment*Azole	fungicide	interaction,	F4,	50=2.674,	P	<	
0.05;	Supplement	1A).	When	testing	for	the	effect	of	the	sporulation	treatment	for	each	
azole	separately,	we	found	that	for	bromuconazole	and	difenoconazole,	the	relative	MIC	
of	cultures	that	had	evolved	with	sporulation	was	significantly	higher	than	the	relative	
MIC	 of	 cultures	 without	 sporulation	 (for	 bromuconazole	 F1,	10	 	=	 8.448;	 P	<	 0.05;	 for	
difenoconazole	F1,	10	=	22.727,	P	<	0.01;	Supplement	1B).	
For	the	cultures	that	evolved	in	the	presence	of	fungicide	and	with	asexual	sporulation,	
we	 found	 that	 the	 relative	 MIC	 values	 significantly	 increased	 at	 the	 end	 of	 our	
experiment	 compared	with	 the	 treatment	without	azoles	 (control	 treatment)	 (ANOVA,	
F5,	30	=	 4.854;	 P	 <	 0.05;	 Post	 Hoc	 LSD	 Test,	 P	<	 0.05,	 except	 propiconazole	 P	 >	 0.05;	
Supplement	1C).	The	relative	MIC	values	started	to	increase	right	at	the	first	cycle	and	
levelled	off	around	the	sixth	week	(Figure	2A).	The	overall	average	increase	in	relative	
MIC	over	all	fungicides	was	3.67±0.90	SEM,	with	the	increase	depending	on	which	azole	
was	used	for	resistance	selection	(Table	1).		
For	the	cultures	that	evolved	without	asexual	sporulation,	exposure	to	azole	fungicides	
also	 increased	 the	 relative	 MIC	 values	 compared	 to	 control	 lineages	 growing	 in	 the	
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absence	of	azole	fungicides	(ANOVA,	F5,	30	=	8.417	P	<	0.001;	Post	Hoc	LSD	Test	P	<	0.01	
except	for	difenoconazole	and	epoxiconazole	P	>	0.05;	Figure	2B,	Supplement	1D).	The	
relative	 MIC	 value	 started	 to	 increase	 at	 the	 first	 week	 and	 then	 all	 remained	 stable	
during	the	following	six	weeks.	The	average	increase	in	relative	MIC	over	all	fungicides	
was	1.86	±	0.56	SEM,	with	again	 the	 increase	depending	on	which	azole	was	used	 for	
resistance	 selection	 (Table	 1).	 Crucially,	 although	 the	 azole‐resistance	 levels	 also	
increased	 in	 the	 treatment	 without	 sporulation,	 the	 average	 relative	 MIC	 value	 for	
cultures	 with	 asexual	 sporulation	 was	 twice	 as	 high	 as	 that	 of	 the	 cultures	 without	
asexual	sporulation.	
When	 analyzing	 the	 absolute	 MIC	 values	 of	 the	 evolved	 strains,	 we	 reach	 the	 same	
conclusion	 that	 asexual	 sporulation	 results	 in	 higher	 azole‐resistance	 levels;	 data	 and	
related	discussion	are	in	Supplement	2.	
Figure	2.	Relative	MIC	value	(Minimal	Inhibitory	Concentration	corresponding	to	
the	level	of	resistance)	and	relative	Mycelial	Growth	Rate	(MGR)	of	azole	
fungicides	for	504	evolved	cultures	with	and	without	asexual	sporulation	
compared	to	the	ancestor	in	the	presence	of	one	of	five	azole	fungicides	
(concentration:	1µg	/mL)		
(b=bromuconazole, 	t=tebuconazole, 	e=epoxiconazole, 	d=	difenoconazole	and	p=propiconazole, 	
c=control: 	no	fungicide. 	Lines	show	the	average	of	six	parallel	 lineages	for	each	treatment). 	Error	
bars	indicate	the	standard	error	of	the	mean	(SEM).	
A,B: 	The	relative	MIC	of	cultures	with	and	without	asexual	sporulation	
C,D:	The	relative	MGR	of	cultures	with	and	without	asexual	sporulation	
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Asexual	 sporulation	 increased	 mycelial	 growth	 rate	 (MGR)	 and	
correlates	with	resistance	level	increase		
Relative	 Mycelial	 Growth	 Rate	 (MGR),	 as	 a	 reliable	 measure	 for	 overall	 fitness	 in	
filamentous	 fungi,	 was	 assayed	 for	 all	 cultures	 that	 had	 evolved	 under	 laboratory	
conditions	in	the	presence	or	absence	of	azole	fungicides	over	seven	weeks.		
Figures	2C	and	2D	show	the	MGR	changes	and	evolutionary	dynamics	averaged	over	the	
six	 replicate	 lineages	within	 each	 treatment.	 Statistical	 analysis	 revealed	 that	 asexual	
sporulation	and	azole	type	both	are	significant	factors	for	explaining	the	differences	in	
relative	MGR	and	MIC	(sporulation	treatment:	F1,	50	=	94.402;	P	<	0.001;	azole	treatment:	
F4,	50=8.471,	P	<	 0.001).	 Similar	 to	 our	 analysis	 for	 relative	MIC,	 there	 is	 a	 significant	
interaction	 between	 the	 two	 factors	 (F	 4,	50	=	 3.509,	 P	<	 0.05;	 supplement	 1E).	 In	 the	
model	testing	the	effect	of	sporulation	treatment	for	each	azole	separately,	the	relative	
MGR	of	cultures	evolved	with	asexual	sporulation	is	significantly	higher	than	the	relative	
MGR	 of	 cultures	 without	 asexual	 sporulation	 (one	 way	 ANOVA,	 all	 P	 <0.01,	 except	
tebuconazole;	Supplement	1F).	
For	 the	 cultures	 that	were	 allowed	 asexual	 sporulation,	 it	was	 found	 that	 the	 relative	
MGR	significantly	increased	at	the	end	of	the	seven	weeks	(Figure	2C)	compared	to	the	
control	 (ANOVA,	 F5,	 30	 =	 11.267,	 P	 <	 0.001;	 Post	 Hoc	 LSD	 Test	 all	 P<	 0.01,	 except	
propiconazole	P	>	0.05;	Supplement	1G).	The	overall	average	 increase	 in	relative	MGR	
over	all	fungicides	was	1.52	±	0.05.	The	relative	MGR	started	to	increase	at	the	first	cycle	
and	 appeared	 to	 level	 off	 around	 the	 sixth	 cycle.	 As	 reported	 for	 the	 MIC	 data,	 the	
increase	 in	 relative	 MGR	 depended	 on	 which	 azole	 was	 used	 for	 resistance	 selection	
(Table	1).		
For	the	relative	MGR	of	cultures	that	evolved	without	asexual	sporulation,	it	was	found	
that	the	relative	MGR	significantly	changed	over	the	course	of	the	experiment	(ANOVA,	
F5,	30	=	9.411,	P	<	0.001;	Post	Hoc	LSD	Test	showed	a	significant	effect	of	difenoconazole	
and	tebuconazole	P	<		0.01;	Figure	2D,	Supplement	1H).	The	overall	average	increase	in	
relative	MGR	over	all	fungicides	was	1.08	±	0.03SEM.	The	relative	MGR	increase	started	
at	the	first	cycle,	but	already	levelled	off	after	the	first	cycle.	Similar	to	the	results	and	
analyses	 for	 relative	 MIC,	 relative	 MGR	 values	 after	 seven	 weeks	 for	 cultures	 with	
asexual	sporulation	were	much	higher	than	those	of	the	cultures	without	sporulation.	
Comparing	the	evolutionary	changes	for	the	five	different	azole	 fungicides	used	within	
the	asexual	 sporulation	 treatment,	we	observed	 that	 the	 selection	response	differs	 for	
the	 different	 azole	 fungicides	 (for	 relative	 MGR	 ANOVA,	 F4,	25	=	 5.469,	 P	<	 0.01	 	 and	
relative	MIC	showed	similar	results;	post‐hoc	LSD	pairwise	comparisons	between	all	five	
azole	fungicides	are	in	Supplement	1I).	Difenoconazole	imposes	the	strongest	selection	
as	 shown	by	 the	highest	 increase	 in	 relative	MGR	and	MIC	whereas	 this	pressure	was	
much	less	strong	for	propiconazole	(Figure	3).	Another	possible	explanation	is	that	the	
mutation	rate	is	higher	in	the	presence	of	difenoconazole	than	the	other	drugs.	
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Generally,	 relative	 MIC	 is	 highly	 and	 significantly	 correlated	 with	 the	 relative	 MGR	
(linear	 regression	 over	 all	 treatments,	 r	 =	 0.811,	 F	 1,	 38	 =72.918,	 P	 <	 0.01)	 over	 all	
cultures	 within	 the	 asexual	 sporulation	 treatment,	 and	 also	 for	 each	 of	 the	 azole	
fungicides	 separately,	 except	 for	propiconazole	 (Table	1).	 This	 indicates	 that	 the	MGR	
change	of	cultures	was	due	to	the	change	in	resistance	level.	In	other	words,	the	change	
in	MIC	is	reflected	in	a	change	in	MGR.	This	is	in	agreement	with	previous	studies,	which	
showed	that	colony	diameter	(mycelial	growth	rate)	 is	a	good	and	reliable	measure	of	
overall	fitness	(assuming	MIC	itself	is	an	important	fitness	component),	since	it	is	highly		
	
Figure	3.	Relative	MGR	values	of	azole	fungicides	for	evolved	cultures	with	asexual	
sporulation	in	the	presence	of	one	of	five	different	azole	fungicides		
(	b=bromuconazole, 	t=tebuconazole, 	e=epoxiconazole, 	d=	difenoconazole	and	p=propiconazole, 	
c=control , 	no	fungicide). 	Bars	show	averages	of	6	replicate	l ineages. 	Error	bars	show	indicate	the	
standard	error	of	the	mean	(SEM). 	 	
correlated	 with	 spore	 production	 (De	 Visser	 et	 al.	 1997;	 Pringle	 and	 Taylor	 2002;	
Schoustra	et	al.	2009;	Schoustra	and	Punzalan	2012).	When	analyzing	the	absolute	MGR	
values	 of	 the	 evolved	 strains,	 we	 reach	 the	 same	 conclusion	 that	 asexual	 sporulation	
results	in	higher	azole	resistance	levels;	data	and	related	discussion	are	in	Supplement	2.	
To	 verify	 that	 increases	 in	 both	 MIC	 and	 MGR	 were	 due	 to	 the	 actual	 fixation	 of	
mutations,	 a	 sexual	 cross	 was	 performed	 between	 the	 ancestral	 genotype	 and	 an	
evolved	strain	with	high	MIC	and	MGR.	The	results	show	a	clear	Mendelian	segregation	
of	 fitness	among	 the	progeny,	 confirming	 that	 fitness	 increase	 is	due	 to	 the	 fixation	of	
mutations	(Supplement	3).	
	
Stability	test	of	azoles	fungicides	over	the	evolutionary	experiment		
The	 stability	 of	 the	 five	 azole	 fungicides	 during	 experimental	 evolution	was	 tested	 by	
growing	the	ancestor	on	media	with	azoles	that	was	first	stored	for	up	to	seven	weeks	at	
37	Ԩ.	No	significant	differences	in	relative	MGR	were	found	between	fungus	inoculated	
on	these	pre‐incubated	media	and	those	on	the	freshly	prepared	media	(ANOVA,	F	7,120	=	
0.442,	P	=	0.874;	Supplement	4).	This	indicates	that	all	five	azole	fungicides	were	stable	
during	the	seven	weeks	of	our	experimental	evolution.	
                                 Asexual sporulation facilitates adaptation 
59 
 
Table	1.The	relative	MIC	and	MGR	of	evolved	cultures	with	and	without	asexual	
sporulation	and	correlation	between	relative	MIC	and	MGR	in	the	cultures	with	
asexual	sporulation.	
Azole	 used	 during	
experimental	evolution	
Endpoint	cultures	
evolved	with		
asexual	sporulation		
Endpoint	 cultures	
evolved	 without	
asexual	sporulation	
	 Relative		
MIC(azoles)	
Av.	±	SEM.*	
Relative	
MGR(azoles)	
Av.	±	SEM	
Correlation	
between		
MIC	 and	 MGR	 (r2	 ,	
p)									
Relative	
MIC(azoles)	
Av.	±	SEM	
Relative	
MGR(azoles)	
Av.	±	SEM	
Bromuconazole(b)	 4.33	±	1.97	 1.51	±	0.20 r2	=0.845,	P=0.001			 2.00	±	0.00		 1.06	±	0.14
Difenoconazole(d)	 4.63	±	1.63	 1.85	±	0.24 r2=	0.855,	P=0.001 1.33	±	0.52	 1.19	±	0.08
Epoxiconazole(e)	 	3.33	±	2.42	 1.53	±	0.23 r2=0.758,	P=0.005	 1.33	±	0.52	 0.93	±	0.09
Propiconazole(p)	 2.33	±	0.82	 1.23	±	0.18 r2=0.411,	P	=	0.087 2.00	±	0.00	 0.99	±	0.07
Tebuconazole(t)	 3.67	±	0.81	 1.46	±	0.33 r2=	0.629,	P=0.019 2.67	±	1.03	 1.19	±	0.12
No	azole	(control)	 1.00	±	0.00	 0.98	±	0.05	 r2=	0.99,	P<0.001	 1.00	±	0.00		 1.00	±	0.00	
	 	 	 	*: 	 	six	biological	replicates	
Incomplete	 dominance	 of	 resistance	 mutation	 in	 diploids	 and	
heterokaryons		
A.	fumigatus	 normally	 grows	as	a	vegetative	haploid,	 although	vegetative	diploids	also	
exist	at	very	low	frequency.	The	dominance	level	of	azole‐resistance	mutations	in	one	of	
the	 evolutionary	 lineages	 was	 assayed	 in	 heterozygous	 diploids	 as	 well	 as	 in	
heterokaryons.	 The	 relative	 MGR	 of	 the	 haploid	 sensitive	 strain,	 the	 highly	 resistant	
haploid	evolved	strain,	the	heterokaryon,	and	the	heterozygous	diploid	were	assayed	on	
medium	with	 1	 µg/mL	 of	 difenoconazole	 (Figure	 4).	 The	 relative	MGR	 values	 (±	 SEM	
over	 3	 replicates)	 of	 sensitive	 A.	 fumigatus	CBS	 140053,	 resistant	 D1‐7,	 diploid	 and	
heterokaryon	were	respectively	0.17±	0.007;	0.43	±	0.012;	0.33	±0.0024;	0.36	±0.0027.	
The	 relative	 MGR	 differed	 significantly	 among	 the	 different	 strains	 (ANOVA	 F	 3,	
8=3749.663,	P	<	0.001;	Post	Hoc	LSD	Test:	all	pair‐wise	contrasts:	P	<0.001).	The	growth	
of	the	heterozygous	diploid	was	78.5	%	of	that	of	the	resistant	strain,	while	the	growth	
of	the	heterokaryon	was	83.7	%	of	the	resistant	strain.	Both	the	phenotype	of	the	diploid	
and	the	heterokaryon	indicated	that	the	mutation	is	incomplete	dominant.		
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Figure	4.	Relative	mycelial	growth	rate	(relative	MGR)	of	the	heterokaryon,	the	
heterozygous	diploid,	the	sensitive	haploid	(AF	nia),	and	the	resistant	haploid	
strain	(cnx	D1‐7#).		
The	relative	MGR	is	defined	as	the	MGR	of	the	strains	grown	on	MEA	medium	with	azole	fungicides	
divided	by	the	colony	diameter	of	the	strains	grown	on	MEA	medium	without	azole	fungicides. 	
Error	bars	indicate	standard	error	of	the	mean	(SEM). 	All	strains	have	a	significantly	different	
relative	growth	rate	at	the	P<0.001	level. 	 	
	
Discussion		
	
Asexual	 sporulation	 results	 in	 rapid	 evolution	 of	 high	 resistance	 to	
azole	fungicides	in	A.	fumigatus		
We	 evaluated	whether	 asexual	 sporulation	 promotes	 adaptation	 to	 an	 azole‐fungicide	
environment	 in	 A.	 fumigatus,	 i.e.	 the	 development	 of	 resistance.	 We	 contrasted	 the	
development	 of	 resistance	 to	 five	 different	 azole	 fungicides	 between	 populations	 that	
went	 through	 repeated	 rounds	 of	 asexual	 sporulation	 with	 continued	 multicellular	
growth	without	asexual	sporulation.	We	found	clear	differences	in	the	achieved	levels	of	
resistance	 between	 cultures	 that	 had	 evolved	 with	 or	 without	 asexual	 sporulation,	
sporulation	leading	to	roughly	twice	as	high	resistance	levels.	Generally,	the	relative	MIC	
correlated	well	with	relative	MGR	for	all	cultures.	Evolutionary	trajectories	of		cultures	
with	 asexual	 sporulation	 showed	multiple	 steps	 of	 increase	 in	 both	 relative	MIC	 and	
MGR,	which	may	be	 indicative	of	 the	successive	 fixation	of	multiple	mutations	 (Lenski	
and	 Travisano	 1994;	 Schoustra	 et	 al.	 2009),	 although	 exceptions	 have	 recently	 been	
reported	 (Lang	 et	 al.	 2013).	 In	 contrast,	 the	 resistance	 level	 of	 the	 cultures	 growing	
without	 asexual	 sporulation	 did	 not	 further	 increase	 after	 taking	 a	 first	 (mutational)	
step.	
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Evolutionary	 mechanisms	 underpinning	 the	 emergence	 of	 azole	
resistance		
Our	results	show	that	the	resistance	level	to	azoles	gradually	increases	when	the	culture	
goes	 through	asexual	 sporulation,	which	suggests	 that	asexual	 sporulation	contributes	
to,	 and	 promotes,	 the	 evolution	 of	 resistance.	 This	 may	 be	 explained	 either	 by	 more	
efficient	 selection	 for	 resistance	 and/or	 a	 higher	 mutation	 supply	 in	 the	 sporulating	
cultures.	
Asexual	sporulation	in	A.	fumigatus	enables	the	phenotypic	expression	of	the	resistance	
by	 providing	 an	 alternation	 between	 multicellular	 and	 unicellular	 stages.	 This	
alternation	provides	the	opportunity	for	mutations	to	be	released	from	the	multicellular	
mycelium	and	to	fully	express	its	phenotype	into	a	newly	formed	mycelium	founded	by	
that	spore.	Life	cycles	with	both	multicellular	and	unicellular	phases	are	widespread	in	
animals,	 plants,	 and	 some	 fungi	 (Maynard	 Smith	 1988;	 Anderson	 1992;	 Kondrashov	
1994b;	Michod	 2007).	 Grosberg	 and	 Strathmann	 (1998)	 argued	 that	 the	multicellular	
stage	 reduces	 genetic	 variability	 and	 leads	 to	 inefficient	 selection	 compared	 to	 the	
unicellular	stage(Grosberg	and	Strathmann	1998).	For	instance,	the	unicellular	stage	in	
the	life	cycle	of	multicellular	organisms	allows	for	the	purging	of	deleterious	mutations	
by	exposing	the	individual	gametes	as	well	as	the	resulting	zygote	to	selection,	while	at	
the	 same	 time	 this	 unicellular	 stage	 reduces	 conflicts	 of	 interest	 among	 genetically	
different	replicators	(e.g.	mitochondria)	within	a	multicellular	organism	(Grosberg	and	
Strathmann	1998;	Bastiaans	et	al.	2014).	Moreover,	the	alternation	of	multicellular	and	
unicellular	stages	also	promotes	 the	selection	of	beneficial	mutations.	 In	 the	case	of	A.	
fumigatus,	 this	 alternation	 includes	 a	 uni‐nucleate	 spore	 stage	 after	 which	 a	 new	
multicellular	 mycelium	 will	 form.	 This	 will	 reduce	 variability	 in	 the	 total	 number	 of	
mutations	per	 individual	by	either	removing	unique	mutations	or	by	completely	 fixing	
them	in	a	culture.		
Following	 this	 logic,	 we	 can	 argue	 that	 the	 asexual	 sporulation	 process	 released	 the	
mutations	 from	 the	 multicellular	 mycelium	 to	 allow	 for	 efficient	 selection	 and	
expression	 of	 beneficial	 traits.	 Blocking	 sporulation	 could	 thus	 reduce	 evolvability	
(Kondrashov	 1994b,	 a).	 This	 aligns	 with	 the	 hypothesis	 that	 asexual	 sporulation	 is	
essential	for	phenotypic	expression	of	azole	resistance	mutations	in	A.	fumigatus.	During	
continued	 mycelium	 growth,	 individual	 resistant	 nuclei	 may	 arise	 but	 these	 are	
outnumbered	by	sensitive	nuclei.	The	resistant	nuclei	can	only	escape	 through	asexual	
sporulation	after	which	 they	end	up	 in	unicellular	 resistant	 spores	 that	may	 then	give	
rise	 to	 a	 resistant	 mycelium.	 Thus	 exclusive	 mycelial	 growth	 (without	 asexual	
sporulation)	 prevents	 the	 emergence	 of	 resistance	 in	 A.	 fumigatus,	 at	 least	 over	
timescales	that	are	relevant	for	the	treatment	of	patients.	
The	mechanism	of	release	of	resistant	nuclei	from	a	sensitive	mycelium	will	work	most	
efficiently	 when	 the	 azole	 resistance	 mutation	 is	 recessive	 and	 therefore	 needs	
homokaryon	 formation	 for	 the	 full	expression	of	 the	resistance.	Therefore,	we	assayed	
whether	azole‐resistance	mutations	from	one	of	the	evolutionary	lineages	are	dominant	
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or	 recessive.	We	 constructed	heterozygous	diploids	 and	heterokaryons	 and	 compared	
the	resistance	level	with	the	haploid	sensitive	and	resistant	strains.	Both	the	phenotype	
of	diploid	and	heterokaryon	indicated	that	the	mutation	showed	incomplete	dominance.	
Thus	homokaryon	formation	by	asexual	sporulation	will	result	in	the	full	expression	of	
the	azole‐resistant	genotype,	and	will	hence	enhance	the	spread	of	the	mutation(s).	The	
extent	 of	 this	 benefit	 for	 resistance	 mutations	 will	 be	 dependent	 on	 the	 selection	
pressure	 imposed	by	the	(azole)	environment.	When	high	concentrations	of	azoles	are	
used,	selection	will	be	stronger	on	the	resistant	phenotype,	and	thus	the	benefit	to	a	full	
expression	of	 the	phenotype	will	be	higher.	The	significance	of	 the	contribution	of	 the	
sporulation	process	to	the	emergence	of	azole	resistance	is	thus	expected	to	depend	on	
the	precise	application	of	the	azoles	in	clinical	and	agricultural	settings.	
Furthermore,	 in	 terms	of	spores	contributing	to	azole‐resistance	development,	asexual	
sporulation	 greatly	 increases	 the	 effective	 population	 size	 allowing	 for	 many	 more	
possible	 mutants	 to	 be	 exposed	 to	 selection	 and	 also	 increases	 the	 mutation	 supply	
through	 the	additional	mitoses	required	 to	generate	all	 the	spores.	Typically	after	one	
week	of	growth,	a	colony	of	A.	fumigatus	may	contain	up	to	109	spores	(Cole	1986;	Latgé	
1999;	Dagenais	and	Keller	2009;	Amorim	et	al.	2010;	Gifford	and	Schoustra	2013;	Gisi	
2013).	While	 the	 number	 of	 nuclei	 needed	 to	 populate	 the	mycelium	 is	 limited,	 upon	
sporulation,	 the	 formation	 of	 hundreds	 of	 millions	 of	 spores	 on	 top	 of	 the	mycelium	
requires	 additional	 mitotic	 divisions,	 with	 the	 possibility	 of	 mutations	 arising	 during	
DNA	 replication.	 Therefore,	 the	 total	 number	 of	 nuclei	 produced	 by	mitotic	 divisions	
during	 sporulation	 by	 far	 exceeds	 that	 present	 in	 the	mycelium.	 As	 a	 result,	 de	novo	
resistance	mutations	 are	more	 likely	 to	 occur	 during	 asexual	 sporulation	 than	 in	 the	
expanding	mycelium.	The	occurrence	of	mutations	has	been	demonstrated	in	Aspergillus	
and	yeast	during	both	meiosis	and	mitosis	(Magni	and	Von	Borstel	1962;	Holliday	1964;	
Käfer	 1977;	 Esposito	 et	 al.	 1982).	 Thus	 a	 large	 spore	 production	 is	 likely	 to	 generate	
numerous	unique	genotypes	carrying	mutations	that	can	be	tested	by	natural	selection,	
for	 instance	 in	 environments	 with	 azoles.	 In	 addition,	 resistance	mutations	 are	more	
likely	 to	 be	 selected	 from	 asexual	 sporulation	 due	 to	 the	 single‐celled	 nature	 of	 the	
spores	that	removes	the	burden	of	the	(partial)	recessivity	of	the	mutations	that	shields	
the	full	expression	of	resistance	in	a	multicellular	mycelium.	
	
Other	potential	resistance	mechanisms		
Aneuploidy	is	well	known	to	underlie	azole	resistance	in	both	Candida	and	Cryptococcus,	
the	 two	 other	most	 common	 systemic	 human	 fungal	 pathogens	 (Selmecki	 et	 al.	 2006;	
Sionov	et	al.	2010;	Ni	et	al.	2013).	We	feel	we	can	exclude	aneuploidy	as	an	explanation	
for	emerging	resistance	in	A.	fumigatus	since,	so	far,	no	aneuploidy	has	been	found	in	A.	
fumigatus.	 Aneuploidy	 in	 A.	nidulans	 has	 been	 associated	 with	 mitotic	 instability	 and	
abnormal	 low‐fitness	phenotypes	 (Kafer	 and	Upshall	 1973)	 and	 also	 in	A.	niger	stable	
aneuploids	 have	 never	 been	 observed	 (Debets	 et	 al.	 1993).	 Furthermore,	 in	 some	
reports,	aneuploidy	in	pathogenic	fungi	such	as	Candida	was	linked	to	the	emergence	of	
drug	 resistance,	 but	 was	 limited	 to	 fluconazole	 therapy.	 The	 prevalence	 of	 azole‐
                                 Asexual sporulation facilitates adaptation 
63 
 
associated	 aneuploidy	 in	 these	 fungi	 appears	 not	 only	 to	 be	 due	 to	 increased	 azole	
therapy	but	also	to	the	high	plasticity	of	their	genomes	(Selmecki	et	al.	2010;	Sionov	et	al.	
2010;	 Kwon‐Chung	 and	 Chang	 2012).	 In	 contrast	 to	 the	 plastic	 Candida	 genome,	 the	
structure	of	 the	Aspergillus	 genomes	appears	rather	stable	 (Gibbons	and	Rokas	2013).	
Further	evidence	that	the	observed	resistance	is	due	to	changes	in	the	DNA	(mutations)	
rather	 than	 ploidy	 change	 comes	 from	 the	 observation	 of	 step‐wise	 increases	 in	
resistance	in	the	evolutionary	trajectories.	This	is	further	supported	by	the	results	from	
a	sexual	cross	of	the	ancestor	and	a	resistant	evolved	strain,	showing	clear	segregation	
of	the	resistant	phenotype	among	the	progeny	(Supplement	3).		
More	 generally,	 other	 parts	 of	 the	 A.	 fumigatus	 life‐cycle	 could	 potentially	 provide	
alternative	or	additional	ways	to	generate	adaptive	variation	through	the	occurrence	of	
recombination	during	 the	sexual	and	parasexual	cycle	 (O’Gorman	et	al.	2008;	Ene	and	
Bennett	2014).	Thus,	whereas	the	abundant	asexual	reproduction	may	be	significant	for	
mutation	supply,	the	much	less	common	sexual	and	parasexual	life	cycle	in	nature	could	
induce	 diversity	 through	 recombination	 (O’Gorman	 et	 al.	 2008;	 Heitman	 et	 al.	 2014).	
Furthermore,	the	parasexual	life	cycle	also	could	promote	adaptation	by	changing	ploidy,	
as	 it	 appears	 to	 do	 in	A.	nidulans	(Schoustra	 et	 al.	 2007;	Anderson	 et	 al.	 2015).	 These	
possibilities	provide	interesting	avenues	for	future	research.		
	
A	scenario	for	the	evolution	of	resistance	in	A.	fumigatus		
Based	 on	 the	 above	 reasoning,	 azole	 resistance	 in	 A.	 fumigatus	 could	 have	 evolved	
through	the	following	scenario	(Figure	5).	All	cultures	were	started	with	a	conidiospore	
sampled	 from	an	ancestral	azole	sensitive	colony	 that	either	may	already	contain	rare	
random	 beneficial	 and	 detrimental	 mutations,	 or	 that	 developed	 mutations	 during	
asexual	sporulation.	This	idea	is	supported	by	the	fact	that	we	found	the	same	resistance	
levels	(MIC	value)	after	the	first	week	of	fungicide	exposure	of	all	cultures.	After	this	first	
week,	however,	continued	mycelial	cultures	did	not	further	increase	in	resistance	since	
potential	beneficial	mutations	that	appeared	for	instance	during	asexual	sporulation	on	
top	of	the	mycelium	were	not	able	to	spread	and	thus	not	available	for	selection.		
In	contrast,	in	the	treatment	including	sporulation,	all	initial	and	subsequent	mutations	
that	 occurred	 during	 sporulation	 could	 fix	 in	 those	 cultures	 and	 contribute	 to	 further	
resistance	 development,	 as	 seen	 in	 the	 stepwise	 increases	 of	 resistance.	 Continued	
mycelial	growth	ignored	all	 these	potential	second	and	higher	step	mutations,	because	
these	 mutations	 were	 less	 likely	 to	 happen	 in	 the	 first	 place,	 are	 at	 least	 partially	
recessive,	 and	 were	 trapped	 in	 a	 predominantly	 non‐resistant	 mycelium,	 resulting	 in	
lower	final	levels	of	resistance	at	the	phenotype	level.		
Asexual	 sporulation	 is	 a	 common	 reproductive	mode	 for	 a	diverse	group	of	 fungi	 that	
includes	 many	 medically,	 industrially,	 and	 agriculturally	 important	 species	 (Springer	
1993;	Adams	et	al.	1998;	Mah	and	Yu	2006;	Metz	et	al.	2011).	Asexual	sporulation	is	a	
conidiation	process	and	a	primary	means	of	dispersion	(Mah	and	Yu	2006;	Metz	et	al.	
2011)	and	can	also	occur	within	the	lungs	of	patients.	In	our	study,	we	illustrate	asexual	
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sporulation	 to	 involve,	 (i)	 the	 alternation	 between	 multinucleate	 mycelium	 and	
uninucleate	conidiospores	which	facilitates	the	expression	of	individual	partly	recessive	
mutations,	 and,	 (ii)	 the	 generation	 of	 large	 numbers	 of	 asexual	 conidiospores	 that	
increases	 the	 effective	 population	 size	 and	mutation	 supply	 of	 a	 colony	 and	 that	 thus	
contributes	 to	 the	 diversity	 of	 populations.	 These	 combined	 effects	 of	 asexual	
sporulation	may	explain	the	rapid	evolution	of	azole	resistance	in	A.	fumigatus	as	well	as	
the	 overall	 diversity	 of	 A.	 fumigatus	 in	 the	 field	 and	 in	 hospitals	 (Samson	 1994;	
Debeaupuis	et	al.	1997;	Chazalet	et	al.	1998).	
	
Relevance	for	azole‐resistance	development		
Our	results	indicate	that	the	risk	of	azole‐resistance	selection	in	A.	fumigatus	depends	on	
the	selection	pressure	‐	i.e.	which	specific	azole	was	used	‐	in	an	environment	that	allows	
asexual	sporulation.	A	recent	assessment	by	Gisi,	 indicated	that	high	concentrations	of	
azole	fungicides	are	used	for	specific	applications,	including	bulb	dipping	and	protection	
of	materials,	such	as	wood	(Gisi	2013).	The	risk	of	azole‐resistance	selection	related	to	
these	 applications,	 however,	 depends	 on	 the	 presence	 and	 exposure	 of	 sporulating	A.	
fumigatus,	 which	 remains	 to	 be	 investigated.	 The	 second	 major	 application	 that,	
according	to	these	principles,	carries	a	high	risk	of	resistance	selection	is	azole	therapy	
in	animals	and	humans	(Gisi	2013)	as	also	azole	therapy	involves	high	exposure	levels	at	
the	site	of	infection.	Asexual	sporulation	of	A.	fumigatus	was	found	in	animal	and	human	
lungs	 with	 cavitary	 Aspergillus	 diseases	 such	 as	 chronic	 cavitary	 aspergillosis	 and	
aspergilloma,	 where	 vegetative	 hyphae	 are	 exposed	 to	 air	 (Figure	 1C)	 (Adams	 et	 al.	
1998).	Clinical	case	series	 indeed	show	that	resistance	emerges	exclusively	when	both	
conditions	are	present:	during	azole	therapy	of	patients	with	cavitary	lesions	(Camps	et	
al.	 2012).	 In	 contrast,	 azole	 resistance	 selection	 during	 azole	 therapy	 has	 not	 been	
reported	 in	 patients	 with	 invasive	 aspergillosis	 (Dannaoui	 et	 al.	 2004).	 Despite	 high	
azole	exposure,	the	risk	of	azole	resistance	development	in	these	patients	appears	much	
lower.	 Our	 results	 now	 support	 the	 interpretation	 that	 this	 is	 due	 to	 the	 absence	 of	
asexual	sporulation	in	the	patients.	
Nevertheless,	azole	resistance	has	been	reported	in	patients	with	invasive	aspergillosis.	
Patients	 are	 believed	 to	 inhale	 already	 azole‐resistant	 spores	 that	 then	 colonize	 the	
patient,	 rather	 than	 that	 the	 fungus	with	which	 they	 are	 infected	 develops	 resistance	
during	 azole	 therapy	 (Verweij	 et	 al.	 2013).	 It	 indicates	 that	 these	 azole‐resistant	
unicellular	 spores	 are	 more	 adapted	 to	 the	 patients’	 ”ecosystem”	 than	 multicellular		
mycelium,	which	 strongly	 supports	 the	view	 that	 a	 regular	unicellular	 life	 stage	 could	
promote	the	removal	of	deleterious	mutations	and	the	selection	of	beneficial	mutations.	
Overall,	 it	 is	 essential	 that	 future	 research	 focuses	 on	 testing	 the	 role	 of	 asexual	
reproduction	of	the	fungus	in	patients	exposed	to	medical	triazoles,	as	this	may	lead	to	
new	management	strategies	that	avoid	or	overcome	resistance	selection.	
Different	 azole	 fungicides	 have	 different	 activity	 against	 the	 ancestor	 (Supplement	 4	
MGR(b)=3.9±0.05mm/day;	 MGR(d)=3.7±0.05mm/day;	 MGR(e)=4.2±0.08mm/day;	
MGR(p)=5.6±0.11mm/day;	MGR(t)=4.2±0.11mm/day;)	and	MIC	(b)=	4;	(d)=2;	(e)=8;		
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(p)=8;	 (t)=4).	 The	 initial	 fitness	 of	 the	 ancestor	 to	 five	 azole	 fungicides	was	 inversely	
proportional	 to	 the	 rate	 of	 adaptation	 of	 the	 ancestor	 to	 five	 azole	 fungicides	
(supplement	5),	which	may	explain	the	differences	in	the	selection	level	of	the	different	
fungicide	 azoles	 against	 A.	 fumigatus.	 Azole	 resistance	 in	 our	 lineages	 is	 incomplete	
dominant,	 and	 explaining	 this	 observation	 requires	 knowledge	 of	 the	 mechanism(s)	
involved.	From	the	evolutionary	trajectory	and	sexual	cross	analyses	it	appears	that	the	
resistant	 strain	 contained	 two	mutations	 (Supplement	 3).	 Maybe	 epistatic	 interaction	
between	these	mutations	may	explain	 the	 incomplete	dominance.	 In	relation	 to	 this,	 it	
would	be	of	interest	to	test	the	predominant	highly	resistant	mutant	TR34/L98H	found	
in	hospitals	for	dominance.	
	
The	 clear	 correlation	 between	 MIC	 and	 MGR	 is	 also	 useful	 for	 future	 studies	 on	 the	
development	 of	 resistance	 in	 fungi.	 For	 susceptibility	 testing,	 the	MIC	 value	 of	 azoles	
against	Aspergillus	are	 influenced	 by	 variable	 factors	 such	 as	 inoculum	 size,	 endpoint	
and	 reading	 time,	 which	 can	 easily	 result	 in	 a	 1–2	 wells	 difference	 in	 the	 MIC	
interpretation	(Gehrt	et	al.	1995;	Llop	et	al.	2000;	Espinel‐Ingroff	et	al.	2001;	Albarrag	et	
al.	2011).	Also	it	is	difficult	to	detect	relatively	small	differences	in	the	level	of	resistance.	
In	contrast,	MGR	is	much	more	accurate	and	easier	to	measure	and	can	thus	be	used	as	a	
reliable	 proxy	 to	 determine	 the	 resistance	 level.	 However,	 for	 the	 cultures	 of	 the	
treatment	without	asexual	sporulation,	we	did	not	 find	a	correlation	between	MIC	and	
MGR,	which	is	likely	explained	by	the	lower	levels	of	MIC	and	MGR	increase	during	the	
evolution	experiment.	Probably	there	are	mutations	that	affect	MIC	but	not	MGR	at	one	
particular	level	of	drug.	
	
Conclusions	and	Future	Outlook	
	
Our	 results	 demonstrate	 that	 the	 full	 life	 cycle	 of	A.	fumigatus	 needs	 to	 be	 taken	 into	
account	 to	 explain	 the	 emergence	 and	 possible	 persistence	 of	 azole	 resistance.	 In	
addition,	the	selection	pressure	appears	to	be	a	key	factor.	As	we	observed	differences	in	
selection	pressure	 for	 the	various	azole	 compounds,	 the	 implications	of	both	 the	dose	
and	 the	molecule	structure	should	be	considered	 in	 future	studies.	While	knowing	the	
exact	identity	of	the	adaptive	mutations	in	A.	fumigatus	was	not	required	to	address	the	
hypotheses	 in	 this	 paper,	 it	will	 be	 an	 essential	 avenue	 of	 future	 research,	which	will	
further	unravel	the	evolutionary	dynamics	of	A.	fumigatus	adaptation	both	in	the	human	
setting	and	in	the	environment.	Understanding	the	key	factors	that	facilitate	resistance	
selection	in	A.	fumigatus	 is	essential	to	design	strategies	that	prevent	or	overcome	this	
emerging	threat.		
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Abstract 
Resistance to azoles in A. fumigatus is an emerging problem for immunocompromised patients. There are currently two presumed routes of the emergence of resistance to medical azoles: (1) through selection pressure of azoles from medical drugs in human patients and (2) through the selection pressure for resistance from the use of azole fungicides in agricultural environments. To assess the potential of selection of resistance to medical drugs in agricultural environments, we performed an evolution experiment with A. fumigatus under selection pressure of one of five different agricultural azoles and assessed cross-resistance to three medical azoles. We found wide-spread cross-resistance indicating that resistance to medical azoles can arise through the selection pressure of agricultural azoles. All evolved lineages showed nearly exactly the same evolutionary dynamic to agricultural azoles and medical azoles, strongly suggesting that the same mutations induce resistance to both agricultural and medical azoles.  From the five agricultural azoles we used, difenoconazole exerts highest selection for overall azole resistance, especially for inducing high resistance to itraconazole. We observed dynamic phenotype changes (morphotype and fitness) over the course of the evolution experiment, which included the colony size (big and small), colony textures (dense and fluffy) and sporulation time (early or late). Whole-genome sequencing revealed that mutations in several targets are involved in the resistance mechanism.  
Key words: Aspergillus fumigatus; experimental evolution; agricultural and medical azoles; azole resistance; evolutionary trajectory. 
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Introduction 
Azole resistance is an emerging health problem in the saprophytic mold Aspergillus 
fumigatus. This fungus is responsible for the vast majority of invasive fungal infections in immunocompromised patients, and has spread globally in the last decades (Bignell 2014; Cuenca-Estrella 2014). (Latgé 1999; Rhodes 2006; Lockhart et al. 2011; van der Linden et al. 2011; Chowdhary et al. 2012a; Snelders et al. 2012; Vermeulen et al. 2012; Astvad et al. 2014; Bignell 2014; Rocchi et al. 2014b; Lavergne et al. 2015; Wiederhold et al. 2015; Patrice Le et al. 2016). Triazoles are the class of antifungal drugs used to treat human infections; itraconazole, posaconazole and voriconazole are the most widely used (Albarrag et al. 2011).  These triazoles inhibit the enzyme sterol 14α-demethylase, which is encoded by the cyp51A gene, thereby blocking its function in the ergosterol biosynthesis pathway. This results in ergosterol depletion and accumulation of toxic sterols (Joseph-Horne and Hollomon 1997). The most common resistance mechanism known includes the alteration of the cyp51A gene (Howard et al. 2006; Howard et al. 2009; Bueid et al. 2010; van der Linden et al. 2011 (Mellado et al. 2007; Snelders et al. 2008; Mavridou et al. 2010; Snelders et al. 2010; Chowdhary et al. 2012b; Pelaez et al. 2012; Rath et al. 2012; Rocchi et al. 2014a; Wiederhold et al. 2015)).  In the last decade, widespread resistance emerged against itraconazole, and more recently to voriconazole, and numerous resistant strains have been isolated from patients.  Interestingly, highly resistant A. fumigatus is also found from soil, flowerbeds and other agricultural environments (Snelders et al. 2009). In fact, azole fungicides are widely used in agricultural settings to control various plant pathogens. Agricultural azoles are triazole derivatives and are unique in that they are the only class of antifungals that are used both in agriculture and in clinical medicine (Verweij et al. 2009b; Snelders et al. 2012; Stensvold et al. 2012). The volume of agricultural triazoles sold has almost doubled between 1995 and 2007 to 130000 kg per year in the Netherlands alone, against a yearly use of around 400 kg of medical azoles (Verweij et al. 2009b). Resistant 
A. fumigatus isolates from patients and the environment share the repeated occurrence of mutations in the cyp51A gene cluster as the resistance mechanism (Domsch et al. 1980; Gisi 2013). This suggests that there are potentially two routes of selection for resistance exist in A. fumigatus strains found in patients (Verweij et al. 2009b; Verweij et al. 2013). The first route is through patients with chronic aspergillus disease as CF patients, who are under prolonged treatment with medical azoles. This medical route to resistance has been demonstrated experimentally (Camps et al. 2012b). The second route is through exposure of A. fumigatus to agricultural azoles used in crop protection, resistance to which could give rise to cross-resistance to medical azoles. Several studies have suggested that azoles used in agricultural settings can select for cross-resistance to medical azoles based on the shared mechanism for resistance (Snelders et al. 2012; Stensvold et al. 2012; Chowdhary et al. 2013; Verweij et al. 2013; Bowyer and Denning 2014; Faria-Ramos et al. 2014). For instance, Snelders et al. (2012) discussed the high 
CHAPTER IV 
76 
resistant strain (isolated from a medical environment) carrying the mutations TR34 /L98H showed resistance to both agricultural and medical azoles and that agricultural and medical azoles target the same active sites in enzymes of the ergosterol pathway of 
A. fumigatus. However, there is no direct evidence that exposure of A. fumigatus to agricultural azoles can lead to cross-resistance to medical azoles. In a previous study that focused on the effects of different modes of fungal reproduction on resistance development, we had evolved A. fumigatus strains over seven weeks in the presence of one of five agricultural fungicides (Zhang et al 2015). In the present study, we assay these evolved strains for cross-resistance to three medical azoles. We further ask whether the increase in resistance to medical azoles mirrors the observed evolutionary dynamics of resistance development to agricultural azoles. Finally, for several evolved populations, we link fitness to population dynamics and to observed mutations at the genome level.  This information is essential to understand the potential routes to medical azole resistance development and associated genetic changes under the selection pressure of agricultural azoles.  
Materials and methods 
Fungal isolates and azoles All evolved fungal cultures used in this study are from a previous study that focused on the role of various modes of fungal reproduction in adaptation (the development of resistance to agricultural azoles) (Zhang., et al 2015). In that previous study, we evolved ancestor A. fumigatus CBS 140053 in the laboratory over seven weeks. Six replicate lineages evolved in the presence of one of each of five agricultural azoles and six lineages evolved without any agricultural azole as a reference (called control lineages).  For one of the reproductive conditions, we weekly transferred a sample of fresh asexual spores to fresh medium. The stored samples for each lineage at each of the seven time points are used in the present study. Thus, the total number of samples was 253 ( (5 azoles+control)*6 replicates* 7 time point + ancestors = 253). The five agricultural azoles (AGRO) used for the selection were bromuconazole, tebuconazole, epoxiconazole, difenoconazole and propiconazole. In the present study we used the medical azoles itraconazole (ITR), voriconazole (VOR) and posaconazole (POS). All azoles were purchased from Sigma Company.  
Susceptibility testing of evolved cultures to the medical azoles We assayed the level of resistance of all lineages that had evolved in the presence (or absence) of one of five different agricultural azoles over seven weeks against the three 
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medical azoles. We performed resistance test following the European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference method (Lass-Flörl et al. 2008). Briefly, resistance level was defined as the minimal inhibitory concentration (MIC) that results in 100% growth inhibition of fungi. The relative MIC was defined as the individuals’ MIC divided by the MIC of the azole sensitive ancestor A. fumigatus CBS 140053. RPMI-1640- 2% G medium (Sigma) was supplemented with each of the medical azoles in concentrations ranging from 0.016 to 16 mg/L in two-fold concentration steps and loaded into a 96-well plate. Spore suspensions used to initiate the assay were prepared from fungal colonies grown on solid medium using saline-Tween (0,8% HCl with 0.05% Tween 80 – Sigma- in water). We estimated the density of spore suspensions on a Coulter counter to standardize the concentration of spores to 1-2.5×105 CFU/mL prior to the MIC assay and then inoculated the standardized spore suspension into flat-bottomed 96-well microtiter plates containing a series with increasing amounts of and incubated at 37℃ for 48 h. We performed readings from the bottom of the microtiter plates using a mirror and determined at which concentration we observed 100% inhibition (Camps et al. 2012b). There were six replicates for each assay. If at a concentration of 16 mg/L no inhibition was observed, we (arbitrarily) classified the MIC as 32 mg/L. We measured the MIC values for each time point for each lineage, allowing to generate an evolutionary trajectory of relative MIC. In these trajectories, stepwise increases in MIC are indicative of the fixation of a mutation conferring resistance (Lenski and Travisano 1994). 
Population dynamics in the evolutionary lineages over time  We selected three lineages from the difenoconazole treatment that achieved the highest resistance increase (lineages D1, D3, D6) for a more in-depth study of the evolutionary dynamics looking at morphological changes. Around 100 spores from samples from different time points of each lineage (D1, D3, D6) were spread onto MEA plates with 1µg/ml of difenoconazole. The morphology of resulting fungal colonies was analyzed using the Z7 programme and proportion of each type was recorded after two days of growth. Various different morphologies were observed, each of which was inoculated into bottle with 1µg/ml difenoconazole, incubating at 37°C for a week to assay total spore production. To measure spore production, we harvested spores from each bottle by adding two mL of saline-Tween and beads into bottle and vortexed for five minutes. The spore production was assayed at Coulter counter (Schoustra et al. 2009) after filtering out large pieces of hyphae.  Further, the mycelial growth rate (MGR) of each morphological type was measured on MEA plates supplemented with 1µg/ml difenoconazole. 
Whole-genome sequencing   We performed whole-genome sequencing on each morphological type found in lineages D1, D3 and D6 (described above). Furthermore, we sequenced three lineages that had 
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evolved in the absence of azoles (C2, C4, C5).  For sequencing, we picked three colonies of the same morphotype and performed a combined DNA extraction. The sequencing was performed by BGI.   Fastq files were analysed for quality using Fastqc (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). We further counted the number of reads and number of nucleotides of all samples, which were well balanced (see table S1). Since most nucleotides had a quality higher than 30 (Q>30) we trimmed the reads using 30 as minimum quality and 70 nucleotides as minimum length (trim-fastq.pl from the popoolation pipeline (Kofler et al. 2011a)). Reads were aligned using BWA mem (v. 0.7.10, -B 4, -O 6, -E 1(http://bio-bwa.sourceforge.net/bwa.shtml)) to a de-novo assembled genome, which was produced using only reads from the ancestor sample (Celera Assembler, 8.3rc1(Myers et al. 2000)).  Aligned reads were filtered for quality (MAPQ > 50) and only reads with both ends aligned were kept. Then we used picard tools (1.107(http://picard.sourceforge.net.)) to remove duplicates and GATK (3.3-0(McKenna et al. 2010)) to realign around indel regions. Then we calculated pairwise fst values between all evolved lines and the ancestor (fst-sliding.pl, popoolation2(Kofler et al. 2011b)). Because we combined DNA of three clones, we essentially estimated the allele frequencies of 0, 1/3, 2/3 or 1. We called SNPs by selecting loci with a pairwise fst larger than 0.05, with a coverage higher than 25X. We then estimated whether a SNP was in a gene and if so, non-synonymous by blasting the variant and ancestral sequence around the SNP (blastx, ncbi database, only for A. 
fumigates). An additional analysis was done to detect structural variants using breakdancer (http://www.nature.com/nmeth/journal/v6/n9/abs/nmeth.1363.html, v 1.1.2) for which we used unfiltered BAM files. All variants found were visually inspected using IGV (James et al 2001, v. 2_3_57). SNPs that were omitted were often found to lay in regions rich in SNPs and in which multiple SNPs were found within single reads.  
Statistical analysis To explain the observed variation in relative MIC of the evolved strains and control against different azoles (one agricultural and three medical azoles), we performed the Analysis of Variance (ANOVA) for the relative MIC data with type of agricultural Azole (Azole) and Resistance to three medical azoles (Test) as fixed factors (model: Relative MIC ~ Azole*Test). Furthermore, because the effect of relative MIC depended on the azole used for the selection (see results), we performed post-hoc LSD tests to check whether the achieved level of resistance depended on the azole fungicide used for selection (model for each test azole separately: Relative MIC~ azole treatment) and which medical azole were used to test (relative MIC~ medical azoles test).  The analysis of the relative MIC are presented as mean values ± standard error of the mean (SEM). p-values of ≤ 0.05 (*) were defined as significant. To test for a correlated response between an increase in resistance to the agricultural azole used for selection and cross-resistance to the medical azoles, we constructed fitness trajectories in all four environments. From these trajectories, we recorded the timing of an increase in 
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resistance (MIC) and we used linear regression asking whether there is a correlation in the timing of an increase in resistance to the agricultural azole and cross-resistance to the medical azole.  
Results 
Susceptibility testing of evolved cultures against agricultural and 
medical azoles We assayed the cross-resistance level to three medical azoles (itraconazole, voriconazole, posaconazole) of all lineages that had evolved under laboratory conditions in the presence (or absence) of one of five agricultural azoles at each of the seven evolutionary time points. The level of resistance of evolved cultures against agricultural azoles had been assayed in a previous study (Zhang et al 2015). Figure 1 shows the evolutionary dynamics of resistance level (defined as the Minimal Inhibitory Concentration of a given evolved culture relative to the MIC of the ancestor) averaged for the six replicate lineages that had evolved under the same conditions. Figure 1A shows data of resistance to the agricultural azole used for selection (taken from Zhang et al 2015), figure 1B-D shows the cross-resistance to medical azoles. Statistical analyses show that on average evolved lineages have an increased resistance to agricultural azoles (Azole), as well as an increased cross-resistance to the three medical azoles (Test) and that this was dependent on the medical azole used for test (Supplementary table 1A). The resistance (relative MIC values) against the three medical azoles increased by 2-3.3 fold (POS), 3-4.6 fold (VOR), strikingly 4.4-35 fold(ITR) at the end of  seven weeks. This cross-resistance is in the same other of magnitude or higher than the resistance increase to the agricultural azole that was used during the seven week selection. The relative MIC of itraconazole against evolved cultures were significantly higher than the MIC of posaconazole and voriconazole (Supplementary table 1B)  The five agricultural azoles that we used during the selection for resistance induced different levels of cross-resistance to the three medical azoles. In particular, for the lineages evolved under the selection pressure of difenoconazole, the cross-resistance against the three medical azoles is significantly higher than the other four agricultural azoles (Supplementary table 1C).  These differences suggest that difenoconazole is a stronger selective agent for the evolution of resistance to medical azoles. According to the medical-resistance breakpoints of different azoles for A. fumigatus using the proposed EUCAST susceptibility testing methodology, a strain with either MIC(posaconazole) > 0.5 mg/L,  MIC(voriconazole) > 2mg/L or MIC(itraconazole) > 2mg/L  is considered resistant to that medical drug (solid lines in Figure 1B-D)(Verweij et al. 2009a). While all lineages have increased their resistance to medical azoles over seven weeks, not all are now resistant in a clinical sense, i.e. have a resistance above the resistance boundary. Counting individual lineages, we obtained out of 253 cultures a  
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Figure 1. Evolution of resistance over seven weekly transfers  Each line shows the average of six replicate lineages that had evolved in the presence (or absence) of one of five agricultural azoles. Error bars indicate the standard error of the mean (SEM). Resistance is given by the relative MIC-value of an evolved strain relative to the ancestor. Panel A: Resistance of evolved lineages against the agricultural azole used for the selection; each series of six l ineages assayed for resistance against their respective azole used for selection (data from J Zhang et al 2015)  b = bromuconazole, t = tebuconazole, e = epoxiconazole, d = difenoconazole , p=propiconazole , c= no azole present.  Panel B: Cross-resistance of evolved lineages against the medical azole posaconazole (POS). Panel C: Cross-resistance against the medical azole voriconazole (VOR). Panel D: Cross-resistance against the medical azole itraconazole (ITR). In panels B to D the horizontal solid line shows the boundary above which strains are considered resistant by clinical standards (resistance breakpoint).  
total of 97 that are resistant to itraconazole, eight to voriconazole and no resistant cultures to posaconazole (Table 1). This is in line with the results described above that indicate difenoconazole imposes the strongest induction of cross-resistance to medical azoles (Figure 1). These results further suggest that posaconazole is the most effective medical azole with the least cross-resistance from agricultural backgrounds and itraconazole is the least effective. Notably, this matches with time since these medical triazoles were clinically licensed: itraconazole in 1997, voriconazole in 2002 and posaconazole in 2006 (Denning et al. 2014; Siopi et al. 2014). 
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Table 1. The number of individual lineages that evolved cross-resistance to 
different medical azoles at a level of clinical resistance (resistance breakpoint, 
Figure 1) after selection on an agricultural azole 
Number of  resistant cultures Stress (Agricultural fungicides) MIC(POS) > 0.5mg/L MIC(VOR) > 2mg/L MIC(ITR) > 2mg/L Bromuconazole 0/42 0/42 26/42 Difenoconazole 0/42 6/42 25/42 Epoxiconazole 0/42 0/42 17/42 Propiconazole 0/42 1/42 8/42 Tebuconazole 0/42 1/42 21/42 Total 0    8    97 
Evolutionary patterns of evolved cultures on agricultural azoles and 
correlated response on medical azoles Under the selection pressure of five agricultural azoles, the resistance level of each lineage to different azoles increased over the seven-week selection period through the successive fixation of mutations. This results in a step-wise increase in resistance (relative MIC) and fitness over time, as is typically observed in laboratory experimental evolution (Lenski and Travisano 1994; Schoustra et al. 2009). We measured resistance (Relative MIC) against the agricultural azole used for the selection and cross-resistance against the three medical azoles and recorded the time points at which an upward step in resistance occurred (Table 2). We compared the evolutionary trajectories over time for the timing and the number of step-wise increases of resistance, asking whether a fixation of a mutation to the agricultural azole leads to a parallel increase in cross-resistance to the three medical azoles. Roughly half the lineages (D1, 3, 6, E4, P3) went through two steps to reach high fitness and half (D4, B5, B6, T4, E1) went through one step. Linear regression analysis shows that lineages on average exhibit the same step wise increase in resistance to the agricultural azole used for the selection and cross-resistance to the three medical azoles (correlation coefficients with statistical significance between of the timing of resistance increase of agricultural azoles and the medical azoles, see Supplementary table 2A, B). This parallel increase in resistance suggests that the genetic changes that underlie the increased resistance to agricultural azoles also lead to cross-resistance to medical azoles. 
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Table 2. Evolutionary trajectories of evolving lineages against agricultural and 
medical azoles 
Population dynamics within three evolutionary lineages Lineages D1, D3, D6 (three lineages that evolved in the presence to difenoconazole) reached high (cross-) resistance after seven weeks of experimental evolution and were selected for whole-genome sequencing. Prior to sequencing, we performed an in-depth analysis of population dynamics for these three lineages to find out whether or not the lineages diversified into different types by diluting and plating the lineages cultures from different time points. We found that the lineages consisted of a mixed population of different morphological types.  In lineage D1, three morphological types appeared: ancestor, middle size and big size (Figure 3). The ancestral morphotype declined from the first week and was completely replaced by the middle size morphotype at the fifth week that had occurred at the second week. It declined sharply at the sixth week and disappeared at the seventh week, when it was replaced by the big size colony that had occurred at the fifth week. The middle size colony appears to be the intermediate type. The shift in morphotypes suggests the middle size colony carries at least one beneficial mutation compared with the ancestral type and that the big type carries at least two mutations compared with the ancestor. This idea is supported by the outcome of a sexual cross between D1-big and a derived ancestor showing segregation of at least two loci among the progeny (Supplementary Figure 5). This is in line with an increased resistance to both difenoconazole and the medical azoles (MIC resistance test) and increased growth rate (MGR) compared to the ancestral type (ANOVA: F 2, 6= 1463.769, P <0.01, Post-Hoc LSD test, P ancestor-middle-big <0.01 Supplementary 3A), and increased spore production (ANOVA: F 2, 6= 69.095, P <0.01, Post-Hoc LSD test, P ancestor-big <0.01, P ancestor- middle = 0.891) (Figure 3, Supplementary table 3B).  In lineage D3, two morphological types (dense and fluffy) occurred during the evolutionary experiment (Figure 3). The ancestral type declined sharply after the first week and was completely replaced by the dense morphotype at the third week. Between the third and fifth week dense morphotype declined in frequency to reach 35% at the seventh week. In the third week, a fluffy morphotype occurred and reached a frequency of 70% at the seventh week. Resistance level to difenoconazole and cross-resistance to 
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the three medical azoles show that the mixed population of fluffy and dense morphotype is more resistant to itraconazole and difenoconazole (MIC resistance test) than the morphotypes in isolation. The growth rates (MGR) of three types of colonies showed the fluffy colony had faster growth rate than other two types (ANOVA: F 2, 6= 10299, P<0.01, Post-Hoc LSD test, P ancestor –dense-fluffy <0.01, Supplementary table 3A). The dense morphotype colony could produce significantly more spores than other two types (ANOVA: F 2, 6= 586.204, P <0.01, Post-Hoc LSD test, P ancestor-dense <0.01; P ancestor-fluffy <0.05) (figure 3, Supplementary 3B).  Within lineage D6, we observed four morphotypes. The ancestral type sharply declined to zero, to be replaced by a fluffy morphotype by the third week. This fluffy type occurred since the second week and completely fixed at the third week, followed by a decline in the fourth week and then remained stable at a frequency of 60%. A big size morphotype appeared at the second week, reached a frequency of 20% before disappearing in the fifth week. The white morphotype has a sporulation defect and occurred at third week and reached a stable frequency of 40%.  Resistance level to the three medical azoles was highest for the mixture of fluffy and white type is better fit in high concentration of itraconazole and difenoconazole (MIC resistance test). The growth rate (MGR) of four types of colonies showed the fluffy type had faster growing than other three types (ANOVA: F 3, 8= 1771.202, P<0.01, Post-Hoc LSD test, P ancestor-big-fluffy <0.01; P ancestor-white =0.103, Supplementary table 3A). During culturing, this white morphotype does not sporulate until the fifth day of culturing and in the end produces significantly 10 times less spores than the ancestral morphotype (ANOVA: F 3, 8= 771.498, P<0.01, Post-Hoc LSD test, P ancestor-fluffy-white <0.01; P ancestor-fluffy <0.05, Supplementary table 3B).   
 
Whole-genome sequence analysis  We sequenced a total of eleven (9) genomes: the ancestor, three lineages that had evolved in the absence of azole for seven weeks (C2, C4 and C5 called control lineages) and the five morphotypes observed in the lineages D1, D3 and D6 (described above). We used the sequence of the ancestor of the evolution experiment for a de novo genome assembly.  We found mutations in all evolved lineages. All SNPs found were visually inspected in IGV (version IGV-2.3.57) using the de novo assembled genome, all samples and filtered bam files. SNPs that were kept after visual inspection are listed in Table 3. All SNPs found were non-synonymous and invariable in the ancestor, indicating that all SNPs were new for the evolved lines. Next to SNPs one deletion (TG) was found in the control 5 lineage, which caused a frameshift with stop codon in a conserved hypothetical protein. In the three difenoconazole lineages, we found different morphotypes evolved during the evolutionary experiment. After sequencing analysis, lineages that evolved under the 
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Figure 3. Population dynamics and characteristics (frequency changes, growth 
rates, spore production and MIC value) of different types in in three 
difenoconazole lineages.    
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pressure of azole treatment and lineages that evolved without azoles both acquired mutations indicating adaptations of the strain to the laboratory environment, which might not be related to resistance increase (Supplement 4). Except these mutations, D1-big size colony contained one CYP51A mutation, a gene known for its potential to harbor resistance mutations. None carried a mutation in the HapE gene, which is another target gene for resistance (Camps et al. 2012a). Others are with potential new resistance mechanisms (Table 3). D1-big with the cyp51 mutation had higher fitness (in terms of MGR and spore production). Further, D1-big carries another mutation in HMG CoA reductase, as is expected since there was an intermediate type (D1-middle) between D1-big and the ancestor. The P ->L substitution at amino acid 320 in HMG CoA reductase was found to be completely divergent in D1-big and D3-dense compared with the ancestor, but as well in the control 5 line, suggesting that this mutation may be a general adaptation to laboratory conditions with an associated increase in azole resistance. In the control 2 line we found three SNPs that were still variable, of which one was also found in d3 fluffy (374 P-> S in Putative amidohydrolase ytc J). These two SNPs are found in both evolved and control lines and are likely due to general adaptations to laboratory conditions. However, beside the P320L change in the HMG CoA reductase in D3-dense, we did not find any additional SNP. While this SNP was also found in the control 5 line, this line also contained a deletion which caused a frame shift and STOP codon in a conserved gene. This means that the control 5 and d3 dense are genetically different. Furthermore, the alternation in the HMG-CoA reductase, a key enzyme in mevalonate biosynthesis, rise the ergosterol has been reported in the A. fumigatus and 
Candida species (Macreadie et al. 2006). In D3-fluffy we found two additional SNPs that were not fixed (yet) that were not found in any other sample. Similarly, in D6-fluffy three new SNPs were found (compared to ancestor) that were private for D6-fluffy, while in d6white we found two private SNPs that were completely fixed. Trace-back experiment confirmed the PtaB Q264STOP is related to phenotype of white (later sporulation), while Hypothetical protein G167D is associated with the increased azole resistance. This co- balanced mixed population within D3 and D6 lineages can be explained by cross- feed or complementation between these two phenotypes. The function of each type in this co-balanced population needs further study. Also, to firmly establish that the mutations we detected through sequencing are the mutations responsible for increased resistance, a formal genetic basis would have to be established to knock-outs and complementation tests. This is beyond the scope of this current study.   
Discussion  In this study, we tested the consequences of prolonged exposure of A. fumigatus to one of five agricultural azoles for cross-resistance to three medical azoles. We found widespread cross resistance to medical azoles in experimental populations after seven weeks of laboratory evolution under the pressure of agricultural azoles. We observed 
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that evolutionary lineages show similar evolutionary patterns to agricultural and three medical azoles, which provides strong evidence that use of agricultural azoles is responsible for cross-resistance to medical azoles. Difenoconazole imposed high selection for cross-resistance, in particular to itraconazole. We further detected population dynamic changes in evolving lineages, with lineages diversifying into several morphological types. Whole-genome sequencing revealed the presence of a mutation known for its effect of increased azole resistance (G138S mutation in the Cyp51 gene) as well as several other point mutations.  
Table 3: Whole-genome sequence analysis of evolved strains  Evolved strain Substitution (SNP/del) Gene  D1 big G138S (SNP) P320L (SNP) CYP51 HMG CoA reductase D3 fluffy S109L (SNP) A276T (SNP) TreA / Ath1 DUF1479 domain protein D3 dense P320L (SNP) HMG CoA reductase D6 fluffy Q107STOP (SNP) G129V (SNP) VK 751--(DEL) TOM70 MnSOD Mdm31 D6white Q264STOP (SNP) G167D (SNP) PtaB Hypothetical protein Control 5 P320L (SNP) 
HRTVIISP551-558 QNCYHFASTOP (DEL) HMG CoA reductase Conserved hypothetical protein Note: Con5 contains an additional deletion (TG) that causes a frame shift (adding stop codon) in a conserved hypothetical gene (see table in supplement).   Interestingly, the resistant strains showed the same step-wise pattern of increase in resistance to agricultural azoles and medical azoles. Step-wise increases in fitness change are indicative for the fixation of a mutation (Lenski and Travisano 1994). In other words, this strongly suggests that mutations conferring resistance to agricultural azoles also confer cross-resistance to medical azoles. This was expected since the medical and agricultural azoles share the same site of action (binding site) and is structurally similar (Snelders et al. 2012). These results provide direct evidence that agricultural azoles can induce cross-resistance to medical azoles in A. fumigatus and is consistent with previous findings that mutations in the cyp51 gene (G138S) confer resistance both to agricultural as well as medical azoles (Chassot C 2008; Gisi U 2008; Snelders et al. 2012).  There has been a long standing debate about the interaction between environmental and clinical routes to azole resistance (Hof 2008; Gisi 2013; Lago et al. 2014). A. 
fumigatus grows and sporulates frequently in natural habitats such as soil and decaying plant material, places that might be contaminated with all kinds of azoles used to control a wide variety of fungal plant pathogens. Our work shows that resistance development to medical azoles through exposure in the environment is a plausible route. It has been suggested that the development of resistance in agricultural environments is less likely 
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than in medical environments due to the 10 to 100 fold lower concentrations of azoles used in agriculture in comparison to medical environments (Gisi and Sierotzki 2008; Kuck 2012). This exposure to low concentrations does not limit the emergence of resistance: our results show that even with azole concentrations as low as 1 µg/ml up strains resistant to 40 fold higher concentrations can emerge. Therefore, a high concentration is not an essential factor for resistance development. In fact, the higher number of growth cycles and associated opportunity for mutations to arise could actually enhance resistance development (Zhang et al 2015) and agricultural fields with relatively low maximum exposure are also highly likely to induce such high stress levels to promote the development of azole resistance. Decaying plant material of different origins, such as compost, self-heated hay and corn heaps, and litter of, for example, ferns, cotton, barley, cabbage and conifers are important habitats for A. fumigatus. These materials are likely to contain sufficient (residual) agricultural azoles to generate a selection pressure for resistance, for example, in discarded peel from citrus fruit that has previously been treated.  A total 30 agricultural azoles have been authorized for agricultural use in the past 20 years, of which five agricultural azoles showed the potential strong selection for resistance (Snelders et al. 2012). In our experiment, we confirmed that these agricultural azoles can induce cross-resistance to medical azoles. Of these five azoles, difenoconazole exposed strongest selection. Thus, the use of similar compounds for medical and non-medical applications may result in the selection of resistance through one application that affects the use of similar compounds in the other area of use. Cross-resistance has been found in other applications as well, for instance, for extended-spectrum beta-lactamase (ESBL) producing Escherichia coli, where the use of antibacterial agents for cattle rearing has selected for antibiotic resistance. The resistant bacteria are transferred to humans through consumption of food containing ESBL E. coli, which may then cause infections in humans that are difficult to treat due to cross-resistance to medical drugs (dos Santos et al. 2013).  Mutation is the driving force for azole resistance evolution. Population dynamic characterization showed that the colony size (big and small), the colony texture (dense and fluffy), and even sporulation (early and late) changed over the evolutionary experiment in the different lineages, which suggested the fungi adapt to the azole environment through different genetic changes. These mutated genes which may relate with growth, sporulation need further study. Interestingly, the sporulation defect mutant in d6 lineage had a high resistance level which could be explained by the trade-off between hyphal growth and resistance traits (Mille-Lindblom et al. 2006). Previous work has shown that mutations in the cyp51A gene  of the ergosterol synthesis pathway can infer resistance to both the agricultural and the medical azoles used, due to the similarities in chemical structure (Snelders et al. 2012; Gisi 2013). With our whole-genome sequencing, we detected mutations in the cyp51A gene, as well as mutations in other targets. It is known that other mutations than mutations in the cyp51A gene can  confer cross-resistance to medical azoles (Camps et al. 2012a). In D6 white, a 
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hypothetical protein mutation is associated with resistance, and needs further gene identification. D3 dense and d1 middle contain a mutation in HMG CoA reductase, a rate-controlling enzyme of the mevalonate pathway, that produces ergostrol. In d3 fluffy and d6 fluffy with variable SNP, are difficult to trace back from evolutionary experiment. This might be explained by sampling error since only three colonies were used for sequencing. In d6 fluffy, Mdm31 is an inner membrane protein of the mitochondria, while Tom70 is located in the outer membrane. Both are in the protein influx pathway of the mitochondria(Bolender et al. 2008) It seems that the mitochondrial dysfunction has been associated with azole resistance. However, the mechanism by which the mutations found in these two phenotypes confer resistance needs, however, to be further studied.  Our results demonstrated population-dynamic changes (colony size, texture, sporulation, and cyp51A mutation frequency) that are associated with increased azole resistance in A. 
fumigatus over seven-week experimental evolution. As we observed differences in selection pressure for the various azole compounds, the implications of both the dose and the molecule structure should be taken into account in future studies. Knowing the exact identity of adaptive mutations in A. fumigatus will be an essential avenue of future research, which will further unravel the evolutionary dynamics of A. fumigatus adaptation both in the human setting and in the environment. Understanding the key factors that facilitate resistance selection in A. fumigatus is essential to design strategies that prevent or overcome this emerging threat.  
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Supplementary data  
Supplementary 1A     Results of an Analysis of Variance (ANOVA) for the relative MIC data with type of Azole (Azole) and Resistance to three medical azoles (Test) as fixed factors (Relative MIC ~ azole treatment*medical azoles test; *: P-values lower than 0.05 **: P-values lower than 0.01).  Source of variation Sum of squares (SS) Degrees of freedom (df) Mean squares (MS) F Significance (P-value) Azole (A) 2248.333 5 449.667 4.074 0.002** Test (T) 3499.056 2 1749.528 15.852 0.000** A*T 3207.611 10 320.761 2.906 0.003** Error 9933.000 90 110.367   Total 23688.000 108    
 
Supplementary 1B  Following Post Hoc LSD Tests to explain which medical azole test has significantly effect on the relative MIC. (Relative MIC ~ medical azoles test; Post Hoc LSD Tests *: P-values lower than 0.05 **: P-values lower than 0.01)  P (Post Hoc) MIC(Itraconazole)  MIC(voriconazole) MIC(posaconazole) MIC(Itraconazole)  P <0.01** P <0.01** MIC(voriconazole) P <0.01**  P = 0.679 MIC(posaconazole) P <0.01** P = 0.679   
Supplementary 1C  Following Post Hoc LSD Tests to explain which agricultural azole has significantly effect on the cross resistance to medical azoles. (Relative MIC ~azoles; Post Hoc LSD Tests *: P-values lower than 0.05 **: P-values lower than 0.01)  Azole              P Bromucon- azole Difenocon- azole Epoxicon- azole Propicon- azole Tebucon- azole Control (no azole) bromuconazole  0.002** 0.42 0.67 0.97 0.94 difenoconazole 0.002**  0.016** 0.006** 0.002** 0.00** epoxiconazole 0.42 0.016**  0.704 0.439 0.516 propiconazole 0.67 0.006** 0.704  0.693 0.757 
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Supplementary 2A  
 
       
tebuconazole 0.97 0.002** 0.439 0.693  0.932 Control(no azole) 0.94 0.001** 0.516 0.757 0.932  
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Supplementary 2B  Linear regression of analysis of correction between MIC trajectory of agricultural azole and MIC trajectory of three medical azoles (POS, VOR, ITR) 
Regression D1(POS) D1(VOR) D1(ITR) 
D1(D) R=0.796, F 1, 22 = 37.983, P <0.01** R=0.873, F 1, 22 = 70.328, P <0.01** R=0.876, F 1, 22 = 72.849, P <0.01** 
Regression D4(POS) D4(VOR) D4(ITR) 
D4(D) R=0.664, F 1, 22 = 17.320, P <0.01** R=1.00, F 1, 22 = -,P <0.01** R=0.646, F 1, 22 = 15.775, P <0.01** 
Regression D5(POS) D5(VOR) D5(ITR) 
D5(D) R=0.624, F 1, 22 = 14.007, P <0.01** R=0.701, F 1, 22 =21.218,P <0.01** R=0.796, F 1, 22 = 38.060, P <0.01** 
Regression D6(POS) D6(VOR) D6(ITR) 
D6(D) R=0.864, F 1, 22 = 64.809, P <0.01** R=0.805, F 1, 22 =40.525,P <0.01** R=0.836, F 1, 22 = 51.118, P <0.01** 
Regression T1(POS) T1(VOR) T1(ITR) 
T1(T) R=0.525, F 1, 22 = 8.361, P <0.01** R=0.659, F 1, 22 =16.844 P <0.01** R=0.650, F 1, 22 = 16.058, P <0.01** 
Regression T4(POS) T4(VOR) T4(ITR) 
T4(T) R=0.974, F 1, 22 = 412.5, P <0.01** R=0.808, F 1, 22 =41.365 P <0.01** R=0.934, F 1, 22 = 149.904, P <0.01** 
Regression B5(POS) B5(VOR) B5(ITR) 
B5(B) R=0.444, F 1, 22 = 5.392, P <0.05* R=1.00, F 1, 22 =-, P <0.01** R=0.965, F 1, 22 = 297, P <0.01** 
Regression B6(POS) B6(VOR) B6(ITR) 
B6(B) R=1.00, F 1, 22 = -, P <0.01** R=0.378, F 1, 22 =3.667, P =0.069 R=0.608, F 1, 22 = 12.891, P <0.01** 
Regression E1(POS) E1(VOR) E1(ITR) 
E1(E) R=0.618, F 1, 22 = 13.606, P <0.01** R=0.714, F 1, 22 =22.846, P <0.01** R=0.799, F 1, 22 = 38.717, P <0.01** 
Regression E4(POS) E4(VOR) E4(ITR) 
E4(E) R=0.836, F 1, 22 = 50.869, P <0.01** R=0.832, F 1, 22 =49.417, P <0.01** R=0.863, F 1, 22 = 64.095, P <0.01** 
Regression P3(POS) P3(VOR) P3(ITR) 
P3(P) R=0.825, F 1, 22 = 47.028, P<0.01** R=0.920, F 1, 22 = 121.352, P<0.01** R=0.74, F 1, 22 = 26.666, P<0.01** 
Regression P2(POS) P2(VOR) P2(ITR) 
P2(P) R=0.079, F 1, 22 =0.138, P=0.714 -- R=0.176 F 1, 22 = 0.7, P=0.412    
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Supplementary 3A  One –way ANOVA followed Post Hoc analysis of mycelial growth rate of evolved isolates and ancestor to show the difference between the evolved isolates and ancestor 
              
Statistic  
Evolved 
types  
Ancestor 
 
d1-middle F 2, 6= 1463.769, P <0.01, Post-Hoc LSD test, P ancestor-middle <0.01** d1-big F 2, 6= 1463.769, P <0.01, Post-Hoc LSD test, P ancestor-big <0.01**  d3-dense F 2, 6= 10299, P<0.01, Post-Hoc LSD test, P ancestor –dense <0.01** d3-fluffy F 2, 6= 10299, P<0.01, Post-Hoc LSD test, P ancestor -fluffy <0.01** d6-big F 3, 8= 1771.202, P<0.01, Post-Hoc LSD test, P ancestor-big <0.01** d6-fluffy F 3, 8= 1771.202, P<0.01, Post-Hoc LSD test, P ancestor-fluffy <0.01** d6-white F 3, 8= 1771.202, P<0.01, Post-Hoc LSD test, P ancestor-white =0.103 
 
Supplementary 3B  One –way ANOVA followed Post Hoc analysis of spore production of evolved isolates and ancestor to show the difference between the evolved isolates and ancestor 
              
Statistic 
Evolved types 
Ancestor  
d1-middle F 2, 6= 69.095, P <0.01, Post-Hoc LSD test, P ancestor- middle  = 0.891 d1-big F 2, 6= 69.095, P <0.01, Post-Hoc LSD test, P ancestor-big <0.01** d3-dense F 2, 6= 586.204, P <0.01, Post-Hoc LSD test, P ancestor-dense <0.01** d3-fluffy F 2, 6= 586.204, P <0.01, Post-Hoc LSD test, P ancestor-fluffy <0.05* d6-big F 3, 8= 771.498, P<0.01, Post-Hoc LSD test, P ancestor-big <0.05* d6-fluffy F 3, 8= 771.498, P<0.01, Post-Hoc LSD test, P ancestor-fluffy <0.01**;  d6-white F 3, 8= 771.498, P<0.01, Post-Hoc LSD test, P ancestor-white <0.01** 
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Supplementary 4. SNPs calling between the ancestor and evolved isolates with 
differnet morphotypes.  Ref chroms-ome (Clinical reference strainAF293) 
New genome (de novo assembly) 
Gene Position Snp anc Con2 Con4 Con5 D1big D3den D3fluffy D6fluffy D6white 
4 /  1784849 3031 / 138096  cytochrome P450 14-alpha sterol demethylase [Aspergillus fumigatus]  Sequence ID: gb|AKE50937.1| 
C -> T 138 G->S C G 54 . . 41 . . 44 . . 60 T S 53 . . 45 . . 42 . . 59 . . 47 
2 /  986005 3218 /  54189  HMG-CoA reductase [Aspergillus fumigatus Z5]  Sequence ID: gb|KMK57733.1| 
C -> T 320 P -> L C P 40 . . 39 . . 54 T L 52 T L 48 T L 40 .  . 38 
.  . 34 
.  . 48 
2 /  3435913 3150 / 226430 Putative amidohydrolase ytcJ [Aspergillus fumigatus Z5]  Sequence ID: gb|KMK61702.1|Or  conserved hypothetical protein [Aspergillus fumigatus Af293]  Sequence ID: ref|XP_755663.1| 
C -> T 374 P -> S C  P  40 
C / T  P / S  41 / 4 
.  .  34 
.  .  34 
.  .  36 
.  .  51 
C / T  P / S  7 / 21 
.  .  40 
.  .  41 
3 /  568217 3074 /  407507 alpha,alpha trehalose glucohydrolase TreA/Ath1 [Aspergillus fumigatus var. RP-2014]  Sequence ID: gb|KEY75594.1| 
C -> T 109 S -> L C S 45 . . 37 . . 39 . . 52 . . 43 . . 46  
C / T S / L 11 / 49 
. . 54 . . 45 
 3144 / 36219 Conserved hypothetical protein [Aspergillus funmigates Af293] Sequence ID: ref|XP_749671.1| 
TG -> (-) Frameshift and stop codon*  
TG  H   (-)  Frameshift 
     
5 /  2390677 3134 /  161643 DUF1479 domain protein [Aspergillus fumigatus Af293] Sequence ID: ref|XP_753711.1| 
G -> A 276 A -> T G A 50 . . 45 . . 39 . . 44 . . 50 . . 40 G / A A / T 19 / 34 
. . 47 . . 47 
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 *From amino acid 551 HRTVIISP to QNCYHFA(STOP) 
 
  
Ref chroms-ome (Clinical reference strainAF293) 
New genome (de novo assembly)  
Gene Position Snp anc Con2 Con4 Con5 D1big D3den D3fluffy D6fluffy D6white 
 3178 78573 PtaB protein [Aspergillus fumigatus Af293]  Sequence ID: ref|XP_755622.1| 
C -> T 264 Q -> STOP   
C Q 35 . . 39 . . 37   
. . 43 . . 38 . . 29 . . 30 . . 34 T STOP 31 
7/  1837636 3183 30261 hypothetical protein AFUB_092560 [Aspergillus fumigatus A1163]  Sequence ID: gb|EDP48538.1| 
C -> T 167 G -> D C G 58 . . 44 . . 38 . . 53 . . 66 . . 42 . . 60 . . 58 T D 48 
 3120 13282 U3 small nucleolar RNA-associated protein Utp11 [Aspergillus fumigatus Af293]  Sequence ID: ref|XP_752827.1| 
C ->G 199 D -> E C D 39 C /G D / E 23 / 24  
. . 44 . . 39 . . 37 . . 40 . . 39 . . 54 . . 38 
 3120 15850 phosphoribosyl-AMP cyclohydrolase [Aspergillus fumigatus Af293]  Sequence ID: ref|XP_752826.1| 
C -> A 325 W-> C  
C W 39 C /A W / C  16 / 15 
. . 40 . . 40 . . 48 . . 38 . . 45 . . 37 . . 41 
 3084 mitochondrial outer membrane translocase receptor (TOM70), putative [Aspergillus fumigatus Af293]  Sequence ID: ref|XP_749301.1| 
C -> T 107 Q  -> STOP 
C Q 43 . . 55 . . 49 . . 37 . . 34 . . 56 . . 51 C / T Q / STOP 25 / 13 
. . 46 
 3120 21378 Mn superoxide dismutase MnSOD [Aspergillus fumigatus Af293] Sequence ID: ref|XP_752824.1| 
C -> A 129 G -> V  
C G 60 . . 36 . . 39 . . 46 . . 53 . . 52 . . 42 C / A G / V 40 / 6 . . 58 
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Supplementary Figure 5 Analysis of the progeny of a sexual cross between D1big and sensitive isolate. The four phenotypic classes suggest two fixed mutations which is in line with the observed two-step increase in resistance (“Growth rate”) during the evolutionary trajectory.  
 1-59 are progeny number; 60-62: parental type 1, ancestor of the evolution experiment (green); 63-65: parental type 2, evolved strainD1big (red) 
 
 S5 .  Segregation of MGR among the progeny from a sexual cross between the ancestral genotype (parental type 1; P1) and an evolved strain (D1big, parental type 2; P2) with high MIC and fitness. MGR of progenies was measured on the MEA containing 1 µg /mL difenoconazole. The top panel  shows all progeny separately and the two parental types for the cross, the bottom panel  shows how the progeny clusters in distinct phenotypic classes (evenly classify the group til l  ANOVA and following post hoc significant test shown). Among the progeny we clearly observe segregation in 4 classes, two parental classes and two recombinant classes. This is indicative of two segregation loci , which in turn suggests that two mutations with an effect on MGR had fixed during experimental evolution.    
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Abstract 
Aspergillus fumigatus causes a range of diseases in humans, some of which are characterized by fungal persistence for many years. A. fumigatus, being a generalist saprotroph, may initially establish lung colonisation by its physiological versatility and subsequently gradually adapt to the human lung environment, through genetic changes. Human-adapted genotypes can be generated by spontaneous mutation and/or recombination and subsequent selection of the fittest genotypes. Sexual and asexual spore formations are considered to be crucial contributors to the genetic diversity and adaptation potential of aspergillus. However, in certain aspergillus diseases, such as cystic fibrosis, A. fumigatus may persist as network of mycelium and develop patient-acquired resistance during azole therapy. Such mycelia may become heterokaryotic by mutation of one of the nuclei or by anastomosis of hyphae from genetically different mycelia. We investigated the relevance of heterokaryosis in the adaptive development of azole resistance in A. fumigatus. We found that azole-exposed mycelial cultured from patients, as well as from laboratory evolution experiments, segregated into different morphotypes with different azole-resistance phenotypes. Individual colonies recovered from the same patient were capable of forming a heterokaryon, whereas those from different patients were heterokaryon-incompatible. We formed heterokaryons and diploids from A. fumigatus strains with different levels of resistance. When exposed to various azole environments, the heterokaryons revealed remarkable shifts in the nuclear ratio, and the resistance level of most heterokaryons exceeded that of the corresponding heterozygous diploids. Our results indicate that heterokaryosis may be a strategy for A. fumigatus to adapt to the lung environment, field and to overcome azole exposure.  
Key words: Aspergillus fumigatus; heterokaryon; azole resistance; diploid; flexible; nuclear ratio; 
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Introduction  The vast majority of invasive mould infections in humans are caused by Aspergillus 
fumigatus. Azole antifungals are the mainstay of management of aspergillus diseases, but treatment is hampered by the emergence of multi-azole resistant A. fumigatus isolates. Azole resistance is now reported globally (Arendrup et al. 2010; Lockhart et al. 2011; Mortensen et al. 2011; Pfaller et al. 2011; Chowdhary et al. 2012; Morio et al. 2012; Gisi 2013; Bignell 2014; Chowdhary et al. 2014), with resistance rates varying between 3.9% and 19% in clinical isolates in the Netherlands (Snelders et al. 2008; van der Linden et al. 2011) and 20% in the National Aspergillosis Centre of the United Kingdom (Howard et al. 2006; Howard et al. 2009; Bueid et al. 2010). The majority of highly resistant mutants have modifications in the coding or promoter region of the cyp51A-gene. This gene encodes the enzyme lanosterol 14- alpha-demethylase (CYP51), the target of azoles that is essential to the ergosterol synthesis pathway. These cyp51A mutations are believed to emerge by exposure of A. fumigatus to medical azoles or azole fungicides (Camps et al. 2012). Although many aspects of azole-resistance development in A. fumigatus remain to be investigated, resistance can be regarded as a fungal adaptation strategy to azole-containing environments, through creating genetic diversity followed by natural selection (McDonald et al. 2016). Genetic variation may be generated during the various aspects of the lifecycle of A. fumigatus: mycelial growth, asexual sporulation and sexual reproduction. Several studies in A. fumigatus have focused on the consequences of asexual (Zhang et al. 2015b) and sexual reproduction for fungal adaptation (Kwon-Chung and Sugui 2009; Losada et al. 2015), but the role of mycelial growth has been largely overlooked.  Although patient-acquired azole resistance appears to be associated with the presence of a cavity, which is an environment that allows asexual reproduction, 
A. fumigatus hyphal biofilms may be present in patients with cystic fibrosis (CF). A variety of azole-resistance mutations has been observed in CF-patients, indicating that fungal adaptation takes place (Arendrup et al. 2010). Somatic mutations may occur during mitotic divisions leading to genetic variation within the mycelium. Such heterokaryotic mycelium may subsequently undergo parasexual recombination and/or segregate a variety of clones.  Heterokaryosis, i.e. genetically different nuclei within the same cytoplasm, is common in fungi.  Hansen (1938) found that in various fungi more than 50% of natural mycelia were heterokaryons that upon single-spore culturing segregated in three morphologically distinct types of pure cultures: one that produces scant aerial hyphae but many conidia, one that produces abundant aerial hyphae but few or no conidia, and an intermediate type (Hansen 1938).  A heterokaryon can result from mutations in one or more nuclei in a homokaryotic mycelium, or from anastomosis of hyphae from genetically distinct homokaryons. The 
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latter is however restricted by heterokaryon incompatibility, a common fungal allorecognition mechanism limiting successful fusion of hyphae to clonally related strains with the same heterokaryon compatibility alleles (Glass and Kuldau 1992; Saupe 2000; Bastiaans et al. 2014; Bastiaans et al. 2015), so mutation is probably a more likely initial cause of heterokaryon formation, especially for isolated long-lasting cultures. Like heterozygosity, heterokaryosis may allow genetic complementation of recessive mutations and heterosis effects. However, heterokaryons are potentially more flexible: in a heterokaryon the nuclear (and allelic) ratio is not strictly controlled, so all possible nuclear ratios can occur from 0 to 100 percent and can change depending on environmental conditions, whereas in a heterozygous diploid the allele ratio is fixed at 50 percent. Heterokaryosis may also lower the fitness of the colony because of genomic conflict between different types of nuclei. Indeed cheater nuclei, that increase their frequency among spores at the cost of overall colony fitness, and are poorly sporulating when homokaryotic, have been found to evolve rapidly under specific conditions in 
Neurospora crassa that allow heterokaryon growth (Bastiaans et al. 2014). These lab findings are reminiscent of the natural heterokaryons by Hansen (1938). Even though heterokaryosis has been described in many fungal species such as Neurospora, 
Aspergillus, including A. fumigatus, and Penicillium(Dodge 1942; Beadle and Coonradt 1944; Pontecorvo and Gemmell 1944; Jinks 1952; Debets et al. 1990), the biological significance is largely unclear (Debets 1998).  Since asexual spores of A. fumigatus are uninucleate, newly formed colonies start as a homokaryon and may produce heterokaryon during mycelial growth. Heterokaryosis is thus a transient characteristic of the mycelium that is lost upon asexual sporulation and dispersal of spores by air or by segregation into homokaryotic sectors. Therefore, heterokaryons may form and persist particularly in long-lived cultures. This may be the case for chronic A. fumigatus infections, where the fungus has been shown to persist sometimes for many years (De Valk et al. 2009). Moreover, in patients who have been treated with triazoles, heterokaryosis might be a strategy to develop resistance (Camps et al. 2012a).  Over time, emergence of azole resistance in chronically colonized patients has indeed been described in consecutive A. fumigatus cultures that were concluded to be isogenic using microsatellite genotyping (Arendrup et al. 2010; Camps et al. 2012b). Evidence for a possible role of heterokaryosis in azole-resistance development was found in evolutionary laboratory experiments where an ancestral strain was allowed to evolve resistance during several weeks of azole exposure (Zhang et al. 2015b). Both from patients and from evolutionary laboratory experiments, different evolved morphological clones of A. fumigatus have been isolated, some of which are poorly sporulating or completely aconidial (Ahmad et al. 2015; Zhang et al. 2015a), Table 1 and Figure 1). Different morphotypes have been encountered especially in chronic infections either sinusitis, aspergilloma or in CF (De Valk et al. 2007; de Valk et al. 2009; Mortensen et al. 2011; Ahmad et al. 2015; Zhang et al. 2015a) but the significance of such polymorphisms has not been studied. 
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Here, we study the relevance of heterokaryosis and morphotypes in the development of azole-resistance in A. fumigatus. We address the following questions.  a. What are the characteristics of different morphotypes of A. fumigatus isolated from evolved cultures of patients or lab experiments?  b. Are the different successive or coexisting morphotypes heterokaryon–compatible as expected for isogenic isolates?  c. What is the azole resistance of heterokaryons relative to that of the individual homokaryon and heterozygous diploids?  d. Is there plasticity in the nuclear ratio within a heterokaryon in response to changing azole concentrations?  
 
Material and methods  Twelve clinical A. fumigatus strains, from four aspergillosis patients from Radboud University Medical Centre, were available (Arendrup et al. 2010; Camps et al. 2012b).  A. 
fumigatus CBS 140053 was isolated from an environmental field in Wageningen, The Netherlands in 1992. CBS 140053 -D1-7#, d3-7# and d6-7# are the evolved strains from a seven-week evolution experiment under the exposure of difenoconazole (1 µg/mL) from which also d3-7#-dense, d3-7#-fluffy, d6-7#white and d6-7#-fluffy stains were collected (Zhang et al. 2015b). The azole fungicide difenoconazole, and three medical azoles (itraconazole (ITR), voriconazole (VOR) and posaconazole (POS)) were purchased from Sigma Company (Sigma Aldrich, Germany) (Zhang et al. 2015b). The number and spore size of A. fumigatus were measured on a Coulter counter (Beckman Coulter, the Netherlands).  
 
Culture media  Minimal Medium (MM) was used for culturing the heterokaryons and heterozygous diploids. MM consists of 6.0 g NaNO3, 1.5 g KH2PO4, 0.5 g MgSO47. 7H2O, 0.5 g KCl, 10 mg of FeSO4, ZnSO4, MnCl2 and CuSO4 and agar 15 g + 1000 mL H2O (pH 5.8). Malt extract ager was used for counting spores and measuring of growth rate, purchased from Sigma Company (Sigma Aldrich, Germany).  
Different morphotypes of A. fumigatus isolated from evolved cultures 
of patients and experimental evolution experiments The strains used in this study are listed in Table 1. From each of four patients, in total twelve clinical isolates were obtained (Arendrup et al. 2010; Camps et al. 2012b). Four successive isolates were collected from the same tissue from patients 1 (aspergilloma) and 2 (chronic granulomatous disease) during treatment, another four strains were from patient 3, a kidney transplant recipient, and patient 4 with invasive aspergillosis. From an evolutionary experiment the ancestral strain CBS140053 and five derived 
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strains evolved during seven weeks on medium with 1 µg/mL difenoconazole were used (Zhang et al. 2015b; Table 1).  
 
Heterokaryon compatibility testing Heterokaryon compatibility of strains was tested following standard methods (Cove 1976; Debets et al. 1990; Todd et al. 2007). Recessive markers (nitrate non-utilizing mutations nia and cnx and a colour mutation) were introduced in the various strains and strains with complementing nia and cnx markers were co-inoculated on medium with nitrate as the sole N-source (Supplement 1). The effects of chlorate and colour makers on the growth rate and ratio changes in the heterokaryon are provided in Supplement 2.  As a control these strains were grown as homokaryons on the same media. Heterokaryons of compatible complementing strains show typical vigorous growth after seven days. Heterozygous diploids were isolated from heterokaryons by means of the sandwich method (Bos et al. 1988).  
Azole resistance assays MGR assays were previously shown to correlate well with MIC assays (Zhang et al. 2015) and were performed as follows by averaging the colony diameters (in mm) as measured in two randomly chosen perpendicular directions after four days of growth colony. Heterozygous diploids and constructed heterokaryons were inoculated on MM medium and MM medium with 1µg/ml of difenoconazole.   
The nuclear ratio in heterokaryons in different azole environments Assuming that the nuclear ratio among the conidiospores reflects that nuclear ratio within the mycelium, we tested the effect of azole on the constitution of the heterokaryon. Briefly, heterokaryons, from sensitive and resistant strains differing in conidial colour, nia or cnx mutation, S (susceptible)&S(CBS-140053& CBS-140053), I (intermediate) &S (D3-7#-dense&CBS-140053) and R (resistant) &S (D1-7#&CBS-140053) were grown on MM plates with or without 1 ug/mL difenoconazole.  After 5 days of growth, spores were harvested from the edge of the heterokaryon into 0.5 mL of saline (distilled water with NaCl 0.8 g/L) supplemented with Tween 80 (0.05 % v/v) and dilutions were spread on a MEA plate. The number of colonies of either colour was counted and the ratio was calculated. T-test was used for analyzing the significance of the nuclear shift.    
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Results  
All isolates with distinct morphology from the same patient or the 
same evolution experiment are heterokaryon compatible. The four A. fumigatus strains from patient 1 and four of patient 2, which were sampled in succession, showed an increase in spore size, a decrease in growth rate and an increase in azole resistance (Table 1, Figure 1). The two isolates of patients 3 and the two of patient 4, isolated from the same clinical sample, were morphologically very distinct (Figure 1).  Also the cultures collected in the seven-week evolution experiment showed different morphology when compared to the ancestor and each other in addition to increasing azole resistance (Table 1, Figure 1). Isolates from the evolution experiments all share a common ancestor and are therefore expected to be heterokaryon compatible. Indeed all isolates were heterokaryon compatible, showing vigorous growth on nitrate medium between isolates with complementing nitrate-nonutilizing mutations (Figure 1, E1, 3, 6 A, column). This indicates a stable heterokaryon compatibility. Also the four isolates from patients 1 and 2 and the two from patient 3 were heterokaryon compatible (examples are shown in Figure 1, P1-3, A column). It was not possible to obtain nitrate-nonutilizing mutants from the non-sporulating isolate from patient 4 and therefore did not allow for heterokaryon testing. Isolates from different patients and lab experiments all showed heterokaryon incompatibility as expected from non-isogenic isolates (Figure 1, B column).
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Figure 1. Compatibility–test of all clinical strains and evolutionary strains A; compatibility test between the isolates from the same patients or lab condition B; compatibility test between isolates from different patients and lab condition 
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A. fumigatus heterokaryons have higher azole resistance than 
heterozygous diploids The azole resistance level, measured as the mycelial growth rate on azole-containing medium, of heterozygous diploids was compared to that of heterokaryons and their constituting haploid strains (Figure 2). The azole resistance of the heterokaryons was significantly higher than of the heterozygous diploids, but lower than of the most resistant haploid strain.  
 
Figure 2. The azole resistance of heterokaryons relative to that of the 
individual homokaryon and heterozygous diploids was measured as the 
mycelial growth rate.  Strains used were: sensitive(S) CBS-140053, intermediate (I) D3-7#-dense and resistant (R) D1-7# (see Table 1).  // :  diploid; & :  heterokaryon 
 
The nuclear ratio in heterokaryons is flexible The growth pattern of heterokaryons was strikingly different on medium without azoles compared to that on medium with 1 µg/mL Difeconazole (Figure 3). Whereas erratic growth of the forced heterokaryon was typically seen on medium without azoles, a more compact circular colony was formed on azole-containing medium. The use of a white spore colour mutation in one of the strains in a heterokaryon allowed for direct testing of the nuclear ratio in a heterokaryon on media with or without azoles (Figure 3). The ratio of white to green colonies from spores of heterokaryons S&S (CBS-140053& CBS-140053), I&S (D3-7#-dense& CBS-140053) and R&S (D1-7#&CBS-140053) was analyzed (Figure 4). For the sensitive heterokaryon S&S (CBS-140053& CBS-140053), there was no significant difference between the nuclear ratio on medium with and without 1µg/ml difenoconazole (T- test, T6, 2 = -2.151 P > 0.05). For the heterokaryons formed between the sensitive and resistant nuclei I&S (D3-7#-dense & CBS-140053) and R&S (D1-7#&CBS-140053), the percentage of intermediate resistant nuclear, I, shifted from 32% to 50%: 1.7 fold (T- test, T6, 2 = -9.843 P < 0.01) and the percentage of R-nuclei (D1-7#) shifted from 25% to 78%: 3.5 fold (T- test, T6, 2 = -38.689 P < 0.01).  The R (D1-7#) nuclei in R&S (D1-7#&CBS-140053) heterokaryon on medium without azole was significantly lower than S (CBS-140053) as compared to heterokaryon S&S 
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(CBS-140053 & CBS-140053) (T- test, T6, 2 = 3.587 P < 0.05), which indicates that the nuclear R (D1-7#) has certain cost of resistance on MM without azole (Figure 4).   
 
Figure 3.  Heterokaryons S- W & R -G (CBS-140053 & D1-7#) growing on 
selective medium MM without (A) and with (B) difenoconazole (1µg/ml). 
C: Colonies grown from spores harvested from heterokaryons .  W: white- spore head; G: green- spore head. Strains used were: sensitive (S) CBS-140053 and resistant (R) D1-7# (see Table 1).   
 
Figure 4. The nuclear ratio changes in three heterokaryons (S & S, I & S 
and R & S), which were exposure to different concentrations of 
difenoconazole (0 or 1µg/mL).  Strains used were: sensitive (S) CBS-140053, intermediate (I) D3-7#-dense and resistant (R) D1-7# (see Table 1) & :  heterokaryon. S&S (CBS-140053& CBS-140053), I&S (D3-7#-dense& CBS-140053) and R&S (D1-7# &CBS-140053).  
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Discussion  In this study, we provide evidence for heterokaryon of A. fumigatus both in clinical isolates and under laboratory conditions. Furthermore, we found evidence that heterokaryosis may play a role in adaptation of A. fumigatus to an azole-environment:  the flexible heterokaryon can adapt to the changing azole environment by altering the nuclear ratio. Which type of nucleus, i.e. azole-resistant or azole-sensitive, is predominant within the heterokaryon is largely determined by the environment the heterokaryon experienced. These observations are relevant for understanding the dynamics of azole resistance in A. fumigatus both in the field and in patients.  Polymorphism is regularly found in patient cultures, but the underlying genetic background and possible clinical relevance has long been neglected (Ahmad et al. 2015; Zhang et al. 2015a). Heterokaryons were first described nearly eighty years ago, and are known to be relevant to many different genera in nature (Hansen 1938). Polymorphisms are also observed in evolutionary experiments where A. fumigatus cultures are exposed to azoles (Zhang et al. 2015). Here we consider aspects of the heterokaryon for formation, storage and expression of genetic variation in A. fumigatus as potential strategy to adapt and persist in a new environment. 
A. fumigatus is generally regarded as a generalist saprotrophic fungus that causes, as a side effect of its metabolic versatility, opportunistic infections in immunocompromised patients. Survival of this fungus in a wide range of environments requires an efficient adaptation strategy. Persistence in the human host represents adaptation to the lung environment, and is often accompanied by development of azole resistance in patients receiving chronic azole therapy. In general fungi may adapt to a new environment through creating genetic diversity, through asexual or sexual reproduction, followed by selection of progeny most capable to survive (Kwon-Chung and Sugui 2009; Dyer and O'Gorman 2012). However, sexual reproduction is not relevant to the human environment, and asexual reproduction may occur only when a pulmonary cavity is present. Mostly, the fungus will be present as mycelium and in some clinical conditions, such as in patients with CF, A. fumigatus is thought to persist by the formation of biofilms (Muller et al 2010). Microsatellite genotyping indicates that in some patients a single genotype may persist for many years (Mortensen et al 2011). As azole resistance is reported in CF-patients, mutations may have occurred during mitotic divisions in the mycelium giving rise to a heterokaryon. Such heterokaryon can store and further facilitate genetic variation by mutation, parasexual recombination and segregation upon selection pressure. Heterokaryons can formally also arise by anastomosis of hyphae from different cultures, but is restricted by a fungal self/nonself recognition system called heterokaryon incompatibility. Heterokaryon incompatibility is widespread in fungi and is expressed as the inability to form a stable heterokaryon between different strains of the same species (Glass and 
                           Relevance of heterokaryosis for adaptation 
113 
 
Kuldau 1992; Aanen et al. 2010). As a result of high polymorphism for heterokaryon incompatibility genes in populations, heterokaryon compatibility is mostly restricted to clonally related isolates and, therefore two randomly picked isolates from nature are most likely heterokaryon incompatible (Debets et al. 1994, Van Diepeningen et al. 1997). Indeed, A. fumigatus isolates from different patients were heterokaryon incompatible indicating that they were of different clonal origin. However, isolates recovered from the same patient, either in consecutive cultures or different colonies from a single culture could form heterokaryon, despite variability in macroscopic morphology and azole-resistance phenotype. This observation is in line with the observation made by Camps et al. (2012) that nine consecutive isolates from a patient with aspergilloma were isogenic and are therefore expected to be heterokaryon compatible. Also isogenic isolates derived from experimental evolution cultures originating from a common ancestor retained heterokaryon compatibility.  
 
Evolutionary mechanisms underpinning the shift in nucleus ratio 
under azole selection pressure  Our data show that the proportion of resistant nuclei in heterokaryon rises in response to the azole environment. This has major implications for the understanding of A. 
fumigatus cultures from a patient biopt. It calls into question whether the primary unit of selection is the heterokaryotic mycelium as a whole or each individual nucleus within the mycelium. This may be explained by either direct selection on individual nuclei with fast division, or direct selection of mycelium (sector/ hyphal tips) as a whole. (I) The selection on individual nuclei The observation that nuclear ratios can become grossly imbalanced supports the concept that the heterokaryon represents a collective population of nuclei, and the actual “unit of selection” could be each individual nucleus (Pontecorvo 1946; Lewontin 1970; Johannesson and Stenlid 2004). Azoles act by targeting sterol 14𝛼𝛼-demethylase CYP51A, which is an important regulatory enzyme in the ergosterol biosynthetic pathway. Hence, the resistant nuclei could produce sufficient ergosterol in the presence of azoles as a result of modification of the CYP51A structure. Division of sensitive nuclei may slow down because of the lack of ergosterol and decrease of the fluidity and permeability of the cell. One explanation is that azole selection triggers the fast division of resistant nuclei in order to sustain the ergosterol production and thus retain hyphal growth. At the next step, due to the difference in nucleus division, after asexual sporulation process, existing ratio shifts in the two types of nuclei may be enhanced and more striking in terms of the resistance phenotype (Figure 5A). (II) The selection on the sector / hyphal tip When a heterokaryon originates from an equal mixture of sensitive and resistant nuclei, the sector/ hyphal tip with resistant nuclei may grow faster with sufficient ergosterol supply, as opposed to those harbouring sensitive nuclei which may extend slower. Therefore the hyphal tip with resistant nuclei will grow faster and proceed into the 
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asexual sporulation process earlier than sensitive hyphal tips. As a result, the sector containing resistant hyphae will produce a larger number of spores, compared with sectors with sensitive hyphae. Overall, when spores are harvested, the proportion of resistant nuclei will outnumber the sensitive nuclei (Figure 5B).  Our data are consistent with previously published observations. Heterokaryons of N. 
tetrasperma possess an additional level of adaptive flexibility to a changing environment, and the phenotype could be altered by changing nuclear ratios(Samils et al. 2014). Early work on ascomycete moulds Penicillium cyclopium and N. crassa has indicated that nuclear ratios of heterokaryons changed depending on environmental conditions in a manner that reflected the underlying relative fitness of the constituent homokaryons grown in isolation (Jinks 1952; Davis 1960). Hence, carrying both nuclear types and the ability to alter the nuclear ratio enables the fungus to survive in different environments.   
 Nuclei selection hypothesis 
 
Figure 5. Above: Nuclei selection hypothesis; below: Hyphal tip selection 
hypothesis.  R (Green nuclei):  resistant nuclei;  S(white nuclei):  sensitive; H: heterokaryon with mixed two types of nuclei .  Green cell membrane: healthy cell membrane with good and enough ergosterol. Black cell membrane: unhealthy cell membrane with the decreased fluidity and permeability . In the heterokaryon, the cell membrane is mixed with two types of cell membrane.  
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Relevance for-azole resistance development Clinical A. fumigatus isolates obtained from clinical specimens were found to be compatible, despite differences in macroscopic morphology. This observation has different consequences. It indicates that azole-resistance development can occur through heterokaryon formation, since new mutations arose in the mycelium. This allows for complementation of the initial cost of resistance and maintenance of genetic variation: depending on the presence of azoles the ratio of sensitive to resistant nuclei will change. But nuclear genotypes will be shielded from strong selection in the heterokaryon, and may persist, be it at low level and contribute to the overall performance of the mycelium. If indeed long-lived mycelium in patients is heterokaryotic, this also has impact on the way fungal infections in patients are analyzed. After plating a biopt sample from a patient a single genotype is not to be expected, and therefore many isolates should be analyzed. Patient-acquired resistance can be proven when a phenotype switch takes place from azole-sensitive to azole-resistant in consecutive isolates recovered from individual patients. This has been observed in isogenic isolates recovered from patients treated with azoles and who have a pulmonary cavity (Camps et al, 2012). It is believed that de novo mutations may arise through asexual reproduction, which are subsequently selected in the azole-environment. In culture, commonly different Cyp51A-mutations are found, which underscores the efficiency of this adaptation strategy. However, azole-resistance mutations have also been recovered from patients without pulmonary cavities, notably patients with CF (Mortensen et al 2011). A. fumigatus is thought to persist in the mucus in the lung through hyphal networks and biofilm (Muller et al 2010). As in CF A. fumigatus is probably trapped in the hyphal form, adaptation through heterokaryon formation is a likely alternative strategy.  The flexible heterokaryon may enable A. fumigatus to adapt to the lung environment by altering the ratio of each type of nucleus and by complementation between sensitive and resistant nuclei (e.g. of the sensitivity to azoles of the sensitive nuclei and to the cost of resistance of the resistant nuclei, or of different resistance mutations in the different nuclei). Genotyping of A. fumigatus strains recovered from CF-patients suggest that variants from a patient are isogenic, and have a heterokaryotic origin. The observation that the resistance level of a mixture of such compatible genotypes differs from each single one indicates heterokaryons may play an important role in the adaptation in A. 
fumigatus. On the other hand, cheating nuclei may also accumulate in a heterokaryon thus attenuating the fitness of the fungal mycelium. Understanding such conditions is very helpful in regulating the resistance unit (spores or hypha) and better managing the azole resistance in A. fumigatus.   
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Conclusions and Future Outlook  Our results demonstrate that the full life cycle of A. fumigatus needs to be taken into account to understand the adaptation and subsequent persistence of A. fumigatus in the human lung. In addition to asexual reproduction, our results indicate that the flexible heterokaryon is another strategy that the fungus can utilize to adapt e.g. to the lung environment and its varying conditions such as azole exposure. Variable macroscopic morphology, which is often found in aspergillus colonies, supports a role of heterokaryosis. Genetic analysis of individual colonies obtained from specimens from CF patients will help us to further understand the role of heterokaryon formation and its relevance for persistence of A. fumigatus and (azole) resistance. Understanding the key factors that facilitate resistance selection in A. fumigatus is essential to design strategies that prevent or overcome this emerging threat.  
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Supplementary data   
Supplement 1  
  A, :  Potential Chlorate mutants appear as sector along the main colony after UV radiation 60s.  B: Master plate of potential chlorate mutants is ready for Nitrate deficiency test C, D, E, F: Nitrate deficiency test                           
Supplement 2  
The effect of chlorate and color makers on the ratio changes in the 
heterokaryon 
 
1) The colour influence on the growth rate of mutants and ratio shift in 
heterokaryon All chlorate mutants with different colour were grown on MM+ ure ± azole. After 4 days of incubation at 37℃. The mycelial growth rates were recorded.  It has shown below, white and green colours do not have influence on the growth rate, (comparison between S-cnx-G and S-cnx-W; I –nia-W and I – nia-G; R-cnx-W and R-cnx-G). In the heterokaryon (I –nia-W&S-cnx-G),  in order to check whether colour influence the ratio shift, we exchange the colours of two types of nuclear, hence, the new heterokaryon(I –nia- G & S-cnx-W) was formed. The figure clearly showed the nuclear ratio shift remained the same, when move from no azole environment to azole containing environment, although the ratio slightly differ (40%- 30%) when compare the resistant nia ratio in each heterokaryon alone MM without azole. 
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             Above: The relative mycelial growth rate (MGR) of each mutant with different chlorate marker and colour on the MM +ure +1µg/ml difenoconazole . The relative MGR is defined as the MGR divided by the colony diameter of ancestor, grown on MM +ure medium without azole fungicides.  Below: The nuclear ratio shift when colour maker exchange completely in heterokaryons (I –nia-W& S-cnx-G and I- nia-G& S-cnx-W)  
2) The chlorate maker influence on the growth rate of mutants and ratio shift 
in heterokaryon  Two chlorate markers cnx and nia were used in this experiment setup. In above graph it have shown the mycelial growth rate of these two mutants grow alone on MM+ure, in comparison between S-nia-G and S-cnx- G,  it showed the growth rate of  mutant with cnx maker have significantly higher than mutant with nia, which indicate cnx has negative effect on the growth alone. However, when R-cnx-G and R-nia-G were compared, cnx seems have positive effect. In sensitive heterokaryon  S-nia-G & S-cnx-W, S-nia-G ratio kept around 40% ± 0.07(SEM)  when exposed to on MM, interestingly, not expected like 50% to 50%,  the ratio of S-cnx –W occupy more than 50%. When this heterokaryon was placed on MM+ 1µg/mL difenoconazole, the S-nia-G ratio shifted slightly, but not significantly. S-cnx –W remains more than 50% percentage. This indicated cnx maker have positive influence on the ratio (figure 4). Maybe cnx also have positive effect in the heterokaryon I-nia-G& S-cnx-
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W, R-nia-G& S-cnx-W, but probably it is not obvious when compared with the cost of resistance of I-nia-G and R-nia-G. 
 
The nuclear ratio changes in three heterokaryons (S & S, I & S and R & S), which 
were exposure to different concentrations of difenoconazole (0 or 1µg/mL). Strains used were: sensitive (S) CBS-140053, intermediate (I) D3-7-dense and resistant (R) D1-7 (see Table 1) & :  heterokaryon. S&S (CBS-140053& CBS-140053), I&S (D3-7-dense& CBS-140053) and R&S (D1-7&CBS-140053). 
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Abstract	
We	 investigated	 two	 compost‐heaps,	 one	 contains	 azoles	 and	 one	 with	 organic	 plant	
material	without	azoles,	for	presence	of	azole‐resistant	and	azole‐sensitive	A.	fumigatus	
isolates.	 The	 azole‐free	 compost	 yielded	 98%	 (49/50)	 sensitive	 and	 2%	 (1/50)	 azole	
resistant	 isolates,	 whereas	 the	 azole‐containing	 compost	 yielded	 8%	 (4/45)	 sensitive	
and	92%	(41/45)	resistant	 isolates.	From	the	 latter,	84%	(37/45)	 isolates	were	of	 the	
highly	resistant	TR46	Y121F/	T289A	genotype	and	8%	(4/45)	had	a	novel	pan–triazole‐
resistance	harbouring	a	triple	tandem	repeat:	TR463/Y121F/	M172I/T289A/G448S.	The	
stark	contrast	between	the	 two	composts	 indicates	 that	azole–containing	compost	 is	a	
hot	 spot	 for	 the	 development	 and	 maintenance	 of	 azole	 resistance.	 Subsequent	
screening	 of	 the	 clinical	 A.	 fumigatus	 collection	 from	 the	 Dutch	 national	 surveillance	
programme	indicated	that	this	resistance	mechanism	was	already	present	in	2012,	and	
is	 now	 found	 in	 all	 participating	medical	 centres.	We	were	 able	 to	 recover	 this	 novel	
resistance	 mechanism	 with	 the	 TR463	mutation	 among	 the	 sexual	 progeny	 in	 the	 lab,	
from	a	 cross	between	 two	 isolates	 of	 the	 same	 compost	 of	 opposite	mating	 type	both	
with	the	TR46.	This	indicates	a	role	of	sex	in	the	emergence	of	this	novel	azole–resistance	
mechanism	 in	 A.	 fumigatus.	Furthermore,	 we	 provide	 further	 evidence	 indicating	 the	
potential	 occurrence	 of	 sexual	 reproduction	 in	 compost,	 but	 this	 still	 needs	 further	
confirmation.	Our	findings	alarm	the	fast	development	of	the	azole	resistance	issue	in	A.	
fumigatus	 and	 further	 indicate	 the	 role	 of	 sexual	 reproduction	 of	 A.	 fumigatus	 in	 the	
development	of	azole	resistance.	
Key	words:	Aspergillus	fumigatus;	novel	new	mutation;	 compost;	azole	 resistance;	hot	
spot;	sexual	reproduction;	ascospores;	conidiospores	
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Introduction		
	
During	 the	 last	 decade	 azole	 resistance	 has	 increasingly	 been	 reported	 in	Aspergillus	
fumigatus	and	is	now	a	global	public	health	concern	(Snelders	et	al.	2008;	Arendrup	et	al.	
2010;	Lockhart	et	al.	2011;	Mortensen	et	al.	2011;	Pfaller	et	al.	2011;	Chowdhary	et	al.	
2012;	Morio	et	al.	2012;	Gisi	2013;	Bignell	2014;	Chowdhary	et	al.	2014;	Wiederhold	et	
al.	2015).	Azoles	are	the	cornerstone	of	treatment	of	aspergillus	diseases	and	resistance	
results	in	increased	morbidity	and	mortality	(Howard	et	al.	2009;	van	der	Linden	et	al.	
2011;	van	der	Linden	et	al.	2015).	Azole	 resistance	may	emerge	during	azole	 therapy,	
but	the	use	of	azole	compounds	in	the	environment	is	thought	to	be	the	major	driver	of	
resistance	selection	in	A.	fumigatus	(Snelders	et	al.	2012;	Faria‐Ramos	et	al.	2014).	The	
broad	 applications	 of	 azoles	 for	 crop	 protection,	 material	 preservation	 and	 possibly	
hospital	 use	 have	 caused	 multiple	 resistance	 mutations	 to	 emerge.	 The	 majority	 of	
mutations	 are	 caused	 by	 alterations	 in	 the	 cyp51A	 gene	 encoding	 the	 target	 protein	
sterol	14α‐demethylase,	such	as	TR34	/L98H	and	TR46	Y121F/	T289A	(Diaz‐Guerra	et	al.	
2003;	Mellado	et	al.	2004;	Chen	et	al.	2005;	Snelders	et	al.	2008;	Snelders	et	al.	2015;	
Wiederhold	 et	 al.	 2015).	 Figure	 1	 shows	 the	 evolutionary	 history	 of	 promoter	 and	
coding	region	changes	in	the	cyp51A	gene	of	A.	fumigatus	in	the	Netherlands.	These	TR	
variants	 confer	 different	 azole‐resistance	 phenotypes,	 although	 most	 result	 in	 a	
panazole‐resistant	profile	(Vermeulen	et	al.	2012;	Verweij	et	al.	2012;	van	der	Linden	et	
al.	2013;	Verweij	et	al.	2013;	Astvad	et	al.	2014;	Lavergne	et	al.	2015;	Pelaez	et	al.	2015).	
The	 continued	 emergence	 of	 new	 resistance	 mutations	 can	 only	 be	 overcome	 if	 the	
critical	steps	in	resistance	selection	are	understood.		
Compost	 is	 believed	 to	 be	 an	 important	 biological	 niche	 for	 A.	 fumigatus	with	 high	
densities	of	conidiospores	and	azole	residues	from	waste	(Millner	et	al.	1977;	Millner	et	
al.	1980).	Whether	A.	fumigatus	is	able	to	complete	the	whole	life	cycle	in	the	harsh	and	
competitive	 compost	 environment	 is	 unclear.	 Such	 knowledge	 is	 essential	 for	
understanding	potential	hotspots	of	development	and	maintenance	of	azole	 resistance	
in	A.	fumigatus.	In	addition	to	azole	exposure	the	mode	of	reproduction	is	probably	a	key	
factor	 for	 resistance	 selection.	We	 have	 previously	 shown	 that	 during	 azole	 exposure	
resistance	selection	is	enhanced	when	A.	fumigatus	reproduces	asexually	compared	with	
non‐sporulating	 controls	 (Zhang	 et	 al.	 2015).	 Beneficial	 spontaneous	 mutations	 via	
asexual	 reproduction	 were	 selected	 and	 accumulated	 over	 time.	 A.	 fumigatus	 is	 an	
ubiquitous	 saprophytic	 mould	 and	 has	 long	 been	 regarded	 as	 a	 strictly	 asexual,	
‘imperfect’,	fungus.	The	last	decade	there	has	been	accumulating	evidence	for	cryptic	sex	
in	this	fungus	from	population	genetics	studies,	genome	analysis,	and	the	demonstration	
of	a	sexual	cycle	under	laboratory	conditions	(Varga	and	Tóth	2003;	Paoletti	et	al.	2005;	
Kwon‐Chung	and	Sugui	2009;	O'Gorman	et	al.	2009;	Dyer	and	O’Gorman	2011;	Dyer	and	
O'Gorman	 2012).	 However,	 direct	 observations	 or	 sampling	 of	 sexual	 structures	 in	
nature	have	not	been	reported.		
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Figure	1.	A.	The	first	year	of	observation	of	different	azole‐resistant	A.	fumigatus	
with	 TR‐promoter	 mutations	 in	 the	 Netherlands	 since	 1998.	 B.	 Genotype	
illustration	of	 the	azole‐resistance	mutations	 in	 the	cyp51A	gene	(promoter	and	
coding	region).		
	
In	fungi	sexual	reproduction	can	enhance	adaptation	to	changing	or	new	environments	
(Hoekstra	2007;	McDonald	et	al.	2016)	as	sexual	progenies	show	larger	genetic	variation	
compared	 with	 asexual	 populations.	 Greater	 genetic	 diversity	 is	 achieved	 through	
meiosis,	 by	 crossing	 over	 and	 chromosome	 segregation.	 Genotyping	 studies	 of	 A.	
fumigatus	indeed	show	high	diversity	(Varga	and	Tóth	2003;	Losada	et	al.	2015;	Pena	et	
al.	 2015;	Teixeira	 et	 al.	 2015),	which	may	be	due	 to	 sexual	 reproduction	 in	nature.	 In	
addition,	 both	 mating	 types	 are	 found	 in	 approximately	 equal	 proportion	 in	 nature.	
Therefore,	 the	sexual	cycle	may	play	a	 role	 in	 the	ability	of	 the	 fungus	 to	adapt	 to	 the	
azole‐environment.	Compost	may	provide	the	right	conditions	for	sexual	reproduction.		
In	 this	 study,	 we	 investigated	 two	 compost‐heaps,	 with	 and	 without	 azoles	 exposure	
respectively.	We	made	use	of	heat	shock	to	selectively	isolate	highly	diverse	genotypes.	
The	 genetic	 diversity	 of	 A.	 fumigatus	 from	 two	 composts	 was	 compared.	 This	
information	 is	vital	 to	understand	 the	hot	spot	 for	emergence	of	azole	 resistance	 in	A.	
fumigatus	 and	 potential	 role	 of	 reproduction	 mode	 in	 the	 development	 of	 azole	
resistance.				
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Materials	and	methods	
	
Sampling	and	screening	 for	heat‐resistant	propagules	of	A.	fumigatus	
in	azole‐	and	non‐azole	containing	compost	
Figure	2.	The	location	and	position	of	samples	taken	from	compost	in	Wageningen	
(W1‐6)	and	Hillegom	(H1‐6)	
	
Six	 samples	 were	 collected	 from	 each	 of	 two	 compost	 heaps,	 one	 containing	 azoles	
(tulip‐bulb	waste,	Hillegom,	The	Netherlands)	and	one	free	of	azoles	(Wageningen,	 the	
Netherlands,	 Figure	 2,	 Supplement	 1).	 	 Samples	 of	 1g	 compost	 were	 screened	 for	 A.	
fumigatus	before	 and	 after	heat	 shock.	 10	mL	of	 sterile	 saline	with	0.05%	Tween	was	
added	into	1g	of	compost	sample.	From	these	suspensions,	before	and	after	heat‐shock,	
for	1h	at	70oC,	50	µl	samples	were	plated	on	MEA	(malt	extract	agar:	(Zhang	et	al.	2015))	
supplemented	 with	 two	 antibiotics	 (streptomycin10	 µg/ml	 and	 tetracycline15	 µg/ml,	
Sigma	Aldrich,	Germany)	 and	 incubated	at	37	 oC.	This	heat	 shock	procedure	has	been	
shown	 to	 kill	A.	fumigatus	 conidiospores,	 but	 not	 ascospores	 if	 present	 in	 the	 sample	
(O'Gorman	 et	 al.	 2009;	 Kwon‐Chung	 and	 Sugui	 2009).	 As	 a	 consequence,	 any	 colony	
growing	after	heat	shock	is	likely	to	have	originated	from	a	sexual	spore.	After	two	days	
the	 colonies	 were	 counted	 and	 the	 survival	 rate	 was	 established.	 The	morphology	 of	
germinating	propagules	in	heat‐shocked	compost	samples	after	9	hours	of	growth	was	
studied	 using	 light	 microscopy.	 To	 test	 the	 differential	 survival	 of	 conidiospores	 and	
ascospores	 in	 compost	 during	 heat	 shock,	 we	 performed	 a	 control	 experiment.	 We	
added	 ~105	 ascospores,	 from	 the	 cross	 between	 CBS	 140053	and	 CBS	 140054,	 or	
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conidiospores,	 from	CBS	140053,	to	1	g	of	autoclaved	compost	 in	10	mL	of	saline	with	
0.05%	Tween	(25	min	at	121	Ԩ).	
	
Identification	and	genotyping	of	presumed	ascospore‐derived	cultures	
from	compost	
We	 randomly	 picked	 50	 cultures,	 that	 all	 showed	 Aspergillus	 morphology,	 from	 a	
Wageningen	 (W,	 azole	 free)	 and	 a	Hillegom	 (H,	 azole	 containing)	 sample	 respectively.		
These	 were	 identified	 as	 A.	 fumigatus	 by	 sequencing	 of	 the	 ß‐tubulin	 and	
carboxypeptidase‐5	 genes	 (O'Gorman	 et	 al.	 2009)	 as	 well	 as	 the	 mating‐type	 gene	
(Paoletti	et	al.	2005)	and	by	their	capacity	to	grow	at	48Ԩ.	Next,	these	were	genotyped	
for	six	microsatellite	markers	(STR3	A,	B,	C	and	STR4	A,	B,	C)	and	the	cyp51A	gene	and	
its	promoter	(de	Valk	et	al.	2005:	Balajee	et	al.	2007;	Snelders	et	al.	2009).		
	
Susceptibility	testing	and	cyp51A	gene	expression	of	TR	variants		
Since	we	 previously	 found	 that	 the	 level	 of	 resistance	 based	 on	mycelial	 growth	 rate	
(MGR)	 is	highly	 correlated	with	 the	 results	 from	 the	MIC	 test,	we	here	used	 the	more	
straightforward	and	reproducible	MGR	measurement	as	described	before	(Zhang	2015).	
The	mycelial	growth	rate	(MGR)	of	TR	variants	TR34	and	TR46,	TR463,	that	were	isolated	
from	compost	heaps,	was	assayed.	Susceptibility	of	the	observed	TR	variants	to	triazole	
drugs	 was	 in	 addition	 tested	 in	 a	 MIC	 assay	 using	 a	 broth	 microdilution	 method	
according	to	EUCAST	protocol	E.DEF	60	9.1	(Camps	et	al.	2012a;	Zhang	et	al.	2015).	The	
cyp51A	 expression	was	analyzed	 from	duplicate	 cultures	of	 three	different	 strains	per	
TR	 variant.	 Expression	 levels	 were	 calculated	 from	 Cyp51A/actin	 mRNA	 ratios	 and	
normalized	for	WT	expression	levels	(Snelders	et	al.	2015).		
	
Clinical	implications	of	environmental	azole	resistance	mutations	
The	 presence	 of	 new	 azole	 resistance	 mutations	 that	 were	 found	 in	 the	 compost	 in	
clinical	 isolates	was	 investigated	using	 the	national	aspergillus	resistance	surveillance.	
In	 five	 Dutch	 University	 Medical	 Centres,	 clinical	 A.	 fumigatus	 isolates	 are	 routinely	
screened	for	azole‐resistant	phenotype	using	agar	supplemented	with	medical	triazoles.	
Isolates	 that	 grow	 in	 the	 presence	 of	 azoles	 are	 sent	 to	 Radboud	 University	 Medical	
Centre	for	MIC‐testing	and	genotypic	characterisation.	Screening	for	triazole	resistance	
mutations	was	performed	using	the	Y121F	mutation	for	TR46/Y121F/T289A	and	/L98H	
for	the	TR34/L98H	mutation.	These	two	mutations	have	been	shown	to	account	for	over	
80%	 of	 clinical	 triazole	 resistance.	 If	 through	 screening	 no	 mutations	 are	 found,	 the	
cyp51A	 gene	 is	 sequenced.	 For	 Y121F	 positive	 isolates	 the	 accompanying	 TR	 was	
determined	 using	 PCR	 and	 for	 selected	 isolates	 relevant	 clinical	 information	 was	
collected.		
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Genotypic	 relationship	 of	 the	 resistant	 A.	 fumigatus	 isolates	 TR463	
Y121F/M172I/T289A/G448S	 from	 environmental	 and	 clinical	
samples	
Dendrogram:	The	dendrogram	was	based	on	a	categorical	analysis	of	six	microsatellite	
markers	 in	 combination	 with	 unweighted	 pair	 group	 method	 with	 arithmetic	 mean	
clustering.	 The	 scale	 bar	 indicates	 the	 percentage	 identity	 between	 selected	
environmental	TR	463		variants	isolates	vs.	clinical	isolates	(Camps	et	al.	2012).	
	
Genotypic	 relationship	 of	 A.	 fumigatus	 TR	 variants	 in	 compost	
Hillegom	
Minimum	 spanning	 tree	 (MST):	 minimum	 spanning	 tree	 showing	 the	 genotypic	
relationship	 between	 all	 A.	 fumigatus	 isolates	 from	 compost	 Hillegom	 (Camps	 et	 al.	
2012b).			
	
Sexual	 cross	 between	 twoTR46	 strains	 of	 opposite	mating	 type	 from	
the	same	compost		
In	 order	 to	 investigate	 the	 possibility	 to	 generate	 TR463	 through	 sexual	 reproduction,	
two	pairs	of	strains	 from	the	same	compost	sample	with	 the	TR46	resistance	mutation	
and	of	opposite	mating	type	(isolates	H40(MAT1‐1)	&	H35(MAT1‐2)	and		H33(MAT1‐2)	
&H29(MAT1‐1))	were	used	for	a	sexual	cross	 following	the	protocol	of	O'Gorman	et	al	
(O'Gorman	 et	 al.	 2009).	 After	 four	 months,	 cleistothecia	 were	 harvested	 and	 105	
ascospores	were	heat	shocked,	and	plated	on	MEA	with	posaconazole	(2mg/L).		
	
Results		
	
Isolation	of	A.	fumigatus	from	azole‐containing	and	azole‐free	compost	
before	and	after	heat	shock		
Before	and	after	heat	shock	of	each	of	 the	six	samples,	 colonies	with	macroscopic	and	
microscopic	 characteristics	 of	 A.	 fumigatus	 were	 recovered.	 Of	 each	 sample,	 20	
randomly	picked	 colonies	were	 confirmed	as	A.	fumigatus	 based	on	 sequence	 analysis	
and	 their	ability	 to	grow	at	48°C.	Before	heat	shock	each	sample	contained	more	 than	
105	CFU.	After	heat	shock,	all	of	the	six	samples	from	the	non‐azole	compost	heap	(W1	to	
W6)	 and	 two	 of	 the	 six	 samples	 of	 the	 azole	 compost	 heap	 (H1	 and	 H4)	 yielded	 A.	
fumigatus	isolates	ranging	from	71	to	~8,000	cfu	per	1g	of	compost	(Figure	3).	
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Genotyping	of	heat‐resistant	cultures	from	compost	
Azole‐resistant	A.	fumigatus	was	found	in	both	compost	heaps,	although	the	proportion	
of	resistance	was	different,	95%	resistance	in	the	azole‐exposed	compost	compared	to	2%	
in	 the	 azole‐free	 compost.	 Genetic	 characterisation	 of	 the	 azole‐resistant	 isolates	
revealed	the	presence	of	a	new	mutation,	consisting	of	three	copies	of	TR46	(TR463)	in	the	
promoter	 and	 four	 mutations	 in	 the	 CYP51A:	 Y121F/M172I/T289A/G448S.	 The	
variation	 in	 the	 cyp51A	 gene	 was	 higher	 in	 the	 azole‐containing	 compost	 (8%WT,	
84%TR46,	8%	TR46	3)	than	the	azole‐free	compost	(98%	WT,	2%	TR34)	(Table	1	and	2).	
The	distribution	of	MAT1‐1:	MAT‐2	among	the	different	genotypes	(11:15	and	15:21	for	
the	 azole‐containing	 and	 azole‐free	 composts	 respectively)	 was	 not	 significantly	
different	from	the	expected	1:1	ratio.		
	
Susceptibility	 testing	 and	 gene	 expression	 of	 the	 TR	 variants	 (TR34,	
TR46	and	TR463)		
The	mycelial	growth	rate	(MGR)	of	the	TR	variantsTR34,	TR46	and	TR463	isolated	from	the	
two	 composts	 is	 shown	 in	 Figure	 4.	 TR463	 exerted	 the	 fast	 mycelial	 growth	 rate	 on	
medium	 supplemented	 with	 posaconazole,	 when	 compared	 with	 TR34/L98H	 and	
TR46/Y121F/T289A	 (ANOVA,	 P	 <0.01**,	 Figure	 4).	 In	 addition,	 the	 high	 resistance	 of	
TR463	 was	 confirmed	 by	MIC	 testing,	 displaying	 a	 pan‐triazole‐resistant	 phenotype	 to	
posaconazole,	 itraconazole,	 and	 voriconazole(Table	 3),	 even	 higher	 than	 the	 pan‐	
triazole	resistant	TR34	and	TR46	(van	der	Linden	et	al.	2013)	.	
Expression	 levels	 assayed	 from	 Cyp51A/actin	 mRNA	 ratios	 showed	 that	 even	 in	 the	
absence	of	 azoles,	 cyp51	A	gene	expression	 level	 in	 the	TR463	was	 significantly	higher	
than	WT,	 TR34/L98H	 and	 TR46/Y121F/T289A,	 which	 suggests	 that	 the	 repeats	 in	 the	
promoter	 region	 are	 able	 to	 generate	 more	 CYP51	 to	 cope	 with	 azole	 stress	 and	
therefore	contributes	to	a	resistant	phenotype	(Figure	5).	
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Table	1	The	genetic	variation	in	azole‐containing	compost	from	flower‐bulb	waste	
in	Hillegom,	The	Netherlands.
A B C A B C
V181‐07 H01 33 10 23 6 13 8 TR46 Y121F MAT1‐2 1
V181‐08 H02 44 8 61 6 12 8 TR46 Y121F MAT1‐2 2
V181‐09 H03 44 8 7 10 9 7 TR46 Y121F MAT1‐2 3
V181‐10 H04 44 8 7 10 9 7 TR46 Y121F MAT1‐2 3
V181‐11 H05 42 8 61 7 10 8 WT NONE MAT1‐1 4
V181‐12 H06 35 9 27 8 10 8 WT NONE MAT1‐1 5
V181‐13 H07 44 8 12 10 8 18 TR46 Y121F MAT1‐2 6
V181‐14 H08 35 11 16 8 7 6 WT NONE MAT1‐1 7
V181‐15 H09 42 9 62 10 8 7 TR46 Y121F MAT1‐2 8
V181‐16 H10 46 8 7 10 8 7 TR46 Y121F MAT1‐1 9
V181‐17 H11 45 8 7 10 8 7 TR46 Y121F MAT1‐2 3
V181‐18 H12 44 8 7 10 8 7 TR46 Y121F MAT1‐2 3
V181‐19 H13 43 8 11 10 8 18 TR46 Y121F MAT1‐2 10
V181‐20 H14 33 10 23 6 10 13 TR46 Y121F MAT1‐2 11
V181‐21 H15 44 8 7 10 9 7 TR46 Y121F MAT1‐2 3
V181‐22 H16 42 8 61 10 7 7 TR46 Y121F MAT1‐2 8
V181‐23 H17 31 8 21 6 12 8 TR46 Y121F MAT1‐2 12
V181‐24 H18 44 8 7 10 8 7 TR46 Y121F MAT1‐2 3
V181‐25 H19 44 8 61 8 10 8 WT NONE MAT1‐1 4
V181‐26 H20 42 8 61 10 9 7 TR46 Y121F MAT1‐1 9
V181‐27 H21 44 9 7 10 7 7 TR46 Y121F MAT1‐2 3
V181‐28 H22 44 8 7 10 7 7 TR46 Y121F MAT1‐2 3
V181‐29 H23 44 8 7 10 9 7 TR46 Y121F MAT1‐2 3
V181‐30 H24 26 8 12 6 7 7 TR463 Y121F MAT1‐1 14
V181‐31 H25 33 10 23 6 13 9 TR46 Y121F MAT1‐2 1
V181‐32 H26 44 8 12 2 8 6 TR46 Y121F MAT1‐2 16
V181‐33 H27 46 8 12 2 8 8 TR46 Y121F MAT1‐2 16
V181‐34 H28 55 8 7 6 8 8 TR46 Y121F MAT1‐1 17
V181‐35 H29 44 8 7 12 9 9 TR46 Y121F MAT1‐2 18
V181‐36 H30 26 8 12 6 9 7 TR463 Y121F MAT1‐1 14
V181‐37 H31 44 8 7 10 8 7 TR46 Y121F MAT1‐2 3
V181‐38 H32 26 7 12 6 8 7 TR46 Y121F MAT1‐1 19
V181‐39 H33 41 8 7 10 8 8 TR463 Y121F MAT1‐2 20
V181‐40 H34 25 18 24 8 10 9 TR46 Y121 MAT1‐1 21
V181‐41 H35 31 8 21 6 13 9 TR46 Y121F MAT1‐2 12
V181‐42 H36 44 8 7 10 8 7 TR46 Y121F MAT1‐2 3
V181‐43 H37 22 4 13 6 9 9 TR463 Y121F MAT1‐1 22
V181‐44 H38 31 8 23 6 13 8 TR46 Y121F MAT1‐2 23
V181‐45 H39 44 8 7 10 8 7 TR46 Y121F MAT1‐2 3
V181‐46 H40 26 8 21 11 8 7 TR46 Y121F MAT1‐1 24
V181‐47 H41 33 10 23 6 13 8 TR46 Y121F MAT1‐2 1
V181‐48 H42 44 8 7 9 9 9 TR46 Y121F MAT1‐2 25
V181‐49 H43 24 6 20 12 8 7 TR46 Y121F MAT1‐1 26
V181‐50 H44 44 8 12 10 8 7 TR46 Y121F MAT1‐2 15
V181‐51 H45 44 8 17 2 3 7 TR46 Y121F MAT1‐2 13
Mating 
type Genotype
Cyp51A 
SNP PCRAZN_NMR
sample 
number
STR3 STR4 Cyp51A 
promoter
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Table	2	The	genetic	variation	in	azole‐free	compost	from	an	organic	plant	waste	
compost	heap	in	Wageningen,	The	Netherlands
	
A B C A B C
V182‐18 W1 34 9 8 7 8 31 WT WT MAT1‐2 1
V182‐19 W2 38 8 12 8 10 20 WT WT MAT1‐1 2
V182‐20 W3 30 8 11 8 9 20 WT WT MAT1‐2 3
V182‐21 W4 29 8 12 7 9 20 WT WT MAT1‐2 3
V182‐22 W5 38 10 46 10 8 8 WT WT MAT1‐1 4
V182‐23 W6 29 7 11 9 9 18 WT WT MAT1‐1 5
V182‐24 W7 26 10 21 8 7 5 WT WT MAT1‐2 6
V182‐25 W8 30 8 11 8 9 20 WT WT MAT1‐2 7
V182‐26 W9 35 8 8 7 9 12 WT WT MAT1‐1 3
V182‐27 W10 25 8 8 6 9 8 WT WT MAT1‐2 8
V182‐28 W11 13 18 8 7 26 5 WT WT MAT1‐2 9
V182‐29 W12 30 8 11 5 9 20 WT WT MAT1‐2 10
V182‐30 W13 9 8 8 8 8 6 WT WT MAT1‐2 11
V182‐31 W14 30 8 8 7 9 19 WT WT MAT1‐1 12
V182‐32 W15 13 8 10 8 8 3 WT WT MAT1‐1 13
V182‐33 W16 30 8 8 5 9 19 WT WT MAT1‐1 14
V182‐34 W17 27 8 30 7 6 5 WT WT MAT1‐2 15
V182‐35 W18 27 8 26 10 8 5 WT WT MAT1‐2 16
V182‐36 W19 24 8 8 8 11 33 WT WT MAT1‐1 17
V182‐37 W20 50 8 8 8 9 25 WT WT MAT1‐2 18
V182‐38 W21 10 8 8 5 7 18 WT WT MAT1‐1 19
V182‐39 W22 30 8 11 5 7 18 WT WT MAT1‐2 20
V182‐40 W23 36 10 30 22 9 8 WT WT MAT1‐1 21
V182‐41 W24 30 18 8 10 26 5 WT WT MAT1‐2 12
V182‐42 W25 50 8 8 10 8 5 WT WT MAT1‐1 23
V182‐43 W26 8 7 11 7 8 10 WT WT MAT1‐1 24
V182‐44 W27 26 8 8 8 9 33 WT WT MAT1‐1 25
V182‐45 W28 30 8 11 8 9 21 WT WT MAT1‐2 26
V182‐46 W29 25 8 21 14 8 5 WT WT MAT1‐2 19
V182‐47 W30 48 12 8 10 26 20 WT WT MAT1‐1 3
V182‐48 W31 27 8 26 10 8 5 WT WT MAT1‐2 28
V182‐49 W32 27 8 26 10 8 5 WT WT MAT1‐2 29
V182‐50 W33 27 8 26 9 8 5 WT WT MAT1‐2 18
V182‐51 W34 28 10 8 8 8 8 WT WT MAT1‐1 18
V182‐52 W35 29 16 8 10 26 5 WT WT MAT1‐2 18
V182‐53 W36 30 8 11 8 9 21 WT WT MAT1‐2 30
V182‐54 W37 38 8 12 5 10 21 WT WT MAT1‐1 24
V182‐55 W38 32 8 8 7 9 19 WT WT MAT1‐2 3
V182‐56 W39 32 8 8 8 9 19 WT WT MAT1‐2 31
V182‐57 W40 28 9 12 8 6 11 TR34 L98H MAT1‐1 14
V182‐58 W41 36 8 9 7 9 8 WT WT MAT1‐2 14
V182‐59 W42 45 9 10 10 8 10 WT WT MAT1‐1 33
V182‐60 W43 37 8 20 6 7 5 WT WT MAT1‐1 34
V182‐61 W44 29 8 11 8 9 27 WT WT MAT1‐2 35
V182‐62 W45 31 8 7 6 8 18 WT WT MAT1‐1 36
V182‐63 W46 34 8 8 5 9 8 WT WT MAT1‐2 37
V182‐64 W47 37 22 21 6 8 5 WT WT MAT1‐2 38
V182‐65 W48 39 8 8 8 9 21 WT WT MAT1‐2 27
V182‐66 W49 15 8 20 5 7 5 WT WT MAT1‐2 22
V182‐67 W50 26 10 8 31 29 6 WT WT MAT1‐2 32
Genotype
Mating 
type
AZN_NMR
STR3 STR4 Cyp51A 
promot
Cyp51A 
SNP PCR
Sample 
number
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Figure	 4.	 The	 MGR	 assay	 of	 three	 TR	 variants:	 TR34	 and	 TR46,	 TR463	 against	
voriconazole,	 itraconazole,	 and	 posaconazole.	 (MEA	 supplemented	 with	 1mg/L	
respectively)(ITR,	itraconazole; 	VOR,	voriconazole;	POS, 	posaconazole; 	none:	without	any	azoles)	
	
Table	3.	The	in	vitro	activity	of	itraconazole,	voriconazole,	and	posaconazole	
against	three	TR	variants:	TR34,	TR46,	and	TR463.	
MIC	range	(mg/l)	 ITR	 VOR	 POS	 	
TR34/L98H	 >16	 4‐8	 0.25‐0.5 Snelders	 et	al.2009	
TR46/Y121F/T289A		 4/16	 >16	 0.25‐2	 van	 der	 Linden	 et	al.	2013	
TR46
3	/Y121F/M172I/T289A/G448S	 >	16	 >16	 1	 This	 study	compost+	clinical	
	 	 	 	 	 	 	 	(ITR,	itraconazole; 	VOR,	voriconazole;	POS,	posaconazole)	
	
	Figure	5.	The	overexpression	of	cyp51A	in	TR	variants	(WT	TR34,	TR46,	and	TR463)	
	
WT                               TR 34                            TR 46                              TR46
3  
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Clinical	 implications:	 analysis	 of	 clinical	 isolates	 from	 the	 Dutch	
national	surveillance	program	and	discovery	of	TR463	Y121F/M172I	
/T289A/G448S	in	two	patient	isolates		
The	 A.	 fumigatus	 culture	 collection	 of	 the	 Dutch	 national	 resistance	 surveillance	 was	
used	to	determine	if	TR463	Y121F/M172I/T289A/G448S	was	present	in	clinical	isolates.	
All	 clinical	 A.	 fumigatus	 isolates	 collected	 between	 2013	 and	 2015	 that	 harboured	 a	
Y121F‐mutation	were	investigated	for	the	presence	of	TR463	by	PCR.	Among	98	Y121F‐
harbouring	 isolates,	 three	we	 identified	with	TR463.	 In	 addition	 one	 isolate	was	 found	
with	 four	 TRs	 (TR464)	 in	 combination	 with	 the	 four	 mutations	 in	 the	 cyp51A‐gene,	
TR464/	Y121F/M172I/T289A/G448S.		
One	TR463/	Y121F/M172I/T289A/G448S	 isolate	was	 recovered	 from	a	 sputum	sample	
from	a	34‐year‐old	female	 in	2013	in	the	western	part	of	 the	Netherlands.	The	patient	
was	 hospitalized	 for	 treatment	 of	 synovial	 cell	 sarcoma	 with	 pleural	 metastasis.	
Computed	 tomography	 of	 the	 lungs	 showed	 no	 evidence	 for	 Aspergillus	 disease.	 A	
second	 patient	 with	 an	 A.	 fumigatus	 isolate	 harbouring	 TR463/	
Y121F/M172I/T289A/G448S	 was	 found	 in	 2014	 in	 another	 hospital	 in	 the	 north	
eastern	part	of	the	country.	The	isolate	was	cultured	from	the	right	ear	of	a	34‐year‐old	
male	 who	 was	 treated	 for	 cholesteatoma,	 without	 evidence	 for	 Aspergillus	disease.	 A	
third	patient	was	admitted	 to	a	hospital	 in	 the	north	west	of	 the	country	 in	2015.	The	
patient	was	treated	for	asthma	as	out‐patient	because	of	shortness‐of‐breath.	CT	of	the	
chest	showed	no	evidence	for	Aspergillus	disease.		
A	fourth	patient	was	identified	through	consultation	of	the	mycology	expert	centre.	An	A.	
fumigatus	 isolate	 was	 sent	 in	 for	 MIC‐testing	 and	 was	 found	 to	 harbour	 the	 TR463/	
Y121F/M172I/T289A/G448S	mutation.	 The	 isolate	 was	 cultured	 from	 a	 43‐years‐old	
patient	with	COPD	admitted	to	a	hospital	in	the	east	of	the	Netherlands.	The	isolate	was	
cultured	in	2012.	The	patient	was	admitted	with	a	community‐acquired	pneumonia,	and	
received	 therapy	 with	 posaconazole	 in	 addition	 to	 antibacterial	 therapy.	 Because	
sputum	culture	remained	positive	after	 two	weeks	of	posaconazole	 therapy,	 the	strain	
was	 sent	 for	 MIC‐testing.	 However,	 a	 definite	 diagnosis	 of	 invasive	 pulmonary	
aspergillosis	could	not	be	made.	
The	TR464	isolate	was	cultured	from	the	ear	from	a	patient	with	chronic	otitis	and	a	open	
cavity.	 There	 fungus	may	 have	 contributed	 to	 the	 chronic	 infection,	 but	 there	was	 no	
evidence	for	invasive	disease.	
	
The	 relatedness	 between	 the	 environmental	 and	 clinical	 TR463	 /	
Y121F/M172I/T289A/G448S	isolates	
The	 relatedness	 of	 all	 TR463	 isolates	 was	 tested	 and	 data	 are	 shown	 in	 Figure	 6.	
Microsatellite	 typing	 showed	 that	 almost	 all	 environmental	 TR463	 clustered	 together	
except	 one	 isolate	 (V181‐39)	 showed	 lower	 variations	 in	 the	 microsatellite	 locus.	
However,	 the	 four	clinical	 strains	exhibited	 larger	variations	 in	 terms	of	microsatellite	
CHAPTER VI 
136 
 
locus.	The	relatedness	factor	ranged	from	33.3	to	66.7.	The	environmental	TR463	(V181‐
30,	36	and	wg‐9,	10,	24,	30,	32,	37)	and	clinical	TR463				(CWZV182‐69)	strain	exhibited	a	
similar	fingerprint	pattern	in	the	microsatellite	analysis	(Figure	6).	
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Genotypic	 relatedness	 of	 	 	 TR	 variants	 (WT,	 TR46,	 and	 TR463	 )	 in	
compost	Hillegom	
A	minimum	spanning	tree	(MST)	was	constructed	based	on	the	six	STRAf	microsatellite	
loci	of	all	TR	variants	(WT,	TR46,	and	TR463)	in	compost	Hillegom	(45	isolates).	The	part	
of	TR46	 (V181‐08,	23,	44)	clustered	with	WT	(V181‐25,	11),	which	 indicates	 that	TR46	
might	 origin	 from	 the	WT.	 Similarly,	 the	 TR463	(V181‐30,	 39)	 also	 clustered	with	TR46	
(V181‐38,	34),	which	suggests	the	possible	origin	of	TR463	from	TR46	(Figure	7).	
	
	
	
	
	
	
	
Figure	7.	Minimum	span‐
ning	tree	showing	the	
genotypic	relationship	be‐
tween	the	A.	fumigatus	WT,	
TR46,	and	TR463	from	the	
same	compost	Hillegom.		
Each	circle	corresponds	to	a	
unique	genotype,	and	the	size	of	
the	circle	corresponds	to	the	
number	of	isolates	with	that	
genotype	(1,	2, 	or	3	isolates). 	
Connecting	lines	correspond	to	
the	number	of	different	
microsatellite	loci 	between	the	
genotypes.	Short	bold	line,	1	
difference;	black	line, 	2	
differences; 	long	gray	line, 	3	
differences; 	dotted	line, 	4	or	
more	differences. 	Red,	
TR463/Y121F/M172I/T289A/G44
8S(n=4); 	green,	azole‐susceptible	
wild	type	(n=4); 	blue, 	
TR46/Y121F/	T289A	(n	=	37). 	
	
TR46	
TR463	
WT	
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Is	 sexual	 reproduction	 in	 compost	 the	 possible	 origin	 of	 TR463	
/Y121F/M172I/T289A/G448S?		
Evidence	 that	 the	 heat‐shock	 resistant	 propagules	 in	 compost	 are	
sexual	ascospores		
(1) Ascospore‐derived	colonies	are	expected	to	show	high	genotypic	variation.		
	
A	high	genetic	diversity	was	found	in	both	compost	heaps	as	shown	in	Table	1	and	2	in	
terms	of	cyp51A	gene	and	promoter	region,	microsatellite	locus	and	mating	type	genes.	
Within	this	population	a	high	diversity	and	equal	mating‐type	distribution	is	consistent	
with	 sexual,	 rather	 than	asexual	 reproduction.	 In	 addition,	 the	discovery	of	 isolates	of	
opposite	 mating	 type	 with	 TR463/Y121F/M172I/T289A/G448S	 suggests	 a	 potential	
origin	by	sex.	
(2)	 TR463	 can	 be	 obtained	 from	 a	 sexual	 cross	 between	 two	 TR46	 strains	 of	 opposite	
mating	type	from	the	same	compost	sample				
After	four	months	of	incubation,	following	a	sexual	cross	between	a	pair	of	TR46	strains	
derived	from	the	azole‐containing	compost‐heap,	~105	sexual	progenies	were	plated	on	
MEA	supplemented	with	posaconazole	(2	mg/L).	Colonies	that	grew	in	the	presence	of	
posaconazole	were	selected	for	sequence	analysis	of	the	cyp51A‐gene.	One	of	which	had	
the	novel	TR463	mutation.	This	new	resistance	genotype	may	have	resulted	from	unequal	
cross	over	(Figure	8).	
	
Figure	8.	Scenario	indicating	how	unequal	crossing	over	in	a	sexual	cross	between	
two	strains	with	a	double	repeat	TR46	can	result	in	a	rare	meiotic	recombinant	
with	the	triple	repeat	TR463.	
	
Whether	 the	 heat‐shock	 resistant	 propagules	 in	 compost	 are	 sexual	
ascospores	remains	an	open	question	
(1)	It	is	believed	that	ascospores,	but	not	conidiospores	are	resistant	to	a	heat	shock	of	
1h	at	70oC	(O'Gorman	et	al.	2009;	Sugui	et	al.	2011).	However,	from	the	reconstruction	
experiment	we	found	that	though	indeed	the	ascospores	are	heat	resistant,	not	all	of	the	
105	conidiospores	in	compost	or	in	saline	were	killed	after	1h	at	70oC.	A	previous	study	
has	 also	 shown	 that	 a	 population	 of	 conidiospores	may	 not	 completely	 killed	 by	 heat	
shock,	 depending	 on	 many	 factors,	 like	 the	 freshness	 and	 concentration	 of	
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conidiospores,	 ,	 the	type	of	strain	and	the	pH	(Tsukahara	1975).	Therefore,	we	cannot	
conclude	that	all	colonies	derived	after	heat	shock	of	compost	material	have	originated	
from	ascospores.	
(2)	 The	morphological	 difference	 between	 germinating	 ascospores	 and	 conidiospores	
was	distinguished	via	two	crests	(ridges).	However,	in	light	microscopy	preparations	of	
compost	suspensions,	structures	reminiscent	of	ascospores	were	seen	(Figure	9,	green	
arrow),	 but	 the	 compost	 material	 interfered	 too	 much	 to	 convincingly	 discriminate	
between	conidia	and	ascospores.		
	
Figure	9.	Crests	differentiate	germinating	ascospores	from	conidiospores.			
A: 	Ascospore; 	B:	Conidiospore; 	C:	Compost	sample	
	
Discussion	
		
In	 this	 study,	 we	 observed	 that	 compost	 with	 known	 azole	 exposure	 harbours	
predominantly	 azole‐resistant	 A.	 fumigatus,	 whereas	 in	 azole‐free	 compost	 almost	
exclusively	wild	type	A.	fumigatus	is	found.	Our	study	suggests	that	azole	exposure	to	A.	
fumigatus	 in	 its	natural	habitat	 at	 least	 sustains	 the	presence	of	 azole	 resistance.	This	
and	 similar	 habitats	 could	 act	 as	 ‘hot	 spot’,	 i.e.	 provide	 a	 source	 of	 azole‐resistant	A.	
fumigatus	 from	which	air‐borne	 conidia	may	migrate	and	 cause	disease	 in	 susceptible	
hosts.		
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We	 were	 able	 to	 identify	 a	 new	 resistance	 mutation	 in	 the	 azole‐exposed	 compost.	
Analysis	of	clinical	isolates	that	had	been	collected	in	the	national	surveillance	program	
showed	that	since	2012	each	year	one	patient	harboured	an	isolate	harbouring	this	new	
resistance	 mechanism.	 Although	 the	 migration	 of	 the	 TR463/Y121F/M172I/T289A/	
G448S	 was	 not	 rapid,	 the	 isolate	 was	 recovered	 from	 unrelated	 patients	 in	 three	
different	 hospitals	 in	 the	Netherlands.	 This	 indicates	 that	 the	 resistance	mutation	 has	
migrated	across	the	country.	Little	is	known	about	the	migration	rate	of	resistance	traits	
in	A.	fumigatus.	 The	TR34/L98H	 is	 the	most	 frequently	 reported	mutation,	 and	 is	 now	
found	 globally	 (Snelders	 et	 al.	 2008;	 Arendrup	 et	 al.	 2010;	 Lockhart	 et	 al.	 2011;	
Mortensen	et	al.	2011;	Pfaller	et	al.	2011;	Chowdhary	et	al.	2012;	Morio	et	al.	2012;	Gisi	
2013;	 Bignell	 2014;	 Chowdhary	 et	 al.	 2014;	 Wiederhold	 et	 al.	 2015).	 The	
TR46/Y121F/T289A	 mutation	 also	 showed	 rapid	 migration	 as	 after	 its	 discovery	 in	
December	2009,	the	mutation	was	recovered	from	patients	from	six	different	hospitals	
in	the	Netherlands	within	one	year	(van	der	Linden	et	al.	2013).	Although	we	found	only	
patient	 colonization,	 we	 believe	 that	 isolates	 harbouring	 TR463	
/Y121F/M172I/T289A/G448S	will	ultimately	cause	invasive	infections	as	the	resistance	
trait	 has	 probably	 survived	 in	 the	 environment	 for	 several	 years,	 in	 competition	with	
other	azole‐resistant	or	wild	type	isolates,	indicating	comparable	fitness.	
Analysis	 of	 the	 collection	 of	 azole‐resistant	 clinical	 isolates	 revealed	 another	 new	
mutation	with	 four	 copies	 of	 the	 TR46.	 Although	 the	 TR464	mutation	 has	 not	 yet	 been	
found	 in	 the	environment,	we	believe	 that	 this	mutation	also	originated	 through	azole	
exposure	 to	 A.	 fumigatus	 in	 the	 environment.	 These	 observations	 indicate	 that	 our	
current	 azole	 fungicide	 use	 is	 not	 durable	 and	 that	 new	 resistance	 mutations	 will	
continue	to	emerge.	The	clinical	consequences	are	that	the	role	of	medical	azoles	in	the	
management	 of	Aspergillus	diseases	will	 be	 increasingly	 threatened.	 As	 the	 arsenal	 of	
available	drugs	to	treat	Aspergillus	diseases	is	already	very	limited,	excess	mortality	due	
to	azole	resistance	can	be	expected	(Verweij	etal.	2015).	Indeed,	case	series	show	high	
mortality	rates	in	patients	with	azole‐resistant	invasive	aspergillosis	(Jan	W.M.	van	der	
Linden	 etal.	 2011).	 Environmental	 resistance	 is	 especially	 difficult	 to	 manage	 as	 it	 is	
found	 in	 any	 Aspergillus	 disease	 and	 may	 occur	 in	 any	 patient,	 even	 those	 without	
previous	 azole	 therapy	 (Verweij	 etal.	 2016).	 Recently	 mixed	 infections	 due	 to	 azole‐
susceptible	 and	 azole‐resistant	A.	 fumigatus	 were	 reported	which	 further	 complicates	
timely	diagnosis	and	successful	therapy	(Kolwijck	et	al.	2016).		
In	order	 to	 tackle	 the	problem	of	emerging	azole	resistance,	 it	 is	 important	 to	 identify	
hot	 spots	 in	 the	 environment	 and	 to	 understand	 how	 resistance	mutations	 arise	 and	
which	factors	facilitate	the	geographical	migration	of	mutations.		
	
Possible	origins	of	TR463	/Y121F/M172I/T289A/G448S		
With	regard	to	the	origin	of	resistant	mutants	TR34/L98H,	TR46/Y121F/T289A	and	TR463	
/Y121F/M172I/T289A/G448S,	with	 the	 combination	 of	 TR	 and	 point	mutation(s),	 TR	
could	 be	 the	 consequence	 of	 unequal	 crossing	 over	 during	 sexual	 or	 parasexual	
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recombination.	 The	 duplications	 in	 the	 promoter	 region	 resulting	 in	 the	 increased	
expression	of	 the	cyp51	gene	may	compensate	 for	 the	 reduced	CYP51	enzyme	activity	
due	 to	 the	 amino	 acid	 changes	 that	 reduced	 the	 azole	 sensitivity.	 Therefore,	 the	 TR	
mutations	 in	 the	 promoter	 may	 be	 seen	 as	 compensatory	 mutations	 to	 the	 azole‐
resistance	point	mutations	in	cyp51A.	
As	 the	 experimental	 sexual	 cross	 showed,	 the	 triple	TR463	can	 result	 from	 the	 sexual	
reproduction	of	two	double	TR46.	However,	TR463	Y121F/M172I/T289A/G448S	may	also	
have	 resulted	 from	 TR46	 via	 subsequent	 mutations	 (Figure	 10).	 In	 an	 evolutionary	
experiment	it	was	shown	that	TR34	evolved	to	TR343	under	the	exposure	to	tebuconaozle	
for	10	passages	(Snelders	et	al.	2012).	It	is	generally	believed	that	microsatellite	loci	and	
the	 mating	 type	 are	 relatively	 stable	 via	 asexual	 and	 sexual	 reproduction.	 From	 this	
azole‐	containing	compost,	the	microsatellite	loci		and	mating	type	gene	of		TR	463	(V181‐
30)(V181‐36)	 are	 similar	 to	 that	 of	 TR46	 (V181‐38),	 suggesting	 a	 possible	 	 clonal	
relationship.	 	However,	 for	 the	 other	 two	TR	463	 (V181‐39,	 43),	 no	matched	TR46	 type	
was	found.	These	observations	do	not	exclude	a	sexual	origin	of	the	isolates.	
	
Figure	10.	The	possible	origin	of	TR463	/Y121F/M172I/T289A/G448S	via	asexual	
reproduction	
	
Sex	in	the	compost?		
In	our	study,	accumulating	evidence	suggests	the	possibility	of	occurrence	of	sex	in	the	
compost,	such	as:	
1.	 Heat‐shock	 treatment	 reduced	 the	 number	 of	 A.	 fumigatus	 colony‐forming	 units	
significantly	(Figure	3),	suggesting	that	most,	if	not	all,	conidiospores	were	killed.	
2.	 Isolates	 obtained	 after	 heat	 shock	 were	 genetically	 widely	 diverse,	 indicating	 that	
these	were	not	derived	from	conidiospores	from	one	or	a	few	single	clones	(Table	1&	2).	
3.	Sexual	crossing	of	two	isolates	with	TR46	yielded	(rare)	progeny	with	the	TR463.		
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4.	Two	mating	types	of	TR463			were	discovered	from	the	same	compost.	
However,	 the	 lack	 of	 direct	 evidence	 of	 ascospores	 in	 the	 compost	 and	 the	 low‐
frequency	 survival	of	 conidiospores	 to	heat	 shock	precludes	 the	definite	 conclusion	of	
the	occurrence	of	sex	in	compost.	In	the	future,	diversity	analysis	before	and	after	heat	
shock	may	be	another	way	of	testing	for	sexual	reproduction	in	compost.	
(1)	Compost	provides	a	favorable	condition	for	sex	
Several	key	factors	for	sexual	reproduction	under	laboratory	conditions	that	have	been	
identified	seem	to	be	met	in	compost	(O'Gorman	et	al.	2009).	Compost	as	a	multi‐organic	
resource,	with	 inside	 the	 heap	 a	warm,	 dark,	 low	 oxygen/high	 CO2	 environment	 as	 a	
result	of	organisms’	activity,	supplies	all	known	essential	elements	for	the	occurrence	of	
sex.	A.	fumigatus	isolates	of	the	two	different	mating	types	are	widely	spread	in	nature	
(Gow	 2005).	 Combining	 these	 important	 elements,	 it	 is	 likely	 to	 find	 ascospores	 in	
compost.		
In	 addition,	 it	 is	 believed	 that	 environmental	 changes	 affect	 the	 switching	 between	
asexual	and	sexual	reproduction.	It	has	been	argued	that	in	many	fungi,	sex	occurs	at	the	
end	of	the	growing	season,	when	the	conditions	for	somatic	growth	become	adverse,	at	
this	moment,	the	cost	of	sex	is	low	(Chamberlain	et	al.	1997;	Hoekstra	2007).	Hence,	a	
dynamic	 composting	 process	 with	 temperature	 gradients	 (20‐70Ԩ)	 and	 gas	 changes	
might	provide	the	suitable	environment	to	sex	when	the	cost	of	sex	is	low.	
(2)	Sex	could	provide	benefits	 for	 the	survival	of	A.	 fumigatus	 in	 the	
compost		
1) Sexual	 reproduction	 can	 generate	 resting	 ascospores	 with	 survival	 structures	
(thick	wall)	to	cope	with	unfavorable	conditions.	
Many	 planktonic	 organisms	 produce	 'resting'	 stages	 by	 sexual	 reproduction	when	 the	
environmental	conditions	deteriorate,	such	as	Daphnia	(Alekseev	and	Lampert	2001).	In	
plants	 seeds	 can	 survive	 unfavourable	 conditions	 as	 well	 (Maynard‐Smith	 1978).	 In	
fungi,	the	outcome	of	sexual	reproduction	most	often	is	the	production	of	resting	spores	
that	are	used	to	survive	in	extreme	condition	and	to	spread,	for	example	Plasmodiophora,	
Neurospora:	the	dormant	ascospores	of	Neurospora	are	activated	by	fire,	and	then	start	
to	germinate	(Macfarlane	1970)	(Henney	and	Storck	1964).	All	resting	spores	are	thickly	
encysted	 in	 order	 to	 survive	 through	 stressful	 times.	 In	 A.	 fumigatus,	 the	 sexual	
ascospores	 have	 a	 thick	 cell	 wall	 and	 have	 the	 capacity	 to	 survive	 adverse	 condition,	
while	 asexual	 spores	 are	 destined	 to	 germinate	 quickly	 or	 act	 as	 fertilizing	 agents	
(spermatia)	 (Chamberlain	 and	 Ingram	 1997;	 Hoekstra	 2007;	 Kwon‐Chung	 and	 Sugui	
2013)).	Related	to	this	ecological	specialization	is	the	tendency	of	sexual	reproduction	to	
be	 induced	 when	 the	 environments	 are	 harsh.	 In	 response	 to	 the	 dynamic	 compost	
environment,	A.	fumigatus	could	increase	survival	rate	via	sexual	reproduction.		
2) Sexual	reproduction	generates	genetically	variable	genotypes	via	recombination	
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It	 is	 known	 that	 sexual	 reproduction	 produces	 genetically	 variable	 offspring	 due	 to	
recombination	 between	 all	 alleles,	 sex	 also	 can	 speed	 adaptation	 and	 eliminated	 the	
deteriorate	mutation	much	more	efficiently	compared	with	asexual	process	(Bell	1982;	
Camps	et	al.	2012;	Losada	et	al.	2015).	Schoustra	has	shown	that	the	different	genotypes	
of	ascospore	achieved	highest	fitness	in	different	environments	in	A.	nidulans	(Schoustra	
et	 al.	 2010).	 Therefore,	 highly	 diversed	 ascospore	 enhances	 the	 survival	 rate	 of	
ascospore	and	maximizing	success	in	the	later	when	the	surroundings	altered.		
3) Sex	can	quickly	generate	resistance	genotypes	
Via	sexual	recombination,	 the	resistant	allele	will	be	re‐shuffled	and	generate	 the	new	
variable	 resistance	 genotypes	 that	 may	 be	 better	 adapted	 to	 the	 changing	 azole	
environment	either	in	the	azole‐exposed	environment	or	in	the	patients.	As	we	found	in	
the	sexual	cross	between	two	resistant	TR46,	the	promoter	could	extend	into	TR463	and	
lead	to	increased	resistance	to	voriconazole,	itraconazole	and	posaconazole.	 	Therefore	
in	 any	 environment	 with	 azole	 pressure	 the	 favorable	 genotype	 will	 be	 selected	
successfully.	
	
Conclusions	and	Future	Outlook	
	
Our	study	shows	that	azole‐exposed	compost	can	serve	as	a	hot	spot	that	facilitates	the	
spread	 of	 azole‐resistant	 A.	 fumigatus.	 Although	 we	 found	 evidence	 that	 sexual	
reproduction	might	take	place	in	the	environment,	we	were	unable	to	provide	definitive	
proof.	Nevertheless,	we	believe	that	the	full	 life	cycle	of	A.	fumigatus	needs	to	be	taken	
into	account	to	explain	the	emergence	of	azole	resistance.		The	continued	emergence	of	
azole	 resistance	 mutations	 warrants	 research	 into	 the	 mechanisms	 of	 resistance	
selection	in	the	environment.	Insights	in	key	factors	involved	in	the	selection	or	spread	
of	 resistance	 in	 A.	 fumigatus	 will	 help	 to	 develop	 strategies	 that	 prevent	 resistance	
selection.	Only	 then	can	 this	 important	 class	be	 rescued	 for	use	 for	crop	protection	as	
well	as	treatment	of	Aspergillus	diseases.	
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Supplementary	data	
	
1. Fungicides	 detected	 from	 the	 azole‐free	 Compost	 W	 and	 azole‐containing	
Compost	H	
Samples		 Detected	fungicides	
W1,	2,	3,	4,	5,	6	 None	
H1,	2,	3,	4,	5,	6	 prochloraz	0.020	mg/kg	
prothioconazole‐desthio	0.25	mg/kg	
imidacloprid	0.013	mg/kg	
boscalid	0.026	mg/kg	
tebuconazool	0.055	mg/kg	
prothioconazole‐desthio	0.068	mg/kg	
	
Methods:		
The	homogenized	samples	are	weighed	into	a	Teflon	jar.	A	(homogenized)	sub‐sample	is	
extracted	with	acetone,	followed	by	extraction	with	dichloromethane	/	petroleum	ether.	
A	portion	of	the	extract	is	evaporated	to	dryness,	re‐dissolved.	
Re‐dissolving	 is	 dependent	 on	 the	 analysis	 that	 follows.	 For	 the	 GC‐MSMS	 (liquid	
chromatography‐mass	spectrometry)	analysis,	the	sample	is	re‐dissolved	in	iso‐octane	/	
toluene	(9:	1).	For	the	LC‐MSMS	(gas	chromatography‐mass	spectrometry)	analysis,	the	
sample	is	re‐dissolved	in	methanol	redissolution	acidified	by	0.02%	HAC.	The	content	of	
ethephon,	dithiocarbamates	and	other	single	residue	methods	are	determined	following	
the	requirements	of	Euro	Finnish.	
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This thesis describes the role of several aspects of the ecology and lifecycle of Aspergillus 
fumigatus in the development of resistance to the azoles in its environment. Understanding the ecology and evolutionary dynamics of A. fumigatus is very important in order to make the right decisions in controlling the recent increase of azole resistance in clinical practice. 
Relevance of the life cycle of A. fumigatus for the emergence of azole 
resistance The various parts of the A. fumigatus life cycle are vital to generate genetic variation by mutation and recombination during mitotic and meiotic divisions. For this thesis I researched how these components of the life cycle relate to the emergence of azole resistance. Asexual reproduction (Figure 2, Chapter 1) is abundant in nature and occurs in patients with cavity aspergillosis as well. Under laboratory conditions, a single spore can form a colony with 5*109 conidiospores within one week of growth. Each of these spores is the result of a mitotic division in one of the approximately 100 conidiogenous phiallide cells per conidiophore. Each phiallide may divide up to 100 times to create strings of conidiospores with up to 104 spores per conidiophore. Under the assumption of a genome-wide single-nucleotide mutation rate of 1-2*10-10 per base per mitotic division, as found in other ascomycetes (Lynch et al. 2008), and a genome size of 30 Mb, a one-week colony of A. fumigatus is expected to have more than 107 SNP mutations. In 
Chapter 3 we provide the experimental evidence for the idea that asexual sporulation promotes the emergence of azole resistance by providing ample mutation supply (Zhang et al. 2015b). However, within and between strain variation in mutation rate during the sporulation process and mycelial growth is still unknown and needs further investigation in A. fumigatus.  For Chapter 4 we sequenced 11 isolates with different resistance levels and morphologies from our evolutionary experiment that is described in Chapter 3. Evolved lineage D1, with increased azole resistance, contains two fixed mutations that have been confirmed to be involved in azole resistance by analyzing the progeny of a sexual cross. One of these azole-resistance mutations is a known CYP51 gene mutation; the other is HMG CoA reductase mutation, a rate-controlling enzyme of the mevalonate pathway that produces ergostrol. The finding that the evolutionary lineages without azole treatment also harbour mutations is consistent with the idea that asexual sporulation generates genetic diversity via mitotic division. Whether these mutations are neutral or are related to adapting to the specific experimental conditions is not clear. Sexual reproduction starts with fusion of two strains of different mating types. New genotypes are generated via recombination of the parental genomes as a result of crossing over and independent assortment of chromosomes during meiosis (Figure 2, 
Chapter 1).  In Chapter 3 we show that the sexual cross between evolved lineage D1 and a sensitive isolate, generates four genotypes, as expected from the independent 
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segregation of the two resistance mutations by meiotic recombination. Sexual reproduction could speed up adaptation via recombination by creating variants with increased azole resistance. We have support for this now from data that show the generation of highly–resistant progeny from a cross of intermediate resistant and sensitive isolates (Figure 1). Furthermore, the new resistant genotype TR463 is generated from a sexual cross of two TR46 parents, presumably via unequal crossover during meiosis. These results provide evidence that sexual reproduction promotes the emergence of new azole-resistance mechanisms. However, details of meiosis in A. 
fumigatus, such as the recombination rates, unequal crossover, and the expansion of repeats or gene copy variation need further investigation. In addition, the contribution of de novo mutations during sexual reproduction is unknown. So far, sexual reproduction has only be observed under strict laboratory conditions (O'Gorman et al. 2009). The data shown in Chapter 6 suggest the potential occurrence of sexual reproduction in nature. However, when, where, and in what frequency sexual reproduction occurs in nature needs a more in depth study. If sex occurs in nature, sexual reproduction may explain the high diversity of microsatellite genotypes in globally collected isolates. 
Figure 1. Segregation of mycelial growth rate (MGR) phenotypes among the 
progeny from a sexual cross between the evolved strain (D3 fluffy, parental type 1; 
P1; with high MIC and fitness) and a sensitive genotype (parental type 2; P2).  MGR of progenies was measured on the MEA containing 1 µg /mL difenoconazole. Columns 1-105 represent individual progeny, 106-110 represent parental type 1, evolved strainD3-5 fluffy (red), and columns 111-115 represent parental type 2, sensitive environmental isolate (green). Note that some progeny (67-103) have higher fitness compared to the resistant parents P1. The parasexual cycle includes mycelium growth, diploidization via nuclear fusion, and haploidization into haploid again. Since the somatic rate of diploidization is relatively low with a frequency around 10-5 (see Chapter 3), recombination via the parasexual cycle is expected to be limited. However with the large number of mitotic divisions occurring during somatic growth and sporulation it is still possible that aspects of the 
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parasexual processes play a role in speeding up the evolution of azole resistance via recombination. For the development of resistance asexual reproduction seems most relevant in generating SNP mutations through large numbers of mitotic divisions, while the (para)sexual part of the lifecycle are more likely to generate structural variation such as duplications and recombined combinations of existing mutations via meiosis and mitotic recombination. 
Do azoles influence the evolution of azole resistance in other ways 
than direct selection pressure?   Our environment is contaminated by azole compounds due to a wide variety of usages: azoles are applied in shampoo, for wood preservation, in wall paper, and on agricultural crops for protection (Verweij et al. 2009; Gisi 2013). In addition, bacteria can produce azole-like compounds (Łukowska-Chojnacka et al. 2016) a so far neglected aspect with respect to azole-resistance development in fungi, and also not addressed in this thesis. All these azoles pose selective pressure on the widely spread A. fumigatus.  In this thesis I have shown that azole exposure to A. fumigatus will provoke a strong selection for azole resistance. The experiments in Chapters 3 and 4 have shown that difenoconazole exerts the strongest selection pressure compared with other fungicidal azoles. This can be explained by the molecular structure of these azoles and their binding sites when they interact with fungal CYP51A. In Chapter 6 I confirm that also in the environment azoles create strong selection pressure. The striking contrast between A. fumigatus isolates from azole–containing composts and from azole-free compost strongly suggests the vital role of azole selection. Whereas in the azole–containing compost most A. fumigatus isolates were azole-resistant (92%), in the azole-free compost most isolates were sensitive (98%). Different azoles select different genotypes of A. fumigatus, as we can see from Figure 2. From the same compost sample containing three different genotypes, wildtype, TR46/Y121F/T289A, and TR463/Y121F/M172I/T289A/G448S, on petri-dishes containing the agricultural fungicide difenoconazole, all three genotypes are able to survive, which may be explained by pre-adaptation in the compost contaminated with agricultural fungicide. However, if they encounter the medical azole itraconaozle, a novel environment, only the TR46/Y121F/T289A genotype can survive. This information underpins the dominant genotype in the clinical isolates rather than environmental isolates due to the second selection of medical azoles.  There may be additional influences from azoles on the evolution of azole resistance. Azoles are not known to be mutagenic or recombinogenic, however, azoles may speed up the adaptation of A. fumigatus by posing (physiological) stress. For instance, azoles slow down growth and disrupt the homeostasis in the cell which may negatively affect 
    General Discussion
153 
Figure 2. The response to agricultural and medical azoles of three A. fumigatus 
genotypes from a natural sample of compost.  A; Only TR4 6/Y121F/T289A is capable to grow on medical azole itraconazole (32g/mL); B: Wild type (small colonies), TR4 6 3/Y121F/ M172I/T289A/G448S (intermediate colonies) and TR4 6/Y121F/T289A (big colonies) grow on agricultural azole difenoconazole (32g/mL).  DNA-repair mechanisms and general “quality-control” of spores which will increase the mutation frequency. Moreover, it has been discussed that sex occurs as a reaction to stressful conditions (Chamberlain et al. 1997; Hoekstra 2007). Azole might be a stress signal for A. fumigatus to go through sexual reproduction to generate more diverse genotypes to cope with stressful or changing environment. Therefore it is possible that azole in the environment speeds up the rate of evolution in A. fumigatus through sex. Therefore it is important to study the role of azole and other stress factors on the induction of sex in A. fumigatus. 
Azole-resistance development routes: Environmental or clinical 
routes, or both? Azole resistance in A. fumigatus is increasing over the years, and especially the mutants TR34/L98H and TR46/Y121F/T289A have spread globally. To answer when and where these types of resistance mechanisms first emerged has become an important puzzle in order to find a solution for this increasing problem (Snelders et al. 2008; Chowdhary et al. 2012; Ahmad et al. 2014; Astvad et al. 2014; Rocchi et al. 2014; Pelaez et al. 2015; Snelders et al. 2015; Wiederhold et al. 2015).  Resistant isolates can be collected from patients with chronic aspergillus disease, such as CF patients who are under prolonged treatment with medical azoles and from evolutionary experiments with around seven weeks of exposure to environmental fungicides (Camps et al. 2012b; Zhang et al. 2015). Chapter 4 describes that the evolutionary patterns of evolved lineages to agricultural azoles are highly correlated to the pattern of the medical azoles, which indicates the possibility of an environmental route to resistance development. However, the frequently found azole-resistance mechanisms containing TR34/L98H and TR46/Y121F/T289A have not yet been discovered from any evolution experiment with various azole types. Interestingly, CYP51-G138S mutants are reported both from the patients with long-term azole treatment and from an evolutionary experiment as well, which supports the possibility of both azole resistance development routes (Snelders et al. 2012).  
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Considering the relevance of all aspects of the life cycle in A. fumigatus in the emergency of azole resistance, it seems that environmental routes have more opportunities to facilitate the development of resistance. A. fumigatus can produce enormous numbers of asexual spores in the environment (Zhang et al., 2015) and it is likely that it can complete the whole life cycle in nature although direct evidence for sexual reproduction is still lacking. However, in patients, a totally different environment, the fungal biomass will be limited and mostly consist of mycelium, and asexual reproduction will occur only in cavitary aspergillioma. Parasexual recombination might occur in patients with a long-lasting infection, but sexual reproduction is highly unlikely in patients. So the wide use of azole compounds in the environment, the prevalence of A. fumigatus in decaying vegetation and no restrictions for completing its lifecycle make it likely that the environmental route contributes mostly to the recent increase of azole resistance. However the clinical route may also contribute to azole-resistance development, especially when asexual sporulation can occur and infections are persistent and lasting for many years. Clearly more research is needed to assess how resistance can develop in patients and in the environment and how these resistant types can spread. It is known that compost is an important ecological niche of A. fumigatus. Compost houses a dense community of various fungi and bacteria which have to compete for their share of the resources. Some bacteria such as Burkholderia andropogonis, Pseudomonas 
chlororaphis are able to produce azole types of compounds, such as 1H- imidazole, 1-ethyl- 5-Cyano-1,2,3- thiadiazole and Banzothiazole (Łukowska-Chojnacka et al. 2016). It is possible that A. fumigatus is exposed to these natural azoles and has acquired resistance as well. Whether this also affects resistance to other azoles is unclear. If A. 
fumigatus has adapted to these azole-like compounds in the compost during its evolutionary history, it is not surprising that A. fumigatus already has flexible defense mechanisms that can quickly develop resistance to new medical azoles. However, how and which type of azole-producing bacteria might contribute to the recent increase in azole resistance of A. fumigatus need further study. 
Morphotypes of A. fumigatus in the environment and patients As shown in Chapter 5, several different morphotypes evolved during the evolutionary experiment in the laboratory, with changes of colony size, mycelium structure, and early or late sporulation. The dynamic morphology changes of A. fumigatus over the azole treatment suggest that morphology is an important factor for A. fumigatus during adaptation to the azole environment. Cooperation between morphotypes and negative interactions such as cheating may also contribute to adaptation to the azole environment at the population level. We have shown such interaction between coevolved morphological types in both lineage D3 and D6 that have higher resistance levels when growing together, but have reduced spore production in the D6 lineage (Chapter 4 and Figure 3). Possibly their morphologies evolved in order to optimize their interactions with the type they evolved with. Notably, the earlier found correlation between MIC value and MGR does not seem to apply for morphological mutations (e.g. see D6 white and D6 fluffy, Figure 3). 
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Figure 3. Interaction between d6 white and d6 fluffy in the present and absent of 
azole environment The mixture has lower mycelial growth rate (MGR) and spore production, however, exerts a higher resistance level in the presence of azole .  Most clinical isolates collected from patients with different aspergillus infection also show morphological variation (Chapter 5, Table 2). In some cases, non-sporulating A. 
fumigatus isolates are found from clinical patients (Zhang et al. 2015a), which is very different from the natural environment with decaying plant material. The human environment clearly differs by a low Fe, low O2, different nutrients, temperature and light conditions as well as an immune system. Loss of sporulation after a long-stay inside a patient, may reflect a pleiotropic effect of genetic adaptations to the human body and/or medical azole treatment. Although it seems that morphology is important for azole resistance in A. fumigatus, generally its role in developing resistance to azole has been neglected and deserves more attention. 
The possible origin of TR34/L98H and TR46/Y121F/T289A and 
TR463/Y121F/M172I/T289A/G448S The pre-dominant resistance genotypes found in A. fumigatus isolates from the Netherlands have a combination of tandem-repeat (TR) variations in the promoter region and point mutations in the open reading frame of the cyp51A gene. The origin of a TR is unclear, but it may be due to a replication error. The point mutations probably occur during mitotic division in the asexual sporulation structures of A. fumigatus. The spontaneous emergence of two genetic changes is highly unlikely to occur at the same time in the same individual and thus one must have been selected first before the other one occurred. It is tempting to speculate that the initial point mutation(s) in the cyp51A gene reduced the blocking affinity of azoles to the CYP51 enzyme as well as reducing the activity of the enzyme. The TR in the promoter would than compensate for the reduced enzyme activity by upregulating the cyp51A gene. 
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Genotype analysis based on microsatellite loci shows enormous diversity in TR34, TR46, and TR463 isolates, which makes it difficult to conclude the possible evolutionary route of these TR variants (Debeaupuis et al. 1997; Duarte-Escalante et al. 2009; Araujo et al. 2010). It is generally believed that the microsatellite alleles and mating-type remain unchanged via asexual reproduction, and even after sexual reproduction (just shuffling genes rather than changing), therefore it is difficult to explain the origin of highly diverse microsatellite loci. One possible explanation is that the microsatellite loci are not stable and influenced by many factors. In Chapter 6 I showed that TR463 can be generated via a sexual cross between two TR46 with opposite mating type and isolated from the same compost sample, even with low frequency of 10-5. This suggests a vital role for sexual reproduction in the development of azole resistance by increasing the tandem repeat number. However, the evolution of TR34 to TR343 after 10 passages of experimental evolution (Sender et al, 2012) suggests that tandem repeat number can also increase via DNA duplication error in asexual reproduction.  
Can A. fumigatus complete its life cycle in nature? There are three main aspects of the life cycle of A. fumigatus that are relevant for fungal adaptation and evolution: asexual and sexual reproduction and the processes associated with the parasexual cycle. As mentioned before, each of these variations can potentially have their role in the development of azole resistance. Asexual reproduction is abundant in nature, as we can see from the isolation of enormous amount of conidiospores from compost, soil, air, and even in the office (Anastasi et al. 2005; Deacon et al. 2009; Gisi 2013; Kwon-Chung and Sugui 2013; Anastasi et al. 2005; Deacon et al. 2009). Asexual reproduction is a very efficient and essential way of (1) dispersal for A. fumigatus due to the large number of conidiospores produced and their airborne character, (2) alternation from the multinuclear hypha to uninuclear conidiospore and further form the homokaryotic cultures, and (3) of mutation supply.   Sexual reproduction in A. fumigatus was discovered in 2009, and has thus far only been demonstrated under specific and strict laboratory conditions (dark, 30oC and oatmeal medium with two opposite mating-type strains). The enormous genetic diversity in the natural A. fumigatus population however suggests the occurrence of sexual reproduction, but whether sexual reproduction really occurs in nature remains an open question. As 
Chapter 6 has shown, compost seems a favourable condition for the occurrence of sex. However, when and where, and under which condition exactly sex can occur in nature is still unknown. Whether our method with heat shock to distinguish the asexual conidiospores and sexual ascospores is a reliable method needs further investigation, before we can conclude whether sexual reproduction has taken place in compost.  Parasexual or somatic recombination starts at the hyphal stage with heterokaryotic mycelium formed by two compatible isolates or upon spontaneous mutation in the 
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hypha. Next heterozygous diploid nuclei can be formed; crossing-over and nondisjunction subsequently result in recombinant haploids. Heterokaryon formation by spontaneous mutation in somatic nuclei is likely to happen during mitotic division and may be especially relevant in long-lived cultures. Heterokaryons can also result from anastomosis between different hyphae. However, fungi have an extensive self-non-self recognition system preventing such heterokaryon formation, so that two random isolates are almost always heterokaryon incompatible. Whether heterokaryon incompatibility is also widespread in A. fumigatus is so far unknown, but highly likely. In Chapter 3, it was shown that diploids could be isolated under laboratory condition with a frequency of approximately 10-5 among spores from a heterokaryon. However, whether diploid formation and subsequent haploidization is able to occur under the conditions in nature requires more in-depth study. Another possible cause of diploid formation is sexual reproduction. In A. nidulans it was reported that approximately 1% of the ascospores is diploid (Pritchard et al. 1954). For A. 
fumigatus this has not been studied, but if this also applies to A. fumigatus a relatively high frequency of diploid isolates would be expected if sexual reproduction is abundant in nature. 
Figure 4. Development of resistance and subsequent 
compensatory mutations in the context of adaptive 
landscapes. Panel (1) shows a stable situation, the isolate is ona fitness peak. Introduction of a fungicide, changes the landscape which lowers the fitness of the given genotype [Panel (2)]. A mutation (green sector) leading to higher fitness can occur [Panel (3)] which results in an adaptive walk to the new fitness peak in the fungicide environment [Panel (4)] . Changing the landscape again by removing the fungicide [Panel (5)] makes that the resistant isolate is no longer on a fitness peak and mutations [Panel (6) red sector] will be selected that compensate for this loss of fitness. The resistant isolate with compensatory mutations approaches a fi tness peak that is high in either absence or presence of fungicides [Panels (7) and (8)]. The figure is adapted from (Schoustra et al .  2006). Colour dots: different adaptive genotypes; X-axis: the appearance of different genotypes over the evolutionary time; Y-axis:  fitness such as MGR. Green landscape:  environment without fungicides. Red landscape: environment with fungicides.  
Compensatory mutation leads to persistent azole resistance in A. 
fumigatus It is believed that resistance always brings along a fitness cost, in particular when a resistant strain is growing in the absence of azoles. This cost can for example be 
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observed as reduced mycelial growth rate compared with a wild-type strain (Chapter 1, Figure 2). Therefore, resistant isolates might lose their advantage over wild-type isolates when they compete in the absence of azole.  This cost would severely restrict the spread of resistant isolates, however, the gain of compensatory mutations eliminates this cost for the resistant isolate and it can reach the same fitness as the wild type in an azole–free environment while keeping its azole resistance. How a compensatory mutation can increase the fitness is shown in figure 4. The possibility for compensatory mutations will make controlling the spread of azole-resistant isolates more difficult as reducing the use of azoles will not necessarily lead to the disappearance of resistant isolates already present in the environment. Therefore it is important to understand the mechanism of compensatory mutations. 
The adaptation of A. fumigatus to the environment/ human host Adaptation is the process in which organisms improve their fitness in a given environment by changing their phenotype using genetic or non-genetic mechanisms. Different adaptations are characterized by the time needed for organisms to attain them and by the duration of the stress condition. The fungal adaptation involves physiological, (epi-) genetic and evolutionary adaptation (Figure 5A). A. fumigatus is a biochemically versatile organism capable of growing under a wide range of conditions (e.g. pH, temperature, nutrient source) based on sensing and according gene regulation. This is an adaptation to its lifestyle: the airborne conidiospores may land upon unpredictable substrates and will thus have to be able to cope with a diversity of environmental conditions. Phenotypic plasticity can potentially ensure survival and reproduction under many conditions and therefore may contribute to the fitness of an opportunistic fungus.  
A. fumigatus has e.g. 22 secondary metabolite genes and high number of efflux pumps to adapt to fluctuating condition (Sugui et al. 2007; Buied et al. 2013; Fraczek et al. 2013) Figure 5B shows A. nidulans is capable to grow on a wider range of pH by coordinating the multi- secondary metabolite genes, such as changing the colony colour, rather than alkaliphilic fungus sodiomyces alkalinus, only is able to survive at the high pH environment. However, physiological adaptations are generally not inherited over generations. (Epi-) genetic adaptation may occur at the DNA (mutation or copy number variation) and chromosome, RNA, and even protein level, when there are longer-lasting directional changes to the environment (Yona et al. 2015), e.g. with widespread presence of azoles. Such conditions may explain the emergence of genetic adaptations such as the cyp51 mutations (G54E and TR34/L98H), and the transcription factor hapE mutation in A. fumigatus (Snelders et al. 2010; Albarrag et al. 2011; Camps et al. 2012a; Kwon-Chung and Chang 2012). Genetic adaptations are generally memorized and can be propagated to the next generation. However, so far no evidence yet for epigenetic changes are involved in azole resistance.  With extended duration of directional changes, genome wide mutations may occur, e.g. to compensate for cost of resistance effects, and lead to gradual evolutionary changes due to the stress as previously discussed in other species (Zong et al. 2012; Long et al. 2016). The combined effect of several mutations across the whole genome might underpin adaptation to directional changes.  
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As shown in Chapter 4, when the sensitive ancestor adapted to the azole environment in seven weeks, several phenotypes evolved during this adaptation process. In D1 lineages, the azole target gene cyp51A mutation was discovered, as a genetic adaptation that can be inherited to offspring by sexual or asexual reproduction. 
 
Figure 5. A: the A. fumigatus adaptation spectrum over the duration of stress 
condition: physiological, (epi)-genetic and evolutionary adaptations.  Physiological adaption is related to the fluctuating conditions such as seasonal or spatial changes. Whereas the (epi)-genetic and evolutionary adaptation fit the long –term of directional changes to the environment.  
B: A. nidulans can grow on a wider range of pH, than alkaliphilic fungus 
sodiomyces alkalinus (obtained from Grzhimaylo, 2015). In D6 lineages, two mutations were identified that were not present in the ancestor. The trace-back check showed that HPT (hpt-protein-AFUB) is highly likely involved in azole resistance, whereas the PTAB mutation is associated to the phenotypic change of later sporulation (white phenotype). This is a typical evolutionary adaptation case in azole-resistance development. 
Hotspots for azole-resistant A. fumigatus 
A. fumigatus has been found in patients, agricultural fields, flower-beds, compost, air, sewers, and even in bathrooms. However, understanding what the hotspots for azole-resistance development and maintenance are, is crucial for more efficient azole-
A 
       pH3               pH4              pH5                pH6                pH7               pH8               pH9              pH10                                                 
B 
CHAPTER VII 
160 
resistance management. In Chapter 6 we showed that the azole–containing compost is a potential hotspot for azole-resistant A. fumigatus. Although the azole concentration we found in this compost is not high as Gisi mentioned (Gisi, 2013), it can still provide the effective selection for azole-resistant A. fumigatus. At the same time, this low concentration will not completely inhibit the growth, asexual reproduction, and potential sexual reproduction of A. fumigatus, so that resistance can develop over long periods. As shown in Chapter 6, the sexual cross between two strains with TR46 produces more fruiting bodies (cleistotecia) on medium with a similarly low amount of agricultural azole compared with azole-free medium. This confirms the vital role of azole in the maintenance of resistance and further resistance development. Overall, effective selection of resistant A. fumigatus can occur if (1) the fungus is able to grow with asexual sporulation or sexual reproduction and (2) there is an effective azole concentration as selection pressure. These two conditions appear to be crucial for the definition of what is a hotspot for the development of azole resistance. Thus, compost heaps contaminated with azoles and A. fumigatus infected patients treated with azoles are both potential hotspots. Extensive sampling for A. fumigatus on places where azoles are used or azole contamination can be expected will have to be done to reveal all potential hotspots for resistance development. 
Can A. fumigatus become a real human pathogen? It is generally believed that A. fumigatus only infects immunosuppressed people, such as patients with HIV. However, it has been found that a healthy dolphin can be struck with an A. fumigatus infection with the TR46/Y121F/T289A resistance mechanism (Paul Verweij, personal communication). Therefore it is uncertain whether A. fumigatus can still only infect immunosuppressed people or it is maybe on its way to become a real human and animal pathogen. If A. fumigatus can persist in the human body for a long time, it may gradually adapt to this new environment and become specialised and evolve into a true pathogen. Especially when the fungal adaptations are not an evolutionary dead-end but can “escape” from a patient to the environment via the dead body or to other patients via cough. Asexual sporulation is known to increase general mutation supply and strongly contributes to adaptation, and subsequently may lead to azole-resistance development (Zhang et al. 2015b). But it may also lead to dispersal of human-adapted genotypes. The current increasing numbers of patients with chronic aspergillosis that are difficult to treat and therefore have fungal growth and selection pressure for an extended period of time in the patient, may therefore pose a serious problem, at least from an evolutionary perspective. 
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Conclusion and future directions In this thesis, I have demonstrated that the evolution of azole resistance is complex as the fungus has different ecological niches and a complex lifecycle and all the factors associated with this may affect the different aspects of azole-resistance evolution. Furthermore, facing up the current dilemma for the treatment of aspergillus infections, neither stopping the azole treatment nor changing to a new azole is the ideal solution. Therefore, the various aspects of the life cycle and azole-selection pressure need to be taken into account for understanding the development of azole resistance in A. 
fumigatus. To control the increasing amount of azole resistance and persistence of azole resistance in A. fumigatus, it is essential to understand all the details of the life cycle and ecology of A. fumigatus and interaction between both before we take actions to control the worldwide increasing problem of azole resistance in the further study. 
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The presented thesis shows the relevance of the life cycle of A. fumigatus to the development of azole resistance and possible evolutionary routes that lead to it. The work highlights the importance of fungal biology and evolution towards understanding the development of azole resistance in fungi. I conclude that azole resistance in A. 
fumigatus is a consequence of selection pressure by azole in the environment on the genetic variation generated via various aspects in the A. fumigatus life cycle. This thesis also introduces an experimental evolution approach to study the dynamics and mechanisms of the evolution of azole resistance. In addition, I investigate what condition can lead an environment to be a possible hotspot for the development of resistance. Finally, I link this to the potential conditions under which resistance can emerge and spread in the lungs of humans and how this depends on the specific azole used. The introduction in Chapter 1 provided detailed information on the azole resistance in 
A. fumigatus. Azole resistance in A. fumigatus has become a global issue and hinders the efficiency of azole treatment in the clinical practice of aspergillosis infections. It is generally believed that there are two possible azole-resistance development routes with a different origin of the resistance: the clinical and the environmental route. That means azole resistance may develop in patients treated with azole creating a selective pressure, but azole resistance may also occur in the environment before A. fumigatus comes in contact with the patient. Different azoles used in agriculture can potentially lead to resistance to medical azoles. The major resistance mechanism is the alternation of the azole target gene cyp51A, encoding a key enzyme in the ergosterol pathway. The prevalence of highly resistant TR34/L98H and TR46/Y121F/T289A has increased over the recent years and spreads globally. It is known there are different modes of reproduction in A. fumigatus, however, the complex life cycle has so far been neglected for understanding how azole resistance develops. Furthermore, direct observation of the development of azole resistance in environmental isolates over evolutionary time is still missing. Finally experimental setting has not been used to explore the variations of agricultural azoles in the selection pressure.  
Chapter 2 discussed the current dilemma on the management of A. fumigatus infections in patients: stopping the use of clinical azoles when resistance arises or changing to new triazoles?  These two solutions are generally acceptable for controlling the emergence of azole-resistant A. fumigatus strains. By stopping the use of clinical azoles, the resistant A. 
fumigatus may initially suffer from the cost of resistance due to the unfavourable free-azole situation. The selective pressure of this cost may then lead to compensatory mutations that cover the cost of resistance potentially resulting in a resistance genotype without any cost. Therefore, compensatory mutations, due to the intermittent use of the clinical triazoles maintain the azole resistance in A. fumigatus. Similarly, changing to a new azole will promote the development of more mutations and may result in pan- resistance to all clinical triazoles. In Chapter 2, we provided a patient case of azole-treatment failure. Upon azole treatment, cultures exert a variety of phenotypes (different resistance level and morphotypes). As the current two treatment solutions, 
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compensatory mutations or multiple mutations may arise and both possibly contribute to treatment failure against A. fumigatus infection.  This chapter raises our concern for managing azole resistance in the clinical practice. To tackle this problem, understanding by what mechanism(s) the resistance emerges, how it can spread, and how resistant genotypes can persist in environments without azoles are important issues.  In Chapter 3, we focused on the role of asexual reproduction in azole-resistance development. It was previously hypothesized that asexual sporulation is required for the expression of azole resistance in A. fumigatus (Verweij et al. 2009), because the asexual sporulation process aids to release the resistant nuclei from multinuclear hypha to single conidiospores, which can grow into a full resistant hypha. We performed an evolution experiment with and without asexual sporulation. We then showed that the cultures which went through asexual sporulation reached a higher resistance level compared to the cultures without asexual sporulation. We concluded that asexual sporulation plays an important role in emergence of azole resistance. Further, we demonstrated that azole resistance is not fully dominant, which fits with the hypothesis that asexual sporulation is required to aid the resistant nuclei escape from the multinuclear hyphae. In addition, we put forward another hypothesis that asexual sporulation could increase the mutation load due to the large number of mitotic divisions during asexual sporulation. The enormous amounts of asexual spores produced enhance the mutation load, and therefore promote the emergence of azole resistance. This discovery highlights the importance of a specific life cycle part that leads to the emergence of azole resistance in A. fumigatus. It may also explain the resistance increase during the treatment of cavity aspergillosis in patients, where asexual sporulation takes place. Furthermore, asexual sporulation may also increase the dispersal of A. fumigatus, explaining the wide spread of TR34/L98H and TR46 /Y121F/T289A mutants.  In Chapter 4, we debate on the two possible routes of azole-resistance development (clinical and environmental routes). For this we performed an evolution experiment where we exposed the sensitive ancestor strain to five agricultural fungicides that have been used over the past 30 years. We checked whether we can get the prevalent TR34/L98H resistance mutant or other highly resistant isolates. Furthermore, we investigated whether the selected resistant isolates had developed cross resistance to medical azoles as well. We showed that the dynamic evolution trajectories of resistance against medical and agricultural azoles have high similarity, strongly supporting the agricultural route hypothesis.  Evolved isolates differed in resistance level, growth rate, colony structures and sporulation time. However no TR34/L98H mutant was found after the evolutionary experiment, but we did find one mutation G138S on cyp51A in one out of 36 lineages. Our results provide the direct evidence of possible environmental route, consistent with the previous studies, where the highly resistant TR34/L98H exerts the cross resistance between medical and agricultural azoles. However, it is not clear 
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whether agricultural azole is capable of inducing the TR34/L98H and/or TR46 /Y121F/T289A.  In Chapter 5, we studied the relevance of the heterokaryotic state in the development of azole resistance in A. fumigatus. A heterokaryon is a mycelium that contains a mixture of genetically different nuclei. We observed various morphotypes appearing in some of the evolved populations during the evolutionary experiment of the previous chapter and similar diversity of morphotypes among isolates from single patients. We speculated whether these morphotypes origin from the same hypha of a heterokaryon or from separately growing mycelia in the experimental populations and the patients. Heterokaryon compatibility testing suggests that all the morphotypes from a single patient and from a single experimental population are compatible, which indicates that heterokaryons are highly likely occurring in patients and in experimental populations, especially in patients with long- term of hyphal growth. Furthermore, we showed how the ratio of the different nuclei is flexible in the heterokaryon and can be used to adapt to the changing azole environments. These results highlight the importance of multiple interacting genotypes in A. fumigatus. The mixture of several genotypes in the hypha can play an essential role in the dynamic adaptation in both the patients and the field. In Chapter 6, we investigated two compost–heaps, one of which contained azoles and one didn’t. We showed that the azole-containing compost contains a larger genetic diversity of resistant A. fumigatus than the azole-free compost. This finding indicates that the azole-containing compost is a hot spot for the development and maintenance of azole resistant A. fumigatus. Importantly, we discovered a novel resistance mechanism with TR463/Y121F/M172I/T289A/G448S that exerts pan- resistance to all medical triazoles. Infections with this novel mutant have been found in several patients in different hospitals in the Netherlands. The occurrence of TR463/Y121F/M172I/T289A/G448S in strains of both mating types and the generation of TR463/Y121F/M172I/T289A/G448S via sexual cross of two TR46 under laboratory condition suggest that the occurrence of sex in the compost is highly likely, however, more evidence is needed to confirm this. This finding underscores the fast development of resistant A. fumigatus strains and indicates a possible role of sexual reproduction in the development of azole resistance.  The thesis ends up with a general discussion Chapter 7. I discuss that the entire life cycle of A. fumigatus needs to be taken into account for understanding the emergence, maintenance and development of azole resistance in A. fumigatus. Asexual reproduction promotes the emergence of azole resistance via an increased mutation load; sexual and parasexual recombination shuffles the genes between genomes by generating genetic recombinants. Subsequently, the azoles act by creating various selection pressures on the genetically diverse genotypes. However, it is unknown whether sexual reproduction occurs in nature and whether that is indeed the driving factor for the development of TR34/L98H and TR46/Y121F/T289A mutants. In addition, the appearance of compensatory mutation and flexible heterokaryon are another two strategies facilitate 
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the persistence of azole resistance in A. fumigatus. I showed in this thesis that the role of all various aspects in the life cycles on the emergence of azole resistance is highly relevant and deserves further study. The ecology (such as compost hotspot) of A. 
fumigatus need be considered for in-depth research.    
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Nederlandse Samenvatting Dit proefschrift toont hoe de levenscyclus van de schimmel Aspergillus fumigatus van belang is voor de ontwikkeling van azoolresistentie en de mogelijke evolutionaire routes die daartoe leiden. In dit werk wijs ik op het belang onze kennis van de schimmel biologie en evolutie voor het begrijpen van de ontwikkeling van azoolresistentie in schimmels. Ik concludeer dat azoolresistentie in A. fumigatus een gevolg is van selectiedruk door azool in de omgeving en de genetische variatie gegenereerd via verschillende aspecten in de A. fumigatus levenscyclus. Dit proefschrift introduceert ook een benadering met  experimentele evolutie om de dynamiek en de mechanismen van de evolutie van de azoolresistentie te bestuderen. Daarnaast onderzoek ik welke omstandigheden in een omgeving kunnen leiden tot een mogelijke hotspot voor de ontwikkeling van resistentie. Tenslotte koppel ik hieraan de potentiele voorwaarden waaronder resistentie kan ontstaan en verspreiden in de longen van mensen en hoe dit afhangt van welk specifiek azool wordt gebruikt. De introductie in hoofdstuk 1 verstrekt gedetailleerde informatie over het probleem van resistentie ontwikkeling in A. fumigatus tegen azool antischimmel middelen. Azoolresistentie in A. fumigatus is uitgegroeid tot een wereldwijd probleem en belemmert de efficiëntie van klinische azool behandeling van aspergillose infecties in de longen (een ziekte die veel voor komt bij patienten met een slecht werkend immunsysteem). Algemeen wordt aangenomen dat er twee mogelijke routes zijn voor de ontwikkeling van azool-resistentie met een andere oorsprong van ontstaan: de klinische en de omgevings route. Dat betekent dat azoolresistentie kan ontstaan in patiënten behandeld met azool waardoor een selectie druk ontstaat, maar azoolresistentie kan ook al voorkomen in de omgeving waar A. fumigatus in contact komt met de patiënt. A. 
fumigatus komt veel voor in de natuur en leeft voornamelijk van dood plantenmateriaal. Hierdoor kunnen de verschillende azolen die worden gebruikt in de landbouw mogelijk leiden tot resistentie tegen medische azolen. Het belangrijkste resistentiemechanisme is aanpassing van het azool doelwitgen cyp51A, wat codeert voor een sleuteleiwit in de ergosterol productie van de cellen. De aanwezigheid van de zeer resistente mutantanten TR34/L98H en TR46/Y121F/T289A is toegenomen in de afgelopen jaren en wereldwijd verspreid. Er zijn diverse manieren van voortplanting bekend in A. fumigatus, echter is de complexe levenscyclus tot dusver verwaarloosd bij de studie naar de ontwikkeling van azoolresistentie. Verder is er weinig bekend over de ontwikkeling van azoolresistentie in milieu-isolaten op een evolutionaire tijdschaal. Tenslotte is er nog geen experimentele aanpak gebruikt om de verschillende agrarische azolen te testen op selectiedruk voor azoolresistentie. 
Hoofdstuk 2 gaat over het huidige dilemma in het beheersen van A. fumigatus infecties bij patiënten: het stoppen van het gebruik van klinische azolen als resistentie ontstaat of de overgang naar nieuwe triazolen? Deze twee oplossingen zijn algemeen aanvaardbaar voor het tegengaan van de ontwikkeling van azool-resistentie in A. fumigatus. Door het 
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stoppen van het gebruik van klinische azolen, kunnen de resistente A. fumigatus stammen aanvankelijk lijden onder de kosten van resistentie die ze hebben in een azol vrije omgeving. Echter door de druk van deze kosten kunnen mutaties worden geselecteerd die de kosten van resistentie kunnen compenseren en dan leiden tot een resistent genotype dat geen extra kosten heeft in een azool vrije omgeving. We verwachten dus dat onderbrekingen in het gebruik van azolen niet zal werken tegen azool resistentie door deze compenserende mutaties. Ook overgaan op een nieuw azool variant zal de ontwikkeling van meer mutaties bevorderen en dit kan dan leiden tot overkoepelende resistentie tegen alle klinische azolen. In hoofdstuk 2, bespreken we ook een patiënt-dossier waar  azool-behandeling heeft gefaald. Gedurende de azool behandeling, zijn culturen geisoleerd uit de patiënt met verschillende fenotypes (verschillende resistentieniveaus en morfotypen). De huidige twee behandel strategieën, kunnen door de compenserende mutaties of diversiteit van mutaties die ontstaan beiden mogelijk bijdragen aan het falen van de behandeling tegen A. fumigatus infectie. De bevindingen van dit hoofdstuk verhogen onze zorgen over het beheersen van azoolresistentie in de klinische praktijk. Om dit probleem aan te pakken, is het belangrijk om te begrijpen door welk mechanisme resistentie ontstaat, hoe het kan verspreiden, en hoe resistente genotypes overleven. In hoofdstuk 3 hebben we ons gericht op de rol van de vegetatieve (ongeslachtelijke) voortplanting op de ontwikkeling van azool-resistentie. Eerder werd verondersteld dat vegetatieve sporulatie nodig is voor de expressie van azoolresistentie in A. fumigatus (Verweij et al. 2009), omdat de aseksuele sporulatie helpt de onstane resistente kernen te isoleren uit de meerkernige schimmel als één-kernige vegetatieve sporen, die kunnen uitgroeien tot een volledig resistente schimmel. We voerden een evolutie experiment met en zonder de rol van vegetatieve sporulatie. Vervolgens bleek dat de culturen met vegetatieve sporulatie een hoger resistentie niveau bereiken in vergelijking met het kweken zonder vegetatieve sporulatie. Wij concludeerden hieruit dat vegetatieve sporulatie een belangrijke rol speelt bij het ontstaan van azoolresistentie. Verder hebben we aangetoond dat azoolresistentie niet volledig dominant is in een heterogene meerkernige schimmel, dit sluit aan bij de hypothese dat vegetatieve sporulatie nodig is om te ontsnappen uit de meerkernige schimmel. Verder stellen we in een andere hypothese voor dat vegetatieve sporulatie de hoeveelheid beschikbare mutaties kan verhogen als gevolg van het grote aantal mitotische delingen tijdens vegetatieve sporulatie. De enorme hoeveelheden vegetatieve sporen geproduceerd verhogen het aantal aanwezige mutaties, en daarmee de kans op de aanwezigheid van sporen die azool resistent zijn. Deze ontdekking benadrukt het belang van dit specifieke deel van de  levenscyclus dat leidt tot het ontstaan van azoolresistentie in A. fumigatus. Ook kan dit het vaker voorkomen van resistentie verhogen bij de behandeling van cavity aspergillose patiënten, waarbij vegetatieve sporulatie plaatsvindt verklaren. Bovendien bevordert vegetatieve sporulatie de verspreiding van A. fumigatus, wat de ruime verspreiding van de TR34/L98H en TR46/Y121F/T289A mutanten zou kunnen verklaren. 
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In hoofdstuk 4, bediscussiëren we de twee mogelijke routes waarop azool-resistentie kan ontstaan (klinische en omgevings-routes). Hiervoor deden we een evolutie experiment waarbij we een niet-resistente stam in aparte behandelingen blootgesteld hebben aan vijf verschillende landbouw- fungiciden, die in de afgelopen 30 jaar zijn gebruikt. We hebben getest of we de veelvoorkomende TR34L98H resistentie mutant of andere zeer resistente isolaten op deze manier kunnen selecteren in het laboratorium. Hierna hebben we onderzocht of de geselecteerde resistente isolaten ook kruisresistentie hadden ontwikkeld tegen medische azolen. We toonden aan dat de dynamische trajecten van resistentie onwikkeling tegen de medische en agrarische azolen hoge gelijkenis vertonen, wat een sterke ondersteuning geeft aan de hypothese van een agrarische omgevings route naar resistentie. geevolueerde isolaten verschilden in resistentieniveau, groeisnelheid, kolonie structuur en sporulatie tijd. Er is echter geen TR34/L98H mutant gevonden in dit evolutie experiment, maar we vonden een een mutatie G138S op cyp51A in één van de 36 lijnen. Onze resultaten leveren rechtstreeks bewijs voor een mogelijke omgevings route, in overeenstemming met eerdere studies, waarbij de hoog resistente TR34L98H mutant kruisresistentie heeft tussen medische en landbouw azolen. Het is echter niet duidelijk of agrarische azool kan leiden tot de mutaties TR34/L98H en / of TR46 /Y121F/T289A. In hoofdstuk 5 bestudeerden we de relevantie van de heterokaryotische toestand op de ontwikkeling van azoolresistentie in A. fumigatus. Een heterokaryon is een mycelium dat een mengsel van genetisch verschillende kernen bevat. De geevolueerde cultures van het evolutie experiment van het vorige hoofdstuk bevatten verschillende morfotypen. Een gelijksoortige diversiteit in morphotypen  was ook gevonden bij verschillende isolaten uit één patiënt. We speculeren of deze morfotypen hun oorsprong hebben in één individueel heterokaryotisch mycelium of in afzonderlijk groeiende mycelia voor de experimentele cultures en de patiënten. Heterokaryon compatibiliteit tests tonen dat alle morfotypen van één enkele patiënt en ook die uit één onderzoekspopulatie compatibel zijn, wat aangeeft dat heterokaryons zeer waarschijnlijk voorkomen bij patiënten en in de experimentele populaties, vooral bij patiënten met een langdurige groei zonder sporulatie. Bovendien toonden we aan hoe de verhouding van de verschillende kernen variabel is in het heterokaryon en kan worden gebruikt door A. 
fumigatus om zich aan te passen aan de aan of afwezigheid van azool in het groeimedium. Deze resultaten benadrukken het belang van de interactie tussen genotypen in A. 
fumigatus. Het mengsel van verschillende genotypen in een mycelium kan wellicht een essentiële rol spelen bij de dynamische aanpassing zowel in de patiënten als in het veld. In hoofdstuk 6 onderzochten we twee compost-hopen, waarvan één azolen bevatte en één niet. We toonden aan dat de compost met azool een grotere genetische diversiteit van resistente A. fumigatus huisvest dan compost zonder azool. Deze bevinding geeft aan dat het azool bevattende compost een hotspot is voor de ontwikkeling en instandhouding van azool resistente A. fumigatus. Verder is een belangrijke ontdekking in de compost dat er een stam met een nieuw resistentiemechanisme (TR463/Y121F/ M172I/T289A/G448S) dat resistent is tegen alle beschikbare medische azolen. Infecties 
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met deze nieuwe mutant zijn gevonden in verschillende patiënten in verschillende ziekenhuizen in Nederland. Het optreden van TR463/Y121F/ M172I/T289A/ G448S in stammen van beide mating types (parings typen) en het genereren van TR46 3/Y121F/ M172I/T289A/G448S via seksuele kruising van twee TR46 onder laboratoriumomstandigheden suggereren dat het voorkomen van de seksuele cyclus van 
A. fumigatus in compost zeer waarschijnlijk is. Echter, meer bewijs is nodig om dit te bevestigen. Deze bevindingen onderstrepen dat de snelle vorming van resistente A. 
fumigatus stammen en wijzen op een mogelijke rol van de seksuele voortplanting hierbij. Het proefschrift eindigt met een algemene discussie Hoofdstuk 7. Ik bediscussieer dat de gehele levenscyclus van A. fumigatus nodig is voor het begrijpen van het ontstaan, het behoud en de ontwikkeling van azoolresistentie in A. fumigatus. Vegetatieve voortplanting bevordert het ontstaan van azoolresistentie via een verhoogde hoeveelheid beschikbare mutaties; seksuele en parasexuele recombinatie wisselt de genen uit tussen genomen door het genereren van genetische recombinanten. Vervolgens zorgt de aanwezigheid van azolen voor verschillende selectie druk op de genetisch diverse genotypes. Het is echter niet bekend of seksuele voortplanting wel in de natuur voorkomt en of dat inderdaad de drijvende factor voor het ontstaan van de zeer resistente TR34/L98H en TR46/Y121F/T289A mutanten is. Bovendien, zijn het optreden van compenserende mutaties en de flexibiliteit van een heterokaryon nog twee strategieën die kunnen bijdragen aan de aanhoudende azoolresistentie in A. fumigatus. Ik heb in dit proefschrift laten zien dat de rol van alle verschillende stadia van de levenscyclus zeer relevant zijn voor het ontstaan van azoolresistentie en dat er meer onderzoek nodig is om precies te begrijpen hoe de hele levenscyclus het ontstaan van resistentie beinvloed. De ecologie (zoals in een compost hotspot) van A. fumigatus zal ook meer diepgaand onderzoek nodig hebben om een oplossing te vinden voor de groeiende azool resistentie. 
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摘要 
本论文研究了烟曲霉生活史与耐药产生的相关性以及可能的耐药进化途径。该论文突
出了真菌生活史以及进化在理解唑类耐药的发展中的重要性。唑类耐药是基于生活史
产生的遗传多样性的基础上唑类药物高效选择的结果。本文采用了遗传进化试验方法
研究唑类耐药演化的动力和机制。结合跨学科（遗传、进化和真菌学）知识探索耐药
产生的原因和传播条件，我们并比较了临床唑类施用的程序以及宿主感染环境对烟曲
霉耐药发展的影响。 
第一章介绍了关于烟曲霉唑类耐药的详细信息。烟曲霉唑类耐药严重阻碍了临床曲菌
感染治疗的效率，并已经成为一个全球性问题。人们普遍认为有两种可能的唑类耐药
发展途径：临床和环境的途径。主要的耐药机制是靶基因-编码麦角甾醇途径中的关键
酶 cyp51A 的突变。感染高抗性菌株 TR34/L98H 和 TR46/Y121F/T289A 的病例逐年增加，
进而在全球蔓延。烟曲霉拥有多样化的生活史（有性、无性和拟性生活史），但是，
人们忽略了这种复杂的生活史对于理解唑类耐药发展的重要性。此外，环境途径的耐
药性的发展途径假说也缺乏直接的实验证据，农业杀菌剂在耐药发展的差异也有待于
进一步的研究。 
第二章讨论了目前临床上烟曲霉耐药性管理上的窘境：停止使用唑类或更换新的三唑
类？在临床上，这两种解决方案通常被采用用于控制病情恶化。然而，停止使用临床
唑类， 耐药的烟曲霉将会承受耐药损失，进而产生补偿性突变。然而， 更换新的药
物，将会导致更多的突变，最终多耐药性菌株的产生。在本章中，我们提供了一治疗
失败的病例，由于在治疗过程中采用两措施，补偿性突变和多耐药性突变可能恶化了
烟曲霉感染的治疗。本章节唤起对临床烟曲霉耐药性管理的担忧，寻求有效管理烟曲
霉耐药性的解决措施破在眉睫。因此， 探索耐药性发生、传播、持久机制是很重要的
措施之一。  
在第三章中，我们探索了无性繁殖对唑类耐药性发展的影响。基于无性繁殖产孢子过
程利于耐药性的表达假说，（VERWEIJ等，2009），即无性繁殖产孢子过程利于耐药型
性菌核从众多的敏感性菌核中释放成独立的耐药性菌株，我们建立并比较了有无产孢
过程的进化试验。试验结果证明，与无产孢子过程相比，产孢子过程产生了更高耐药
性的菌株。我们证明了无性繁殖产孢子过程促进了耐药性的出现。不完全显性的抗性
也支持了产孢子过程助于耐药性菌核逃离敏感菌核菌丝的假说。此外，我们还提出了
另一种假说，即无性繁殖产孢子过程可以增加突变量，由于无性繁殖产孢子过程经历
大量的有丝分裂。这一发现强调了烟曲霉无性生活史对耐药性发展的重要性，同时这
一发现有助于解释有产孢子过程参与的腔曲菌病病人，在治疗过程中耐药性不断增加
的现象。最后，产孢子过程也利于烟曲霉的传播，导致高耐药性菌株 TR34/L98H 和
TR46/Y121F/T289A的全球性传播。 
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第四章中，针对有争议的烟曲霉耐药性的发展（临床和环境的途径），我们设计了遗
传进化试验，暴露敏感的烟曲霉于 5 种农用杀菌剂下，我们欲检测环境耐药性的途径
的可能性，暴露于农用杀菌剂是否导致对临床药物的抗性。在遗传进化过程中， 我们
发现，敏感菌株进化获得不同的抗性， 菌丝生长速度，菌落结构以及不同产孢时间。
虽然没有发现广泛流行的高耐药性 TR34/L98H 突变体，但是我们 36 个进化组里发现了
一个 cyp51A-G138S 突变体。对临床药物和农业杀菌剂唑类的动态进化轨迹表现出很高
的相似性，这一发现极大支持了环境耐药性进化假说。我们的研究结果提供可能的环
境耐药性途径的直接证据，与以往的研究，高抗 TR34/L98H 交叉抗性于临床药物和环境
农业杀菌剂唑类是一致的。但是，目前尚不清楚环境杀菌剂唑类是否能够诱导产生
TR34/L98H或 TR46/Y121F/T289A。 
 
第五章中，结合第四章的进化实验中的多形态烟曲霉，并从临床患者多株烟曲霉的观
察中，我们欲检测是否菌丝异合体参与烟曲霉唑类抗性的发展中。异核体菌丝伴随参
与真菌生活史的各个阶段。在本章中,我们研究了异核体与烟曲霉唑类耐药性的相关性。
异核体相容性试验表明，所有这些多形态菌落是可兼容性的，这表明异核体很有可能
发生在患者和实验室的长期菌丝生长阶段。此外，试验显示异核体是如何灵活地适应
不断变化的唑类环境。此研究有助于我们理解异核体在野外以及病人体内动态的抗性
适应性。相关的异核体进一步形成二倍体以及单倍体化这些潜在的对抗性发展的研究
有待于更进一步的探索。 
 
在第六章中，我们调查了唑类污染和有机两种堆肥中烟曲霉的种群情况，结果表明，
唑类污染的堆肥中包含三种烟曲霉基因型: 野生型(4%), 抗性 TR46/Y121F/T289A (92%) 
和新突变体 TR46
3/Y121F/M172I/T289A/G448S(4%), 远远大于绝大多数敏感性为主的有
机 堆 肥 (98%) 野 生 型 ,2% TR34/L98H 。 启 动 字 进 一 步 延 长 的 新 突 变 体
TR46
3/Y121F/M172I/T289A/G448S 对所有的临床药物均具有抗性.同时,此突变体已经感
染荷兰各地医院的数位病人 ,引起严重性感染 ,甚至死亡。新型突变体
TR46
3/Y121F/M172I/T289A/G448S 存在两种交配型, 并且在实验室条件下两个 TR46的有
性杂交产生 TR46 
3/Y121F/T289A 的试验表明有性生殖可能对产生新型的更抗性的烟曲
霉起着巨大的作用。然而是否有性生殖可以在野外发生需要更多的证据.但是新型突变
体的发现引起我们对抗性快速发展和临床治疗的担忧。 
 
第七章以对整个论文的讨论结束本论文。人类机遇性病原菌抗性研究是一个复杂的问
题,因为烟曲霉多样性的生态位,以及多样化的生殖方式提供了烟曲霉面对唑类压力的
具备条件.烟曲霉多样化的生活史,生态热点位以及唑类的抗性筛选等因素需要考虑到
理解烟曲霉唑类抗性的发生,发展以及持续。这样方可制定有效的,具有针对性的预防
烟曲霉唑类抗性发生,传播以及感染度的措施。 
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At this moment, firstly, I want to say to myself, “congratulations, Jianhua, you made it, you are a very brave girl, you should be very proud of yourself.” Indeed, from a little Chinese girl, travelling far away from eastern China, now you became into an independent PhD girl. This is a very big step for you, and it was not that easy at all. At the age of 26, you decided to turn your life upside down and inside out. With your poor English, you managed to arrive to Wageningen safe and sound. You were not afraid at all, even though you never went abroad ever before. Even at the moment the bus driver dropped you off somewhere not matching with the stop you wanted. A little Chinese girl pulled a huge suitcase along the wild fields and tried to ask directions all the way and finally arrived at the Bornsesteeg. But Wageningen left a very good first impression on you at that first arrival. Fresh air, sometimes mixed with horse poop and green grassland with ponies. You started to enjoy these surroundings and breathed the fresh air along the way home (indeed it is much cleaner than Beijing’s air). The second day after you arrived, you started your project. You started a new life in a completely unfamiliar environment. You even don’t know who are your colleagues, so you accidentally joined the EPS PhD symposium in Utrecht. But you grew very fast, you made new friends and got into your project more and more after half a year. Yes, after four years you are not the little struggling girl any more, you are a very brave and independent girl. You have achieved and succeeded using the “weird Chinese logical way of thinking” --- not all Chinese logical thinking fits here, e.g. China is big, The Netherlands is small, everything is very different except that the sun rises from east and sets from west, but still with 6/7 hours delay..... :). But it is not that bad to think about the Dutch problems with the Chinese way of thinking. :)  :)  Bas, Sijmen, Fons, I appreciate all help from you guys very much. You are the witness of my changes over these four years! Even though so far I am not sure who is my major supervisor, I am so happy that each meeting could stimulate you guys to lots of brainstorming. You are the best supervisor group ever. Sijmen acts like my big brother, especially at the beginning you gave me a lot of support. You are so patient to guide me and show me around the lab the first time.  Fons, I would like to name you as my older friend. A magic and creative person, full with lots of ideas, but I could not always understand what you are talking about due to my poor knowledge at the beginning. I am very happy that I could communicate with you about everything so freely over four years of study. :) :) What a success! Every time, I come out from your office, sky became much bluer even when it is a raining day! Fantastic! Thanks for lots of leisure talk, and a “romantic walk” (you drived the car and I cycled). When you tell me your phone is blocked, I could not stop laughing, sorry for that. I have never done this ever before, “laughing at” the supervisor in front of the supervisor, that is so amazing!!!. Discussing with supervisor when I eat apples, so relaxed discussion, I never did that before.   
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Bas, you are the first person I contacted when I applied for this subject. Thanks you for initiating this very interesting project. I am super happy with the subject so far and with it growing so fast. There are more and more collaborations and new projects coming in. I believe our lab will be the aspergillus center one day! :) :) I was so surprised with your height at my first sight, it means I have to lengthen my neck and tilt my head to talk to you every time, and it is painful :) :) :). Paul, thanks very much for your expertise. You are my clinical dictionary. It was so amazing that we could talk via email with around 10 emails per day back and forth. Also thank you for all clinical materials that you provided me. Willem, a humorous guy, I like your attitude, and love to make jokes with you. First time we met, I said my English was not good, you said that your Chinese was not good either. Thanks for your kind encouragement. Another thing, I want to ask you, at our first meeting you told a story about a guy who works with azole resistance but could not pronounce azole well, I wonder what is your feeling when you hear my way of pronouncing azole :)  :)  :)  :) . Must be fun, right?  Thanks so much for this amazing supervisors team group, it is because of you guys, I fell deeply in love with my subject, and it is so much fun in science. I love it! Fantastic idea! Ingenious design! Super funny fungi! I enjoyed so much to work with you guys! At the same time, we also buildup huge network and collaborate with CLM (Duurzame landbouw -Gezond voedsel - Vitaal platteland), National Institute for Public Health and Environment (RIVM) and Praktijkonderzoek Plant & Omgeving Bloembollen, Boomkwekerij & Fruit. Thanks Anton Rietveld (RIVM), Jeanne van Beek & Peter Leendertse (CLM, experienced advisor sustainable cultivation), and Henk Gude (PPO) for all your expertise. Every time we have a great discussion and new inspiration. Thanks Peter Leendertse for analyzing the azole concentration in the compost. Thanks Henk Gude and André Conijn for showing us the tulip field and helping us collecting all samples. Also thanks Jacques Meis and Ferry Hagen from the Department of Medical Microbiology and Infectious Diseases, CWZ Hospital for contribution of discovery of new resistance mutation. Lastly, also thanks many clinical advisors from Dutch national surveillance programme for screening the new mutations. Lastly, thanks Prof Wei Liu from the Peking University First Hospital Research Centre, and Prof Li Han from Institute for Disease Control& Prevention, AMMS of China for supporting us to collaborate with China. Ton, from Radboudumc, thanks a lot for your encouragement and guidance you give me about how to operate the scary A. fumigatus at the beginning of my PhD.  Thanks Jan for a lot of experiment support, without you, the chapter could not be completed. Thank you two for taking care of me every time, when Paul is busy. :)  Eveline, I am very happy you join our group finally. Since the first day of my arrival, I have started to read your thesis. Very informative and a lot of interesting results; I 
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followed your step and start my project. Thanks for your support and lots of discussion. From now on, we can discuss more and I believe we will be a great Aspergillus girl team.  Bertha, and Marijke, our great technicians, without you, our lab could not run smoothly. I learned a lot from you two. Also thanks for showing your grandbabies to me. I am so happy to talk with you. Thank you Bertha for giving me lots of comforts when I am disappointed. I still remember that big hug from you after my crying. Gabriella, thank you so much for your great company. I like chatting with you. You always encourage me when I feel sad. You are a great listener and care people’s feeling. Thanks for sharing your life story with me. Thanks for your great ladybug, I do take care of them very good.  Wytske, our secretary, thank you for helping me arranging quite a lot of things before I came, also applying for new room at Bornsesteeg. I am happy all office work went smoothly under your help.  Duur, Sabine, Alex, Margo, Lennart and Eric (Aanen group), thanks for your discussion every Tuesday morning, even though most times I was struggling with understanding the Basidiomycete biology. Claudio, my communism friend, we started more or less at the same time. We went to conferences and travelled together. We had lots of great times together. One day I was so surprised I have more pictures with you than with Eric :)  I like your smiling face on every picture.  I enjoyed chatting with you and thanks for teaching me how to play poker (that magic heavy box with colored chips), and also the sequence game, which I feel I am kind of good at.  Lidia, it is so nice to have you as a friend, I love to have girl talk with you and Vivian. We all are so excited to talk, it puts smiles on our faces. Thanks for your showing me the belly-dance. It was such great fun to shake my hip continuously, even the day after my neck felt painful....... strange :).  I was so enjoyed by your belly dance, amazing...., let us dance next time again!  :) :) Alex, my tablemate, roommate, colleague, friend...... it is so difficult to give a conclusion about our relationship. We “fight” quite some times, but all ends in a good way. It is quite amazing we did not become enemy even at the situation that we have to meet 16 hours per day (more or less). But on the other way around, we become closer and closer. I was touched by your behaviour when you helped me complain to Duur just because I was upset. Hey, buddy, you do care about my feelings :)  :)  :)  . Thanks Alex, I am very happy especially after you become postdoc, you try to make different food every day and let me try as well. I quite enjoyed all food, tasty soup (I guess I am addicted to it now) and deserts. And funny thing, I taught you 谢谢, you replied 谢谢谢。Speechless :):) . By the way, I want to watch the stars with you one day...... you promised to me!! Last thing, thanks for your beautiful drawing on my balloons, I love them. 
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Anna, thanks so much for introducing Russian culture to me, tasty beef soup, cutest Matrioska (my favourite gift, small rat stay inside of cats, isn’t that amazing?) Vivian, my best Greek friend, even though I only know one Greek. :) Thanks for your company and sharing all happiness and sadness with me. We had a lot of fun at the bar, at my home playing Games, eating Chinese food and Greek food. I was so touched that you came from Utrecht and cooked big cheese cake and bean soup for us which was enough to eat for a few days, amazing cook.  :) :)  Guiling Ren, Yuanyuan Zhang; Bo Wang, Zhen Wei, Yanli Wang, Tao Zhao, Pingping Huang, Xianwen Ji, Bing Bai, Wei Song; Hui Li, Hanzi He, Junwei Liu, Jun He, Yunmeng Zhang, Xiaohua, Hucheng Li, Defeng Shen, Tingting Xiao, Xu Cheng, Feng Zhu, Xi Chen, Xiaoqian Shi, Xiao Lin, Tingting Xiao, Yanting Wang, Huchen Li, Kaile, Xuan Xu thanks for all your company during my PhD period. We cycled around Wageningen in the spring, picnicked in the park in the sunny summer, picked chestnut in the golden autumn and made dumplings and played karaoke in the winter. All your company makes me feel at home. Zhen, Yuanyuan, do you remember the first time we travelled to Germany? We walked so far because we just wanted to find that famous desert cafe, what persistent girls. Zhen, Guiling, let us go to Walibi again. We had great fun there, even though you felt sick three times. It was so funny we felt so scared that we only could play some kids game (something like horse stuff). But even worse, the kids in front of us felt so excited and we felt terrified. But thank you Guiling, you accompanied me to play in the swing, but you suffered sickness afterwards. In the end, I had to go in the roller coaster alone, so scary that I didn’t have time to open my eyes and be scared.  Guiling, do you still keep the tiger and donkey from Winnie the Pooh? I still remember how crazy we were when we saw lot of cute dolls in the market. Shopping girls nonstop shopping :) :) . By the way, thanks for your very useful suggestion on designing the vase and autumn leaves in my room. I like your room. :) If one day you open a designing company, please do not forget to employ me :) :)  Come on, Guiling!!! Tao, are you still thinking to form a music band? :)  (Guiling, Yanli, me, we are so happy to sing to music that you played on the guitar). We felt 10 years younger when we sang these university songs. One day, when you want to form a band, please don’t forget to ask us. :) :)  Yanli, thanks for bringing mahjong all the way from China, can you imagine how wonderful it is to play mahjong outside of China. Full of laughers at my home, Junwei was busy with counting the dots on the mahjong whole night, Defeng cheated to win....... hope you guys enjoyed a lot with mahjong. Let us play again.   Jelle, a happy guy, with lots of ideas. I am so happy I can say happy Monday, Tuesday, Wednesday, Thursday, and Friday to you whenever I saw you. Such a happy guy with messy hair, thanks for sharing your happiness, sadness with me and I enjoyed a lot your 
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great piano music. Thanks for your simultaneous Translation of Dutch talk for me. So sweet! Alex, Claudio, Valeria (sorry so far I could not pronounce your name 100% correctly), Vivian, Cris, Florien, Tina, Lennart, Kritty, Margo, Anneloes, Kim, Pingping, Justin and Joost. All my tablemates, thanks for your company, snack sharing, Chinese dinner night, movie night, poker night, Picnic on the river bank, cycle in the forest, mahjong night, Guito night, Greek night, steps party, beer night. I had so much fun to stay with you guys. Oh, Valeria, you could watch star at your place, it must be amazing, right...... like ”little prince”...:) :) Cris, a very good runner, thanks for sharing your marathon stories with me, funny snack and running golden medal! Ramon, I like your banana tree nearby you, wish it will fruit one day. Thanks for your provide all nutrient for my plants, even it did not bloom at all after our lots of efforts. Lennart, enjoying reading a paper stained with coffee, which could keep you awake. Kritty, thanks for experiencing a typhoon with me in the campus, we survived. I am still imaging how you try to escape the strong wind, have to stop by a pole in the middle of nowhere (sound like a Pole-dancing girl in the strong typhoon of the Netherland). Is that cool?  Margo or mango?  Both are tasty, thanks for inviting us for concert, we enjoyed a lot, fantastic group. Thanks for Tania and Andre for the tasty Portugal tea and amazing Bacalhau. Thanks to my students Merijn, Lydia, Douwe, Luuk, Lisa, Bart, Suze and Laurens, you are very great students, well organized, so happy to supervise you guys again. Andy, my new tablemate for a whole, I feel a little close to you maybe because we are both from far away, :)   :)  :)  like a warm lunch.  :) :), and New Zeeland can grow the Chinese kiwi in the best way. Marjon, awesome princess; Diego, an experienced dancer. You are an amazing musician team, so lovely group! Sabine, Alex, Anneloes, Cris, Lennart and Ramon, thanks for your company in the GATC. We were the green people and “pretended” we were teachers. At the end, more than 80% passed the exam. Amazing, Fons, you did a great job! I also want to thank the whole genetics group, such lovely people. I enjoyed cycling with you guys, boating, making fire, building shelter, making pancake, Bas’ way of plowing, making coffee, baking bread in the fire. So amazing! All group people worked so hard in the rain. That was such a great lab-out. Frank, Corrie, Duur, Anneloes, Jelle, Valeria, we were almost the best group just one cent less. Unfair, Unfair :) :) I have to say Mark is a very smart guy; he read the Bible to the owner and won at the end.  Andy, my driving instructor, thanks so much for your patience and great encouragement. I enjoyed so much every time when I drive. It is because of you, I feel it is so much fun to drive. I learned calmness and responsibility from you. I am confident I will be a good driver one day, I will just take a little a lot bit more time! :)  Bareld, my garden neighbour, thanks for your company as well. I enjoyed all leisure talks with you! Thanks for your tasty berry and taking care of my garden when I am away! 
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Thanks for sharing your rich life experience with me! By the way, how your cats are doing?  I was surprised you have never spent longer holidays because of your cat. So I hope you can have a longer holiday one day! I appreciate  the understanding and support from my family in China very much.  I am so sorry I could not attend lots of important celebrations. Thanks to my dear sister Jianhong (建红) and brother- in law Yuanyuan（元元） for taking care of our parents when I am away. Thanks to my nephews Dacong(大聪), Ercong（二聪）, Jingming（婧
茗）for bringing lots of fun for my life. Thanks to my dear brother Xue (雪)and sister- in law Dandan (丹丹) for encouraging me when I confront the difficulties abroad. Thanks to my dear friends 二牛，莎莎, 俊刚 for your great support! I wish all of you have a great happy life ahead.  I want to thank all Eric’s family: Carla, mama Tineke, papa Lauke, Marcel, Lauke, Anneke, Lukas, Peter, Marissa, Kasper, and Karlijn. Thanks for all of you accepting me and welcoming me as a family member. I always do feel family love from you guys, we went camping together, de tour of France, football match, purple flower park, boating, fireplace night, sinterklaas and car racing........I think I never can forget these amazing moments ever. Eric, what do you want hear from me?  :) :) probably too much to write down, let us talk in bed :):). However, I will give you a short summary: thank you for bringing endless happiness to me. I feel endless love from you. My cook, my lover, my driver, my boy!  
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